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Introduction 
Ankylosing spondylitis (AS) is a slowly progressive, chronic inflammatory disease, 
affecting predominantly the sacroiliac joints and the spine1"3. The most striking 
pathological finding is multiple focal microscopic inflammatory lesions confined to 
the ligamentous attachement (enthesophathy) with bony erosions and new bone for-
mations4. This may lead to fusion - ankylosis - of the sacoriliac joints and syndes-
mophyte formation in the spine, resulting in limited mobility of the back. Peripheral 
arthritis is present in 32% of cases5"7, but it is possible that this figure is an 
underestimate because arthritis of root joints - hips and shoulders - have frequently 
not been counted. This is remarkable since the latter joints are more frequently 
involved than other peripheral joints8. Commonly associated extra-articular features 
are acute anterior uveitis, aortitis, inflammatory bowel disease and oral ulcers1,9"11. 
Patients with AS carry in approximately 90% of cases the HLA-B27 antigen12. 
Although the precise etiology is still unclear, it has been suggested that next to this 
genetically determined host response (HLA-B27)13"21, environmental factors do play 
a role, such as the possible role for Klebsiella in triggering AS. However results of 
this study remain controversial22. In addition, a possible role for a gut-derived 
factor involved might be suggested because of the high frequency of (sub)clinical 
inflammatory bowel disease23,24, the association of AS with ulcerative colitis and 
Crohn's disease25, and a frequently raised IgA21·26"2*. 
To establish the diagnosis AS the Rome2', New York30, and modified New 
York criteria31 have been developed in the past As stated by the European Spon-
dylarthropathy Study Group (ESSG) these criteria are too restricted and new 
criteria have been proposed32, that will encompass a wider spectrum of disease 
within the spondylarthropathies. As a result of the restrictions of the current 
criteria, the final diagnosis of AS only can be established if there is clear evidence 
of radiological sacroiliitis, resulting in a delay of diagnosis between 4 and 13 
3 33 
years • . 
The aims underlying the treatment of AS are the control of inflammation, and 
related to this, the modification of the course of the disease. At present drug 
treatment is mainly symptomatic, using non-steroidal anti-inflammatory drugs 
(NSAIDs)34;î5. Additionally, physiotherapy is applied often intermittently36, and 
eventually ergotherapy is often helpfull. NSAIDs reduce pain and stiffness and 
decrease inflammation. However, these drugs commonly cause gastro-intestinal 
(Gl) side effects with a wide variety in symptoms and severity37"41. Because of this, 
a large number of these drugs are now availabe, and still extensive efforts are being 
made to improve commonly used NSAIDs. 
ß-cyclodextrin-piroxicam (Brexine) is the complexed form of piroxicam with ß-
cyclodextrin, a cyclic oligosaccharide of 7a (1-4) linked D-glucopyranose units42, 
ß-cyclodextrin-piroxicam is absorbed faster and peak concentration is higher 
without alteration of the area under the curve43. This might lead to potentially less 
mucosal damage, because exposure of the GI mucosa to the drug will be reduced. 
All literature available on ß-cyclodextrin-piroxicam has recently been reviewed44, 
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including several studies in which improved GI toxicity of ß-cyclodextrin-piroxicam 
has been reported45-48. 
In this thesis ß-cyclodextrin-piroxicam was compared with naproxen over the 
long term in patients with ankylosing spondylitis. Efficacy of these two drugs is 
described in chapter 2. GI toxicity was evaluated by evaluation of the prevalence 
of GI symptoms, next to assessment of the degree of mucosal damage by measure-
ment of faecal blood loss (FBL), using the HemoQuant Assay49 (chapter 3). 
Additionally pseudoporphyria, a supposed rare side effect due to naproxen, 
occured in two patients of this clinical trial. Literature concerning pseudoporphyria 
due to naproxen was reviewed and the cases were described in chapter 4. 
Directly related to the previously mentioned GI toxicity of NSAIDs is the 
possible interaction with peptic ulcer treatments, such as H2-receptor antagonists. 
Cimetidine and ranitidine are two widely used Hj-receptor antagonists, which are 
commonly co-administered with NSAIDs in order to heal NSAID-induced peptic 
ulcers. H2-receptor antagonists might influence pharmacokinetics of other drugs, 
because H2-receptor antagonists are known to: 1. diminish gastric acid secretion, 
leading to an increase of gastric pH51, thus possibly influencing absorption; 2. 
inhibit the metabolic pathway of hydroxylation" by binding to cytochrome P^ , 
leading to inhibition of metabolite formation of drugs; and 3. be excreted by 
glomerular filtration and tubular excretion, which might be influenced by other 
drugs such as NSAIDs. We studied the possible interaction between ß-cyclodextrin-
piroxicam and two H2-receptor antagonists, Cimetidine and ranitidine; both the H2-
receptor antagonists and ß-cyclodextrin-piroxicam were studied during steady state 
conditions (chapter 5). The method for solid-phase extraction of Cimetidine from 
plasma with subsequent analysis by high performance liquid chromatography was 
improved for this pharmacokinetic interaction study (appendix). 
Recent years have witnessed a growing interest in the use of second-line drugs 
as a treatment for seronegative spondylarthropathies, especially in AS. All the 
literature was reviewed (chapter 6). Methotrexate appeared promising, and in 
chapter 7 we report an open study with methotrexate in patients with severe AS. 
To assess functional status in chronic rheumatic diseases questionnaires are 
commonly used52"54. In this study we translated, modified and validated a question-
naire for the assessment of functional status in AS, in essence a French question-
naire55,56 (Chapter 8). This newly evaluated and validated Dutch Functional Index 
was applied to the clinical studies, presented in this thesis. 
One major problem in As is the difficulty in assessing disease activity in axial 
arthritis. In axial arthritis, in particular, most clinical variables are not very 
sensitive to change8,57,58. Laboratory variables are frequently not abnormal or only 
seem to reflect peripheral arthritis1,6,7. Besides this, disease activity can fluctuate 
largely: Goodacre et al. for example found almost individual patterns of disease 
activity in AS with exacerbations and remissions occurring at least once during a 
one-year period60. Data of the two clinical studies - ß-cyclodextrin-piroxicam versus 
naproxen in AS and methotrexate in severe AS - were used to select variables 
assessing disease activity and a first step was made for the development of a 
disease activity score (chapter 9). 
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Apart from the assessment of disease activity, attention was paid to the 
assessment of outcome of this disease and a radiographic scoring system was 
developed and evaluated. A part of this radiographic scoring system was the Larsen 
hip score59 and a modification of the lumbar spine score as published by Taylor et 
al60. Radiographs of patients participating in the NSAID study were scored with 
this new radiographic scoring system. Attention was paid to differences in radiogra-
phic scores between ß-cyclodextrm-piroxicam and naproxen, and responders and 
non-responders. Regarding differences between men and women conflicting results 
have been published61'64. The relation of commonly used variables with this 
radiographic scoring system was studied additionally (chapter 10). 
The main conclusions of this thesis are summarized in chapter 11. 
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ß-cyclodextrin-piroxicam ν naproxen in AS 
Summary 
Nonsteroidal antiinflammatory drugs (NSAIDs) are used as a symptomatic treat­
ment in the majority of patients with ankylosing spondylitis (AS). Complexation of 
Piroxicam with ß-cyclodextrin (Brexine*) leads to improved absorptionkinetics, thus 
reducing gastrointestinal (GI) toxicity. In this study 48-week double-blind study 
efficacy and toxicity of ß-cyclodextrin-piroxicam (20 mg OD.) with naproxen (500 
mg B.ID.) was compared in 59 AS patients, entering after a washout period. 
Patients were seen 12 times. Comparison over the whole study period showed no 
significant differences, although eight out of 109 tests favoured ß-cyclodextrin-
piroxicam. The frequency and the profile of GÌ side effects were equal. 21 Patients 
did not complete the study of whom 11 because of inefficacy (7 naproxen, 4 ß-
cyclodextrin-piroxicam), and overall efficacy (completion ν drop-out) was not 
statistically different. In conclusion, ß-cyclodextrin-piroxicam and naproxen had 
similar efficacy and toxicity over the long-term. 
Introduction 
Ankylosing spondylitis (AS) is a chronic inflammatory condition, in which 
sacroiliitis is the hallmark lesion, and pain and stiffness are the main symptoms. 
Involvement of the spine may lead to spinal ankylosis. The precise pathogenesis is 
still unclear and although involvement of gram negative bacterial infections 
strongly have been suggested1"3, no causal treatment is available. Therefore 
chronical intermittent nonsteroidal antiinflammatory drugs (NSAIDs) are used as a 
symptomatic treatment in the majority of patients. In the United Kingdom for 
example it was estimated that about 80% of AS patients are taking NSAIDs4. 
Because of a large interindividual variability in efficacy and toxicity, a number of 
different NSAIDs are needed for the treatment of AS. Gastrointestinal (GI) side 
effects are commonest, and to improve GI tolerance extensive efforts have been 
made, such as altering the route or the form of administration. Despite the chronic 
nature of AS, most clinical trials with NSAIDs published had a study duration of 2 
to 12 weeks5, and it ought to be advocated that such studies should have a much 
longer study duration in order to pass judgement on overall efficacy*. 
Piroxicam is a widely used potent NSAID. Its half-life is on average 45 hours7, 
thus allowing once daily administration, ß-cyclodextrin is a soluble oligosaccharide 
obtained from the common starch by enzymic hydrolysis. It is able to complex with 
drugs by encapsulation and acts as an inert carrier8, ß-cyclodextrin-piroxicam 
(Brexine") is the complexed form of piroxicam with ß-cyclodextrin, and compared 
with the parent compound it has an about SO times increased solubility rate. As a 
consequence its peak concentration is higher and achieved faster910. Apart from the 
systemic inhibition of prostaglandin synthesis by NSAIDs, GI damage is related to 
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the contact-time of the drug with the Gì mucosa. A reduction of this contact-time, 
as obtained by the complexation with ß-cyclodextrin, might result in less mucosal 
damage. This has been repotted in several studies with ß-cyclodextrin-piroxicam in 
which GI mucosal damage was assessed either by endoscopy or by measurement of 
faecal blood loss, although not all studies showed statistically significant differen-
ces11·13. 
The aim of the study we describe was to compare the efficacy and toxicity of 
ß-cyclodextrin-piroxicam with naproxen over the long-term in patients with AS. 
Patients and methods 
The study was conducted at the departments of rheumatology of the University 
Hospital Nijmegen St. Radboud and of the St. Maartenshospital Nijmegen, the 
Netherlands. Full approval of both ethical committees was obtained. 
Patients 
Patients with AS fullfilling the modified New York criteria15 of either sex, aged 
between 16 and 60 years, were selected. They were excluded from the study if they 
had any evidence of: 1. previous hypersensitivity to NSAIDs; 2. other major side 
effects on NSAIDs like GI hemorrhage or perforation; 3. active peptic ulcer disease 
in the previous years; 4. serious comorbidity or impaired organ function; 5. depres-
sion or other mental disorders; 6. alcohol or drug abuse; 7. pregnancy or breast 
feeding. In addition to the above criteria, only those patients with an active disease 
after a washout period for NSAIDs were admitted to the study. Active disease was 
defined as a clear need for analgesics or NSAIDs with at least two of the following 
features: (a) back pain during the night and/or the day; (b) morning stiffness of at 
least 15 minutes; (c) pain and stiffness in both buttocks; (d) pain and stiffness of 
the chest. 
After written informed consent 64 patients started a washout period. Of them 
59 deteriorated and were allowed to enter the trial. 
Study design 
The trial was designed as a 48-week double-blind single-observer study in which ß-
cyclodextrin-piroxicam at a dose of 20 mg O.D. (S.A. Nycomed Christiaens N.V., 
Belgium) was compared with naproxen at a dose of 500 mg B.I.D (S.A. Nycomed 
Christiaens N.V., Belgium). The double-dummy technique was used for blinding. 
Compliance was checked and stimulated at every visit by pill-counting. Patients 
were sequentially assigned to one of the treatment groups, balanced16 for age, sex, 
peripheral arthritis, and extent and duration of the disease. Concomitant treatment 
for other chronic and acute diseases was allowed, except for other NSAIDs, 
analgesics, anticoagulants, barbiturates, oral steroids and drugs interfering with 
absorption. Physical therapy was continued if started prior to the washout period. 
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Participation in an AS-exercise group, exercises at home and swimming were 
allowed at any time of the study. 
Patients were interviewed and examined at a prestudy screening, during which 
also routine laboratory tests, an ECG and chest X-ray were made. After the 
washout period, of which the duration was depending on the patients deterioration, 
the trial medication was started. Assessments were made at start of the medication 
(week 0) and at weeks 2, 4, 8, 12, 18, 24, 30, 36, 42 and 48, generally at the same 
time of the day. 
Measurements 
Every visit the following variables were assessed: 
a) Objective clinical variables: 
* occiput-wall-distance, measured in cm with the patient standing as erect as 
possible with heels and back against the wall; 
* chest expansion, assessed as the difference in cm between the circumference of 
the chest at nipple line on full inspiration and full expiration. The better one of 
two measurements was recorded; 
+ Schober 10 cm test"; 
* fingertip-to-floor-distance, recorded as the distance in cm between the third 
fìnger and the floor with the patient bending forward maximally, without flexing 
the knees; 
* lumbar lateral flexion, measured as a percentage of the body height18; 
* the number of swollen joints (n=53); 
* enthesis index: pain graded as 0 = no pain; 1 = pain reported by the patient after 
request; 2 = spontaneous pain reported by the patient; 3 = severe pain leading to 
wincing or withdrawing. Enthesis examined are nuchal crests, manubriostemal 
joint, costochondral joints, greater tuberosity, medial and lateral epicondyl, 
medial and lateral condyles of the femur, calcaneal insertions of the plantar 
fascia and the achules tendons, the sacroiliac joints, the cervical, thoracic and 
lumbar spinous processes, the ischial tuberosities and the anterior posterior iliac 
spines. The maximal score of the enthesis index being 9019; 
* root joint index: pain of shoulders and hips by palpation and/or passive move-
ment was assessed with pain graded from 0 to 3 (see enthesis index). The sum 
of the score being the index; 
* mobility of the cervical spine, measured in degrees; rotation measured with a 
goniometer and lateralflexion, anteflexion and retroflexion with a hydrogoniome-
ter. 
b) Subjective patients variables: 
* Spinal pain during the day, spinal pain during the night and general well-being 
were assessed by using Visual Analogue Scales (VAS). VAS of 100 mm were 
used in which 0 mm corresponds with no pain or very good and 100 mm with 
intolerable pain or very poor; 
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* Duration of morning stiffness, recorded in minutes after arising with a maximum 
of 360 minutes. 
c) Laboratory variables: 
* HLA-B27; 
* Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complete blood 
cell count, serum Creatinin, liverfunction tests, immunoglobin A, G and M, 
Creatinin Phosphokinase; 
* Urinanalysis. 
d) Functional assessment: 
A Dutch Functional Index for AS20 in essence a modification of the functional 
index of Dougados et al21,21 was completed at week 0 and every 12 weeks 
thereafter. 
e) Side effects: 
Side effects or other discomfort related to the study medication were obtained at 
every visit by direct questioning or as spontaneously reported complaints. 
Statistical analysis 
Patients' characteristics of both treatment groups being age, sex, duration and 
extent of the disease, duration of the washout period were compared using a t-test 
or chi-square test. Assessments at screening visit and at week 0 were used to test 
comparability of both groups. 
If necessary, logaritmic or square root transformation was applied, to obtain 
normality. The flare in disease activity, induced by the washout period, was 
evaluated in a within-group comparison, using paired t-tests between the prestudy 
screening visit and week 0. For a within-group comparison of improvement due to 
treatment paired t-tests were applied to weeks 0 and 2, thus analysing short-term 
efficacy of each treatment separately. These within-group comparisons between the 
prestudy screening visit and week 0, and between weeks 0 and 2 indicates the 
sensitivity to change of assessed variables. 
Response to treatment was analysed in two ways: 1. The patients situation 
after 2, 12, 24, 36 and 48 weeks of actual treatment between the two groups was 
described and analysed applying t-tests; 2. Out of the variables which changed 
significantly from week 0 to week 2 in the within-group comparison, subjective, 
clinical and laboratory variables were selected (fingertip-to-floor distance, chest 
expansion, Schober 10 cm test, enthesis index, spinal pain during the night, general 
well-being, morning stiffness, CRP and Dutch Functional Index). The size of the 
changes due to treatment, calculated as the differences between weeks 0 and 12, 
was evaluated by t-testing. 
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Table 1. Characteristics of patients 
age (years) 
sex ratio male : female 
disease duration (years) 
number of patients with: 
HLA-B27 
peripheral arthritis 
presence of syndesmophytes 
on X-rays of lumbar and/or 
cervical spine 
number of patients with 
different symptoms of disease 
activity at week 0: 
spinal pain 
pain and stiffness in buttocks 
chestpain 
morning stiffness ¿ I S minutes 
naproxen 
37 ± 9 
23 : 7 
9 ± 8 
26 
2 
B-cyclodextrin-
piroxicam 
4 0 1 8 
2 2 : 7 
11 ± 7 
29 
I 
21 21 
27 
7 
28 
16 
27 
14 
25 
8 
*: mean ± standard deviation 
Overall efficacy, i.e. patients who completed the study ν patients who were 
withdrawn due to either inefficacy or side effects, was analysed with a chi-square 
test 
Results 
Patients 
No patient had to be excluded because of non-compliance. The randomization 
procedure resulted in 29 patients in the ß-cyclodextrin-piroxicam-treated group and 
30 patients in the naproxen-treated group. Patients' characteristics at the start of the 
study are shown in Table 1. The number of symptoms for active disease at study 
entry were not different (see Table 1). Between the two treatment groups there 
were no statistically significant differences at the prestudy screening visit, weeks 0 
and 2 (see Table 2). 
The study was completed by 38 patients. For reasons of inefficacy and side effects 
21 patients did not complete the study of whom 11 because of inefficacy (7 
naproxen, 4 ß-cyclodextrin-piroxicam); one patient discontinued treatment because 
of the combination of inefficacy and side effects (naproxen). 
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Response 
Paired t-tesüng showed significant changes between the piestudy screening visit 
and week 0 in the majority of assessed variables in both treatment groups, reflec-
ting a flare of the disease (see Table 2). Sensitivity to change was tested by 
applying paired t-tests on variables of weeks 0 and 2. In both treatment groups 
significant improvement could not only be seen in subjective variables such as 
pain, morning stiffness and general well-being, but also in laboratory variables and 
variables measuring spinal mobility, except for measurements of the mobility of the 
cervical spine. The Dutch Functional Index, assessing functional status, improved 
significantly in both groups from week 0 to 12. 
Table 2 describes means and standard deviations of all assessed variables for 
each treatment group per measurement occasion. In only a small number of 
variables significant differences were found between the two treatments. Differen-
ces between weeks 0 and 12 were calculated of a selected group of variables and 
are shown in Table 3, to which t-tests were applied. C-reactive protein tended to 
favour ß-cyclodextrin, though not significantly (p < 0.06). 
Signs of synovitis (n=3) did not improve on study treatment. 
Side effects 
Similar frequencies of side effects were seen in both treatment groups (Table 4). 
The number of patients discontinuing treatment was not different for the two 
groups irrespective of the nature of the side effect The profile of GI symptoms 
Table 3. Size of change due to treatment from week 0 to 12 (median, 
percentiles 10 and 90) 
ß-cyclodextrin-piroxicam naproxen p-value' 
fingertip-to-floordisL (cm) 
chestexpansion (cm) 
Schober (cm) 
enthesisindex (0-90) 
spinal pain night 
(VAS 100mm) 
general well-being 
(VAS 100 mm) 
morning stiffness 
(minutes) 
C-reactive protein (mg/1) 
Dutch functional index (0-3) 
plO 
- 12.9 
-0.6 
-0.6 
-22.2 
-62.0 
-46.4 
-324.0 
-42.6 
-0.77 
p50 
0.0 
1.0 
0.5 
-6.0 
-23.0 
-18.0 
-30.0 
-13.0 
-0.15 
*: t-test after transformation (to normality) 
p90 
6.9 
2.0 
2.1 
0.0 
5.0 
6.6 
0.0 
3.0 
0.25 
plO 
-14.0 
-1.0 
-0.6 
-23.2 
-58.2 
-49.4 
-240.0 
-43.6 
-0.93 
p50 
-3.0 
1.0 
0.0 
-7.0 
-14.0 
-16.0 
-30.0 
-12.0 
-0.14 
p90 
4.2 
2.6 
1.0 
6.4 
10.2 
11.4 
1.0 
14.6 
0.33 
0.70 
0.83 
0.14 
0.80 
0.42 
0.83 
0.30 
0.06 
0.69 
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Table 4. Side effects 
Naproxen* ß-cyclodextnn-piroxicam 
discontinuation of treatment due to: 
GI-symptoms 5 3 
other symptoms not related to the GI-tract 2 2 
GI-symptoms* 
number of patients reporting QI-symptoms 12 12 
pyrosis 5 5 
ructus 1 0 
abdominal discomfort 3 5 
nauseousness 2 1 
loss of apetite 0 1 
flatulence 1 1 
obstipation 2 0 
diarrhoea 1 1 
peptic ulcer 2 2 
proctitis 1 0 
Other symptoms not related to GI-tract* 
patients reporting symptoms 5 2 
sleepiness/drowsiness 1 0 
sleeplessness 1 0 
headache 1 0 
toxicodermia 0 1 
psuedoporphyna 2 0 
generalised edema and weight gain 0 1 
- one patient experienced both headache and GI-sidc effects leading to discontinuation of treatment 
*· more than one symptom can occur in a patient 
was similar. The occurrence of pseudoporphyna in two naproxen-treated patients 
was remarkable as this is reported to be a rare side effect23. Central nervous system 
side effects only occurred in the naproxen-group 
Overall efficacy 
21 Patients were withdrawn prematurely from the study due to adverse drug 
reactions and lack of efficacy. The mean number of weeks patients continued in the 
study was 41 (standard deviation = sd = 14 weeks) and 36 weeks (sd = 16 weeks) 
for ß-cyclodextnn-piroxicam and naproxen respectively and revealed no statistical-
ly significant difference. Overall efficacy, i.e. patients who completed the study ν 
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Table 5. Distribution of completers and non-completeis 
completing the 
yes 
no 
total 
study naproxen 
17 
13 
30 
ß-cyclodextrin-
piroxicam 
21 
8 
29 
total 
38 
21 
59 
chi-square test not significant (p = 0.32, continuity correction) 
patients who were withdrawn due to either inefficacy or side effects, revealed no 
differences between the two treatments as analysed using a chi-square test (Table 
5). 
Discussion 
In this 48-week clinical trial a new formulation of piroxicam - ß-cyclodextrin-
piroxicam - and the commonly prescribed naproxen were compared in AS. ß-
cyclodextrin improves absorptionkinetics of piroxicam8·9 and it is suggested that this 
causes less mucosal damage, which was confirmed in studies with chronic treat-
ment of NSATDs by an improved GI tolerance10"13. 
Evaluation of treatment in AS is difficult because of the heterogeneity of the 
disease, resulting in heterogeneity in patients, like those with elevated acute phase 
proteins, clear enthesMs, peripheral arthritis and extensive spinal ankylosis. Apart 
from this, laboratory variables seem to have little relation to disease activity24"28, 
and therefore do not reflect treatment effects. Variables assessing spinal mobility 
appear to be a combination of momentary disease activity and irreversible damage 
caused by the disease, thus influencing sensitivity to change. When comparing 
treatments, groups of patients should therefore be balanced heterogeneity of the 
disease. In this study patients were allocated to either treatment, balanced for age, 
sex, peripheral arthritis, and duration and extent of the disease. As can be seen in 
Table 1, patients' characteristics and criteria for active disease were similar at the 
start of the study in both groups. In this study, with most patients having longstan-
ding disease, the majority of variables showed significant deterioration after a 
washout period. In addition, after two weeks of treatment a significant improve-
ment could be seen. It can be concluded that both treatment groups consisted of 
patients with active disease who were sensitive to change. 
Comparison of all variables at each measurement occasion showed no signifi-
cant difference between the treatment groups, although it was striking that eight out 
of 109 tests favoured ß-cyclodextrin-piroxicam. This number of significant tests 
might be attributed to coincidence. The size of the change due to treatment on the 
short-term have been analysed by calculation of the differences between weeks 0 
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and 12, thus reducing the influence of the heterogeneity in disease duration, 
severity and extent of the disease of the studied patients. For this analysis selection 
of variables was based on significant changes found with paired t-tests between 
weeks 0 and 2, in order to test only sensitive variables. Overall efficacy and the 
number of weeks patients participated in the study were similar if drop out was 
chosen as the main criterium. The frequence and the profile of side effects did not 
differ between treatments and no differences in GI toxicity could be found in 
contrast with previous reports of piroxicam29, in which piroxicam compared with 
other NSATDs caused more GI toxicity. 
The concluded absence of difference in efficacy might be subject of a type Π 
error. After the inclusion period of this study, Bellamy et al30,31 published tables 
with sample sizes per treatment group for commonly used variables with correspon­
ding clinically important differences or deltas. According to these tables there was 
an optimal sample size for a maximal delta for Schober 10 cm test, chest expansi­
on, night pain and general well-being, and a minimal sample size for functional 
status in our study. Cervical anteflexion and retroflexion, lumbar lateral flexion, 
fingeitip-to-floor-distance, occiput-to-wall-distance and morning stiffness were other 
variables reported in these tables, and those variables required an optimal sample 
size varying from 91 to 291 patients per treatment group. Thus, in a part of the 
assessed variables sample size was sufficient to detect significanties. 
In conclusion, ß-cyclodextrin-piroxicam and naproxen had similar efficacy and 
toxicity in this study, in which sample sizes per treatment group for five important 
variables were sufficient. 
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Gl toxicity during NSAIDs in AS 
Summary 
Aim of the study was to compare gastrointestinal (GI) toxicity of ß-cyclodextrin-
piroxicam and naproxen during a 48-week study in patients with ankylosing 
spondylitis (AS) using clinical symptoms and faecal blood loss (FBL) as variables. 
FBL was measured at weeks 0, 4, 24 and 48 using a modified HemoQuant Assay, 
ß-cyclodextrin-piroxicam and naproxen revealed no differences in FBL and GI-
symptoms over 48 weeks. GI-symptoms and FBL were not correlated. FBL increa-
sed from weeks 0 to 4 (p - 0.055) and decreased subsequently to weeks 24 and 48 
(p < 0.001), indicating a mechanism of gastric adaptation. FBL was on average 
1600 ml per year in AS patients, which is four times the FBL in healthy controls. 
Introduction 
Nonsteroidal antiinflammatory drugs (NSAIDs) are widely used because of their 
antiinflammatory and analgesic effects. However, one of their major disadvantages 
is the high frequency of gastrointestinal (GI) side effects, varying from pyrosis and 
nausea to peptic ulcer disease, gastric hemorrhage and ulcerations of the small and 
large intestine1"*. Two independent mechanisms apparently play a role in GI 
damage by NSAIDs2: first, a systemic effect due to inhibition of prostaglandin 
synthesis, and second, a direct damaging, local effect5. Recently it has been 
suggested that it might be possible to bypass the systemic effect of NSAIDs by 
selective inhibition of cyclooxygenase 2, found to be the predominant cyclooxyge-
nase isoform throughout all stages of inflammation6. However, by now, most 
attention has been paid to influencing the local damaging effects of NSAIDs, for 
example altering the route or form of administration in order to decrease the local 
damaging effect of the drug itself. 
Brexine is the complexed form of piroxicam with ß-cyclodextrin, a cyclic 
oligosaccharide of 7a (1-4) linked D-glucopyranose units7. The pharmacokinetic 
profile of ß-cyclodextrin-piroxicam is identical to that of piroxicam except for 
absorption kinetics, caused by complexation with ß-cyclodextrin. ß-cyclodextrin-
piroxicam is absorbed faster and peak concentration is higher without alteration of 
the area under the curve8. This might lead to less mucosal damage, because 
exposure of the GI mucosa to the drug will be reduced. This reduced GI toxicity 
has been reported in several studies with ß-cyclodextrin-piroxicam9"13. 
Next to the prevalence of GI symptoms, GI toxicity of NSAIDs can be 
evaluated as the degree of mucosal damage. The latter can be assessed directly by 
endoscopy1* or indirectly by measurement of faecal blood loss (FBL). Blood loss in 
stools can be measured quantitatively by measurement of 51Cr labeled erythrocytes 
or by measurement of fluorescing haem-derived porphyrins, the latter method 
known as the HemoQuant Assay. Advantages of measurement with the HemoQuant 
technique is that it is a non-invasive technique, and that the entire GI tract can be 
evaluated. In particular with respect to this last point it has to be stressed that 
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Table 1. Characteristics of patients at start of study 
ß-cyclodextrin- naproxen 
Piroxicam 
number of patients 23 28 
male 16 21 
HLA-B27 positive 23 24 
age (years)* 41 ± 9 39 ± 9 
disease duration (years)" 10 ± 8 9 ± 8 
*: mean ± standard deviation 
NSAID-enteiOpathy not only involves the upper GI tract, but also the lower GI 
tract4·15·16 
However, NSAID-related GI toxicity has been studied in only small numbers of 
healthy volunteers and scarcely in patients, and the time of drug administration 
varied from 4 to 28 days17"21. Two studies form an exception by evaluating a larger 
number of patients (6523 and 249") and by administration of NSAIDs for 6 weeks 
and 1 year respectively. The gastric mucosa has shown evidence for a mechanism 
of adaptation to aspirin in studies in animals25,26 and man27,2", and to indomethacin 
in man29. This mechanism has not been reported in response to other NSAIDs. This 
adaptation occurred within 4 weeks but could take up to 9 weeks26, for which it is 
important to perform studies on the longterm. Since many patients with AS use 
NSAIDs for many years, and in addition, the prevalence of (sub)clinical inflamma-
tory bowel disease has been reported to be increased in spondylarthropamy30·31, it 
should be stressed that it is important to evaluate longterm effects of these drugs on 
GI mucosa. 
The aims were to study and compare GI toxicity on the long-term of two 
NSAIDs, ß-cyclodexrrin-piroxicam and naproxen, the relation between GI com-
plaints and the amount of FBL, and to study FBL in patients with AS. For these 
purposes patients with AS were studied in a 48-week clinical trial. GI toxicity was 
evaluated using clinical symptoms and faecal blood loss (FBL) as variables. 
Patients and methods 
Patients 
This study was part of a 48-week double-blind randomized clinical trial comparing 
naproxen with ß-cyclodextrin-piroxicam (Brexine) in patients with AS. The 
following criteria were used: 
Inclusion criteria: 1. age 1 6 - 6 0 years; 2. patients with ankylosing spondylitis 
according to the modified New York criteria32; 3. clear evidence of activity of the 
disease when not treated with antiinflammatory drugs. 
Exclusion criteria: 1. previous hypersensitivity to NSAIDs; 2. previous major side 
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effects on NSAIDs like GI hemorrhage or perforation; 3. active peptic ulcer disease 
in the previous years; 4. serious systemic disease or impaired organ function; 5. 
depression or other mental disorders; 6. alcohol or drug abuse; 7. pregnancy or 
breast feeding. Additionally for this GI toxicity study: 8. the presence of hemorr-
hoids. 
After written informed consent, 59 patients were enrolled in the clinical trial, and 
51 of them fulfilled the inclusion criteria for study; patients' characteristics are 
shown in Table 1. 
Study design 
The study was performed at the rheumatology departments of the University 
Hospital Nijmegen St. Radboud and St Maartenskliniek Nijmegen, the Netherlands 
with one observer (MC). All patients were seen twelve times during 48 weeks, 
starting after a prestudy screening visit and a washout period. Study-medication 
was naproxen 500 mg b.i.d. and ß-cyclodextrin-piroxicam 20 mg o.d. Medication 
was supplied double-blind using the double-dummy technique for the whole study-
period. Between the two study-drugs there was no cross-over in case of discontinu-
ation. Compliance was checked and stimulated by pill-counting at every visit. 
Patients were allocated to one of the treatment groups balanced for sex, age, 
severity and extent of the disease". FBL was measured at week 0 (after a washout 
period serving as a baseline) and at weeks 4, 24 and 48. Patients who had to stop 
study-medication because of a lack of effect or an adverse drug reaction were 
treated with other NSAIDs and/or sulfasalazine, and continued in the GI toxicity 
study despite discontinuation of study treatment (intention to treat analysis). Side 
effects were reported spontaneously and asked for by the investigator. 
Instruction, diet and faeces collection 
Instructions, which had to be followed three days prior to faeces collection, were 
given to all patients. In order to prevent self-induced gum-bleeding dental flossing 
was forbidden and only soft tooth brushes were allowed to use. To rninimize the 
possibility of gum-bleeding caused by food, hard fruits and fish with bones were 
forbidden. In case a patient had easily gum-bleeding it was forbidden to brush teeth 
for this period and the patient was supplied with a mouthwash. Female patients, 
who were still menstruating, were asked not to collect stools during their period. 
A diet, in which red meat was forbidden34·3', was prescribed to be held three 
days prior to faeces collection. Intake of alcohol was not restricted, but advised to 
use as sparse as possible36. 
Complete stools were obtained on two consecutive days for 48 hours on four 
occasions (week 0, 4, 24 and 48). Patients were given plastic containers of 1 litre. 
Faeces was collected seperate from urine and collected directly into plastic 
containers to avoid loss of hemoglobin transfer from stools to toilet water36. 
Containers with faeces were stored at room temperature till they were brought to 
the hospital. The visit at the hospital always took place within at maximum two 
days after the stool collection. At this visit blood was taken for determination of 
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Table 2. Median daily faecal blood loss, and percentiles 10 and 90 (ml/24 hours) 
of the two treatments 
week 
0 
4 
24 
48 
ß-cyclodextrin-piroxicam 
plO 
3.2 
3.9 
2.3 
1.8 
p50 
5.2 
6.3 
4.0 
5.2 
p90 
11.4 
13.6 
9.6 
9.9 
η 
21 
19 
21 
20 
naproxen 
plO 
1.9 
2.3 
2.3 
1.4 
p50 
6.2 
6.0 
4.4 
3.9 
p90 
11.9 
16.5 
9.0 
8.4 
η 
25 
28 
22 
17 
hemoglobin. Principally all 51 patients collected stools at weeks 0, 4, 24 and 48, 
whether they were still using the study drug or not. 
The HemoQuant Assay 
Quantitative hemoglobin loss in the faeces was determined using the modified 
HemoQuant Assay38. Analyses were performed blinded for treatment. In short, the 
haem was extracted with acidified isopropanol and reduced (removal of the iron ion 
out of the haem) into fluorescing protoporphyrines, which were measured by means 
of fluorescence. In the modified procedure (personal communication of the same 
authors38) reduction of haem was performed at 60° Celsius with 2 ml of a solution 
of 0.5 g FeS04.7H20 in 9 ml aqua and 6 ml HCl (37%), instead of 2 ml of the 
oxalic reagent at 100° C, as published previously38. 
Stools were stored in plastic containers at -20° Celsius until analyses. Before 
analysis stools were defrosted and whole stools of 48 hours weighted, diluted with 
two parts of water and homogenized using a domestic blender. One-gram samples 
were put into 10 ml polyethylene tubes for the determiniation of haem-derived 
porphyrins. 
The total amount of haem-derived porphyrins were measured, and not the 
amount of haem separately. A porphyrin molecule is similar to a haem molecule 
except that in haem an iron ion is present. The amount of porphyrins equals the 
amount of haem in a sample. The total blood loss in ml per 24 hours was calculat­
ed from the known dilution factor, the blood hemoglobin concentration of the 
patient, the total amount of faeces produced and the amount of porphyrin in the 
faeces. In the usual HemoQuant Assay FBL is calculated as mg Hb per g faeces. 
Fibers in the diet dilute faecal hemoglobin because of increased bulk and signifi­
cantly decrease the faecal hemoglobin concentration35. FBL in this study was, 
therefore, calculated in ml blood per 24 hours. 
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Figure 1. Boxwhisker plots of median faecal blood loss of all measurements 
occasions 
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Statistical analysis 
Median FBL and percentiles 10 and 90 were calculated for each treatment group 
for each measurement occasion. Due to the observed skewness in the FBL-data 
logaritmic transformation was applied. A t-test was calculated to compare the two 
treatments using FBL of weeks 0, 4, 24 and 48. For all measurements together 
differences of FBL at weeks 0, 4, 24 and 48 were calculated and a paired t-test on 
these mean differences was done. Correlations were calculated in order to deter­
mine a possible influence of the length of the washout period on the difference in 
FBL between weeks 0 and 4. To analyse a relation between FBL and occurence of 
GI complaints, a 3-way ANOVA was calculated with patient, week and occurence 
of GI complaints as independent variables and FBL as dependent variable. 
Results 
In total, 184 stools for FBL-measurements were available. Not of every patient 
FBL could be measured on all four occasions, and several times faeces collection 
was postponed because of menstruation. No patient experienced such severe 
gumbleeding that faeces collection had to be put off. Apart from this, two patients 
were lost-to-follow-up: one patient because of severe complications of ulcerative 
colitis (belonging to the naproxen-treated group) and one patient because of refusal 
at week 36 (piroxicam-treated group). 
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Table 3. Gastrointestinal symptoms 
number of patienta 
reporting OI symptoms 
symptoms* 
pyrosis 
ructus 
abdominal discomfort 
nauseousness 
loss of apetite 
flatulence 
obstipation 
diarrhoea 
ß-cyclodextrin 
Piroxicam* 
23 
10 
5 
0 
4 
1 
0 
0 
0 
0 
(43%) 
naproxen' 
28 
12 (42%) 
5 
1 
3 
2 
0 
1 
2 
1 
number of patiens which 
had to stop treatment 
due to OI symptoms 3 
endoscopy 3 
peptic ulcer 2 
proctitis 0 
no abnormalities 1 
X-ray stomach/colon 1 
peptic ulcer 0 
proctitis 0 
no abnormalities 1 
': percentage is given as a percentage of all patients per treatment group 
*: in a patient more than one symptom can occur 
There were 81 FBL measurements in the ß-cyclodextrin-piroxicam group and 
103 in the naproxen group of patients who did not discontinue study treatment, and 
these were used for evaluation of GI toxicity of the two treatments. Median FBL 
with its 10 and 90 percentiles for each treatment are shown in Table 2. A t-test did 
not reveal any statistically significant differences for the four measurement 
occasions between ß-cyclodextrin-piroxicam and naproxen. 
GI symptoms and complaints occurred in both treatment groups. The number of 
patients which reported GI symptoms were 10 and 12 for ß-cyclodextrin-piroxicam 
(η = 23) and naproxen (n = 28), respectively (see Table 3). Treatment was stopped 
due to GI symptoms in 3 (ß-cyclodextrin-piroxicam) patients and 5 (naproxen) 
respectively. Endoscopic evaluation was performed in six patients: peptic ulcers 
have been found in 4 patients (2 ß-cyclodextrin-piroxicam, 2 naproxen), proctitis in 
1 patient both cases. A 3-way ANOVA did not show any relation between the 
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occurence of GI symptoms and the amount of FBL (p > 0.05). 
All 184 stools for FBL were used to study FBL in patients with AS using 
chronically NSAIDs, and in addition to study a possible mechanism of gastric 
adaptation. FBL at week 4 (6.3 ml/24 hours, range 1.9 - 28.3) was increased 
compared to baseline, week 0 (5.4 ml/24 hours, range 0.3 - 11.6). This increase 
revealed no statistically significant difference applying paired t-test (p = 0.055). 
Subsequent FBLs showed a reduction to week 24 (4.1 ml/24 hours, range 0.9 -
10.2) and week 48 (4.9 ml/24 hours, range 1.0 - 12.4), both highly statistically 
significant applying paired t-tests (p < 0.001). Analyses of FBL at weeks 0, 24 and 
48 were not statistically significantly different between the two groups. FBL of all 
four measurement occasions is shown in figure 1. The difference in FBL between 
weeks 0 and 4 was not related to the length of the washout period, which was on 
average 14 days with a range from 3 to 42 days. FBL in patients with AS using 
NSAIDs chronically was calculated to be on average 1600 ml per year. 
Discussion 
The prevalence of GI side effects and the quantity of FBL per 24 hours were used 
to evaluate NSAID-induced GI damage in this 48-week study in patients with AS. 
Comparison of ß-cyclodextrin-piroxicam with naproxen showed that both 
treatment groups were not statistically different regarding median daily FBL at all 
four measurement occasions. Comparison with other studies using these drugs is 
difficult, because on the one hand correlations between different methods of 
assessment mucosal damage are moderate and quite variable40"43. In addition, 
dosages of drugs, study period, time of administration and kind of populations 
(patients or healthy volunteers) differed largely. Because a relation was found 
between use of alcohol and FBL44, intake of alcohol was forbidden in most studies 
with healthy volunteers. In most longterm studies with patients as in this study use 
of alcohol was allowed, although it was advised to use alcohol as sparsely as 
possible with at maximum one unit per day. 
As has been shown in many studies23,43, no correlation was found between GI 
complaints and mucosal damage measured as daily FBL. The number of peptic 
ulcers is too small to analyse a possible relation between the amount of FBL and 
the development of peptic ulcers. 
Median daily FBL showed a trend to increase from baseline (week 0) to week 4 
and a statistically highly significant reduction from week 4 to weeks 24 and 48. 
This increase at week 4 and subsequent reduction suggests a mechanism of gastric 
adaptation, which has been observed in animals and humans after aspirin intake24"27, 
and in indomethacine in man29, and could take up to nine weeks to occur26"28. The 
mechanism is thought to be based on an increased epithelial cell regeneration and 
mitoses44. 
In healthy volunteers FBL, measured using the modified HemoQuant Assay38, is 
on average 1.1 ml per 24 hours, with an upper limit of 2.7 ml per 24 hours38, 
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which means that FBL is on average 400 ml per year. In this study FBL was found 
to be larger compared to FBL in healthy volunteers38 and estimated to vary on 
average between 1600 and 1900 ml per year, after gastric adaptation and at 
baseline (week 0), respectively. By measurement of FBL the entire GI tract can be 
evaluated, and the increased FBL, even after gastric adaptation, suggests that a 
larger part of the GI tract is involved than only the gastric and duodenal mucosa. 
FBL at baseline (week 0) did not show a significant difference with FBL at weeks 
24 and 48, besides, no correlation has been found between the amount of FBL and 
the length of the washout period. This might be explained by the fact that low 
grade bowel inflammation has been found to be present in about 70% of patients 
using NSAIDs chronically, and this inflammation might persist for up to 18 months 
after discontinuation of NSAIDs3. Additionally, the prevalence of (subclinical 
inflammatory bowel disease has been reported to be increased in spondylarthro-
pathy30,31, which might be worsened by use of NSAIDs16,17. Therefore, it seems 
worthwhile to study second-line drugs in AS, since these drugs might be less 
haimfull to the GI tract compared to NSAIDs45. Besides, second-line drugs might 
influence the course of (sub)clinical inflammatory bowel disease. 
In summary, there seems to be some evidence for gastric adaptation reflected in 
an increase and subsequent reduction of FBL. Further studies in patients have to be 
done regarding this mechanism of gastric adaptation. The lack of correlation 
between GI complaints and the amount of FBL was in accordance with other 
studies2,23, ß-cyclodextrin-piroxicam and naproxen did not differ in the amount of 
daily FBL and the frequency of Gl-complaints on the longterm. Finally, FBL in 
patients with AS is increased compared to FBL in healthy volunteers, probably 
related to chronic use of NSAIDs and the increased prevalence of inflammatory 
bowel disease. This once more stresses evaluation of second-line drugs in AS. 
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Pseudoporphyria due to naproxen 
Summary 
Pseudoporphyria is a photo-induced blistering disorder with increased skin 
fragility, caused among others by nonsteroidal antiinflammatory drugs (NSAIDs). 
Lesions heal with scarring and milia. Porphyrin screen studies are normal in this 
disease. Histology and immunofluorescence resemble porphyria cutanea tarda. In 
this report we describe a cluster of three cases of naproxen-induced pseudoporphy­
ria, and review briefly previously reported cases induced by naproxen. The 
majority of reported cases involve children. Physicians should be aware of this 
reversible skin disorder. 
Introduction 
Pseudopoiphyria is a blistering disorder with increased skin fragility. It resembles 
porphyria cutanea tarda (РСГ) in its reaction to the intake of certain drugs and 
sunlight exposure, but without disorders in the porphyrin metabolism. Only sunlight 
exposed areas of the skin are involved; face, dorsal surfaces of hands and feet and 
less often the neck sparing the area underneath the chin and behind the ears. 
Mostly blisters heal with scarring and milia. Blisters are subepidermal and histolo­
gy is identical to abnormalities found in PCT. PCT patients lack uroporphyrinogen 
decarboxylase, an enzyme of the haem biosynthesis, by contrast in pseudoporphyria 
porphyrin screen in erythrocytes, urine and faeces is normal. Pseudoporphyria due 
to naproxen was believed to be a rare adverse reaction to the drug, although by 
now a hundred cases have been reported. 
We report here three cases of pseudoporphyria due to naproxen and review 
briefly the literature, the establishment of diagnosis and hypothetical mechanisms. 
Cases 
Case 1 
During holidays at the Canary Islands a 42-year-old white woman experienced 
blistering and skin fragility of the dorsa of both hands, fingers and feet for eight 
weeks. Her medical history included a moderately active ankylosing spondylitis 
since three years and in the past a pityriasis rosea. She had been taking an oral 
contraceptive for several years and naproxen 500 mg b.i.d. for eight months. Before 
she was treated with other nonsteroidal antiinflammatory drugs (NSAIDs), of which 
some caused gastrointestinal side effects. There was no history of hepatitis, 
porphyria or other photosensitivity disorders. Examination of the skin revealed 
small blisters with slight scarring from old lesions. No hyperpigmentation, 
hirsutism, milia or atrophic scarring were present. Laboratory examination, repeated 
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twice, revealed normal liverfunction tests and a normal porphyrin screen in 
erythrocytes, urine and faeces was demonstrated twice. Perilesional skin biopsies 
showed subepidermal bullae formation. Direct immunofluorescence of the perilesio-
nal skin showed aspecific condensation of IgM and Ç, at the edge of the bulla. 
IgG, fibrinogen, IgA and Clq were diffusely deposited in the dermal layer. Indirect 
immunofluorescence revealed no abnormalities. No signs of bullous pemphigoid 
were present. Naproxen was discontinued, but new lesions occurred for another 
eight weeks, thereafter blistering ceased with minimal scarring. 
Case 2 
A 58-year-old white man, who was taking sunbeds regularly for several years, had 
a six-week history of blistering and skin fragility of the dorsa of both hands. His 
medical history comprised a longstanding moderately active ankylosing spondylitis 
and prostatism, without hepatitis, porphyria or photosensitivity disorders. The 
patient reported that be had experienced the same lesions about five to six years 
ago but to a lesser extent and degree. In the past he had been treated with other 
NSAIDs, all discontinued because of inefficacy. On both occasions he was using 
naproxen 500 mg b.i.d. Examination of the skin showed small blisters and some 
old lesions with slight scarring. No other abnormalities of the skin were seen. 
Liverfunction tests, porphyrin screen in erythrocytes and urine revealed normal. 
Skin biopsies were not conclusive because of a sampling error. He decided to 
continue naproxen because of good efficacy, despite advise to stop, and started to 
use a sunfilter when taking sunbeds. Skin lesions healed with scarring within a few 
weeks. Almost 1.5 years later, no new skin lesions occurred despite naproxen use, 
but slight skin fragility remained. 
Case 3 
A nine-year-old white girl with polyarticular systemic-onset juvenile chronic 
arthritis revealed blistering and skin fragility of the face and dorsa of both hands, 
aggravated by sunlight exposure. She had no history of hepatitis, porphyria or 
photosensitivity disorders. She was taking methotrexate 10 mg weekly and na-
proxen 250 mg b.i.d. (20 mg/kg/day). She had not been treated with other NSAIDs. 
Skin examination showed blistering with crustae and scarring of old lesions. 
Liverfunction tests were normal. A skin biopsy was not felt to be justifiable in 
view of the age of the patient and the site of the blistering. After naproxen was 
changed into diclofenac, no new blistering occurred and lesions healed within 
several weeks. 
Discussion 
Though other NSAIDs are known to cause pseudoporphyria as well, the majority of 
cases published were caused by naproxen1"9. A total of 100 cases of pseudopor-
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phyria due to naproxen are known, remarkably 74 of these were children. The 
mean age of children was seven years (range 1-18 years) and of adults age ranged 
from 21 to 84 years. In adults it appeared that mostly women were involved (14 
women versus seven men, five not reported), in most cases involving children sex 
was not reported. Most cases manifested itself during summer, not always clearly 
related to sunlight exposure, three cases occurred after visiting a tanning salon. 
Dose of naproxen in adults was 250 to 1500 mg/day and in children the mean dose 
was 13 mg/kg/day and the use of naproxen ranged from a few weeks to several 
years before onset of pseudoporphyria. Most frequently lesions occurred on the 
dorsal surfaces of hands and feet, in less cases in the face, in a few cases on the 
neck and in one case also on both knees. Scarring usually remained after healing 
but showed a tendency to fade. Porphyrin screening was done in the majority of 
cases and revealed normal. Histology was reported in 16 cases and in 11 of these 
19 biopsies immunofluorescence was done, all biopsies were conclusive for PCT-
like abnormalities. Naproxen was stopped in all patients after which skin lesions 
healed. In 14 cases the time needed for healing was described and was on average 
five weeks (range 1 week to 2 months). 
All three cases described here manifested itself in the summer of 1992, which 
was an ordinary Dutch summer, though one case manifested itself at the Canary 
Islands. Pseudoporphyria due to naproxen was not seen ever before at our clinics. 
Our two adults took part in a 48-week double-blind study comparing ß-cyclodex-
trin-piroxicam (n=30) with naproxen (n=29) in ankylosing spondylitis. One of our 
cases (case 2) differs from other cases in the literature as skin lesions healed while 
naproxen was still being administered but this patient had started to use a sunfilter. 
One case of pseudoporphyria due to nalidix acid behaved similarly10. No porphyrin 
screen was done in case 3, but the causal relation with discontinuation of naproxen 
and subsiding of characteristic skin lesions confirm the diagnosis. 
Although phototoxicity is widely accepted, several hypotheses have been 
developed. Naproxen is known to stabilize the liposomal membrane in vitro and to 
be a potent inhibitor of cyclo-oxygenase. In most hypotheses sunlight plays a 
central role. The inflammation of the sun exposed skin may be due to: a. the 
chemical structure of NSAJDs itself which may induce photosensitization of the 
skin 4,n; b. the release of free oxygen radicals by naproxen which may contribute to 
the phototoxic reaction*·', probably as well aggravated by complement compounds7. 
Other hypotheses suggest that pseudoporphyria patients have minor disturbances 
of haem-biosynthesis leading to symptoms in case of excessive sunlight expos-
ure5,12, perhaps sometimes associated with intake of alcohol5, estrogens5 or eventual-
ly minor skin trauma6. This relation with sunlight exposure is confirmed especially 
in three patients with vitiligo in whom bullae were only present on areas of 
vitiligo12"14. Not only exposure to a high intensity of sunlight may induce pseudo-
porphyria, but also multiple prolonged low-grad exposure may cause skin lesion 
resulting mostly in decreased adhesion of dermis and epidermis9,15. 
It is not easy to explain the larger frequency of pseudoporphyria due to 
naproxen in children (Allen et al6 even reported that 6% of all children using 
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naproxen experienced pseudoporphyria), especially as far less children than adults 
use naproxen. Possibly children experience more frequently trauma of the skin 
during sunlight exposure and are more exposed. 
Pseudoporphyria might be seen as a 'diagnosis per exclusionem'. РСГ, 
epidermolysis bullosa acquisita (EBA) and hydroa vacciniforme must first be ruled 
out as a diagnosis. Clinically and histologically pseudoporphyria are similar, except 
that there is a negative porphyrin screen in pseudoporphyria. In EBA sites prone to 
minor trauma, i.e. dorsae of hands, elbows and knees, are most frequently affected, 
sites which can be involved in pseudoporphyria too. However, histologically in 
EBA deposition of antibodies in the sublamina densa can be seen on indirect 
immunofluorescence analysis16. In addition, treatment of pseudoporphyria contains 
discontinuation of the drug9 in contrast to treatment of EBA, which requires mostly 
administration of corticosteroids and is often unsatisfactory. Especially in children 
hydroa vacciniforme must be considered in the differential diagnosis, related to 
recent vaccination. 
For establishment of the diagnosis the following diagnostic criteria for pseudo­
porphyria have been published by Suarez et al9: a. clinical lesions consisting of 
bullae and erosions on sun-exposed skin; b. granular IgG and Ç, on direct immu-
nofluorescence and negative findings on indirect immunofluorescence analysis; 
these histologic findings resemble those of PCT; and с negative findings on 
porphyrin studies. 
It may be concluded that the pathogenesis of pseudoporphyria due to naproxen 
is still not clear, but there seems to be a relation to sunlight exposure and perhaps 
minor skin trauma. Discontinuation of naproxen is the best treatment. One should 
be aware of this adverse drug reaction, especially in fair skinned patients and even 
more in children. 
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Interaction of ß-cyclodextrin-piroxicam with H2-receptor antagonists 
Summary 
The pharmacokinetic interaction between β-cyclodextrín-piroxicam and Cimetidine 
and ranitidine has been studied under steady state conditions in 16 healthy male 
volunteers, aged 18 - 35 years, at random divided into two groups, ß-cyclodextrin-
piroxicam was administered once daily (20 mg), Cimetidine (400 mg) and ranitidine 
(150 mg) both twice daily, one hour prior to ß-cyclodextrin-piroxicam ingestion, β-
cyclodextrin-piroxicam was studied at 4 different periods, the first and last period 
ended with a washout period, in the 3rd period the H2-receptor antagonist was 
administered concomitantly. Plasma and urine samples were collected regularly at 
each seventh day of a period. Basic pharmacokinetic parameters were calculated 
for piroxicam, Cimetidine and ranitidine, and of each drug the percentage of the 
dose excreted unchanged in urine were determined, including the 5-hydroxy 
metabolite of piroxicam. Data of all volunteers of the different periods have been 
analyzed using paired t-tests, and revealed no statistically significant differences. 
The differences between Cimetidine and ranitidine have been analyzed applying t-
tests on increments of a subset of parameters of the four different periods. No 
statistically significant differences have been found between the two H2-receptor 
antagonists. Pharmacokinetics of Cimetidine and ranitidine were consistent with 
literature. In conclusion, there is no interaction between ß-cyclodextrin-piroxicam 
and the H2-receptor antagonists Cimetidine and ranitidine, under steady state 
conditions in healthy volunteers, absorption of ß-cyclodextrin-piroxicam is unchan-
ged during administration of Cimetidine and ranitidine. 
Introduction 
Nonsteroidal antiinflammatory drags (NSAIDs) are widely prescribed because of 
their antiinflammatory, analgesic and antipyretic effects1. However, they frequently 
cause gastrointestinal (GI) side effects, varying from mild abdominal discomfort to 
peptic ulceration and occasionally hemorrhage2,3. Extensive efforts have been made 
to reduce the prevalence of GI side effects by altering the route or the form of 
administration. However, NSAIDs are known to inhibit prostaglandin synthesis sys-
temically, resulting in vulnerability of the GI mucosa4. Peptic ulcers and NSAID 
gastropathy are treated with H2-receptor antagonists' and proton pump antagonists6, 
without reduced efficacy during concomitant administration of NSAIDs7. By now, 
no preventive effects have been found with H2-receptor antagonist administration8,9. 
Various interactions between NSAIDs and H2-receptor antagonists have been 
reported, recently reviewed by Dixon et al.10. 
Piroxicam is a widely used NSAID in rheumatologic practice. It has a long 
half-life of on average 45 hours (range 30 to 60 hours1112), thus, allowing once 
daily administration. Usually two or more peaks are observed in the concentration-
time profile at two to 12 hours after dosing13. Piroxicam is largely eliminated by 
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biotransformation, namely hydroxylation followed by glucuronidatìon and about 2 
to 8% of a dose is excreted unchanged in urine14,15. Its major, inactive, metabolite 
5-OH-piroxicam is mainly excreted in urine unchanged or as glucuronide16. 
ß-cyclodextrins are able to form inclusion compounds and modify the behavior 
of many drugs in aqueous solution, increasing solubilization, stabilization and 
pharmaceutical availability17, ß-cyclodextrin-piroxicam is the complexed form of ß-
cyclodextrin and piroxicam. This complexation has led to an improved absorption 
in the first two hours1', and a reduced prevalence of GI side effects is suggested 
and found in several studies with ß-cyclodextrin-piroxicam1*'23. Changes in gastric 
pH scarcely influence the dissolution of the ß-cyclodextrin complex. The equilibri-
um of free and ionized drug will shift at larger pH and the amount of ionized, non-
absorbable, drug will increase. Besides the altered absorption kinetics, the pharma-
cokinetic profile of ß-cyclodextrin-piroxicam is similar to that of piroxicam18. 
Anti-ulcer treatments still have to be prescribed and thus possible interactions 
with H2-receptor antagonists might occur. Hj-receptor antagonists reduce gastric 
acid secretion, leading to an increase in gastric pH up to 4 м , thus possibly influenc­
ing absorption of other drugs. Cimetidine and ranitidine are two H
r
receptor an­
tagonists, differing from each other in their structural formula; Cimetidine having an 
imidazole ring and ranitidine having a furane ring25. Cimetidine is weaker than 
ranitidine in inhibiting fT-secretion25'28, and binds more avidly to the haem portion 
of the cytochrome P ^ system of mixed function oxidases, leading to a more 
powerful inhibition of the metabolic pathway of hydroxylation29. This influence on 
the metabolic pathway probably is the basis for the large number of interactions of 
mainly Cimetidine with other drags30,31. Cimetidine and ranitidine are excreted by 
glomerular filtration and tubular secretion, and the percentage of the dose excreted 
unchanged in urine of Cimetidine is on average 7S%32 and of ranitidine 70% to 
78%33,34. Renal excretion might be influenced directly or indirectly by other drags, 
such as NSAIDs. 
The interaction of piroxicam with ranitidine and Cimetidine has been studied in 
rats and humans. In general a clear influence of Cimetidine on piroxicam pharmaco­
kinetics has been observed35"37, and a lack of this interaction with ranitidine38. In 
rats both piroxicam and ranitidine were administered intravenously at high doses, 
and plasma piroxicam concentrations and plasma half-life were significantly 
increased during Cimetidine administration38. Almost similar results were found in 
two studies with healthy male volunteers: in both studies piroxicam was given as a 
single oral dose of 20 mg and Cimetidine 300 mg four times a day35 or 200 mg 
three times a day38. In a 2-way cross-over study in 11 (évaluable) arthritic patients 
both Cimetidine and nizatidine caused a small but statistically significant change in 
the ratio of the areas under the curve (AUC) of 5-OH-piroxicam and of piroxicam 
in plasma37. The authors considered this change clinically not relevant, however, an 
influence on the half-life of piroxicam cannot be ruled out as this was not inves-
tigated. In an intrasubject comparison of 10 healthy male volunteers a small but 
significant increase in the area under the curve (AUC) of 15% was found35. Said 
and Foda38 studied 12 male healthy volunteers, divided into two equal groups, and 
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Table 1. Characteristics of healthy male volunteers (mean ± standard deviation) 
Cimetidine group ranitidine group 
(n-8) (n=8) 
age (years) 25 ± 4 24 ± 3 
body mass index (kg τη"1) 22.4 ± 1.9 22.9 ± 2.5 
weight (kg) 74 ± 9 77 ± 10 
Cimetidine increased the AUC and plasma half-life significantly. Two placebo-
controlled cross-over studies in 18 healthy volunteers were performed by Dixon et 
al36: in the first study piroxicam (20 mg) was taken twice daily for 10 days with a 
single dose of ranitidine (150 mg), in the second study ranitidine (150 mg) was 
administered twice daily with piroxicam (20 mg) as a single dose. No interaction 
between ranitidine and piroxicam was found. 
Up until recently only one study has addressed the interaction under steady 
conditions of both piroxicam and H^-receptor antagonists37. In our study clinical 
practice was mimicked by assessing the interaction under steady state conditions of 
piroxicam as well as of the H2-receptor antagonists, Cimetidine and ranitidine. 
Furthermore, special reference was paid to the influence of the H2-receptor 
antagonists on the absorption kinetics of ß-cyclodextrin-piroxicam. The phar-
macokinetics of both (ß-cyclodextrin-)piroxicam and the H2-receptor antagonists 
were analysed in plasma as well as in urine. Measurements were paired because of 
the known large interindividual variability in piroxicam pharmacokinetics. 
Materials and methods 
Selection of volunteers 
Healthy male volunteers, aged between 18 and 35 years, were selected after 
complete interview, physical examination, routine laboratory tests and an ECG. 
They were excluded if they had evidence of: a. previously experienced side effects 
to NSAIDs or Hj-receptor antagonists; b. history of blood dyscrasias or coagulation 
disorders; с depression or other mental disorders; d. alcohol, nicotine or drug 
abuse; e. use of medication other than study medication one month before the start 
of the study period; f. smoking39,40; g. use of alcohol two weeks previously to 
enrollment in the study. Smoking, consumption of alcohol, and use of medication 
other than study medication was disallowed during the whole study period. 
Study design 
The study was conducted at the department of pharmacology of the Catholic 
University Nijmegen, the Netherlands, after approval of the ethical committee was 
obtained. Volunteers (n=16), enrolled into the study after written informed consent, 
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were allocated to one of the H2-receptor antagonist groups. The allocation proce­
dure41 was guided by the body mass index (weight/height2, kg/m2) and age. 
Characteristics of volunteers are shown in Table 1. 
ß-cyclodextrin-piroxicam (20 mg tablet Brexine* S.A. Nycomed Christiaens 
B.V., Belgium) was given once daily in the morning, and ranitidine (ISO mg tablet 
Zantac*, Glaxo B.V., the Netherlands) and Cimetidine (tablet 400 mg Tagamet*, 
SmithKline French B.V., the Netherlands) were both adminstered twice daily. The 
H2-receptor antagonist was administered one hour prior to ß-cyclodextrin-piroxicam. 
During the first two days of drug ingestion of the three drugs a double dose was 
administered. Tablets were ingested with a 150 ml tap of water. Volunteers were 
supplied with tablets for eight days every period and compliance was checked and 
stimulated by tablet counting. 
Volunteers participated in the study for 40 days, divided into four periods 
during which ß-cyclodextrin-piroxicam was administered (see Figure 1). Every 
seventh day of a period blood samples, starting with a predose sampling, were 
taken at times 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24 hours after ß-
cyclodextrin-piroxicam ingestion. Urine was collected over the following time 
intervals 0-1, 1-2, 2-3, 3-6, 6-9, 9-12, 12-24 hours, starting with a predose collecti-
on. Period 1 and 4 both contained a washout period for ß-cyclodextrin-piroxicam 
starting at the seventh day (see figure 1) and additonial blood samples were taken 
after the last dosing at times 36, 48 and 96 hours and at times 36, 48, 96 and 168 
hours for period 1 and 4, respectively. After the last dosing, urine portions were 
collected in period 1 over the time intervals 24-48 and 48-% hours and in period 4 
over the time intervals 24-48, 48-96 and 96-168 hours for period 4. Additionally, a 
predose blood sample was taken at day 5 of period 2, 3, and 4. In total, of each 
volunteer 70 blood and 39 urine samples were obtained. 
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Figure 1. Schedule of the study 
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The H2-receptor antagonists, Cimetidine and ranitidine, were administered concomi-
tantly during period 3 and at day 7 blood and urine samples were taken, starting 
with a predose sampling, at times 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 13, 25 hours after 
the morning dose. Urine samples were collected over time intervals: 0-1, 1-2, 2-3, 
3-4, 4-7, 7-10, 10-13, 13-25 hours. 
Prior to predose sampling volunteers had to stay fasted overnight Every seventh 
day of a period volunteers were not allowed to leave the clinic until the last 
samples were taken in the evening. After ß-cyclodextrin-piroxicam ingestion meals 
and Quid intake were standardized for 12 hours. Meals were given after 2.5, 5 and 
10 hours after the ß-cyclodextrin-piroxicam ingestion. Fluids supplied were tree of 
caffeine. Side effects were asked for each visit as well as consumption of alcohol 
and tobacco. 
Laboratory procedures 
During the frequent blood sampling over 12 hours, an intravenous catheter was 
used, flushed with heparin solution after sampling. Blood was stored on ice until 
centrifugation at 3000 rpm for 10 minutes. Plasma was collected from each 
specimen and stored at -20° С pending analysis. Urine was collected over the 
defined time intervals, the volume measured and samples stored at -20° С pending 
analysis. 
Analysis of piroxicam 
The development, validation and the analyses of piroxicam in plasma and urine and 
of 5-OH-piroxicam in urine have been performed at the Department for Bioanalysis 
of Pharma Bio-Research Laboratories B.V. (Assen, the Netherlands)42. Procedures 
were in accordance with the guidelines for Good Laboratory Practice as published 
by the US Food and Drug Administration and the Organization for Economical 
Cooperation and Development. 5-OH-piroxicam has been determined after de-
glucuronidation with ß-glucuronidase. 
Analysis of ranitidine and Cimetidine 
Concentrations of Cimetidine and ranitidine were measured by high performance 
liquid chromatography (HPLC) after solid-phase extraction (according to a method 
which will be published in detail elsewhere)43. Briefly, 5 μg of either ranitidine or 
Cimetidine were added as internal standard to 500 ul of plasma or 1000 ul urine. 
Following protein precipitation in plasma with 5% (w/v) metaphosphoric acid, the 
supernatant was brought to pH 2.6 with a phosphate solution containing 0.02 M of 
the ion-pairing agent octanesulfonate and loaded onto a Bond Elut PH Column 
(Analytichem Int., Haba City, CA). After washing the column four times, Cimetidi­
ne and ranitidine were eluted with 0.75 ml of a solution consisting of acetonitrile: 
0.01 M phosphate buffer/0.005 M octanesulfonate (30:70). Urine samples were 
extracted on the same columns, but under alkaline conditions without octanesulfo­
nate, essentially based on a method described by Chiou et al44. Separation of 10 ul 
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eluate was achieved on a Hewlett Packard 5 μιη LiChrosorb RP-18 column (200 χ 
4.6 mm) at 40° С The mobile phase, consisting of a 22:78 mixture of the elution 
fluid mentioned before, was delivered at a rate of 1 ml/min and column effluent 
was monitored at a wavelength of 228 nm. Retention times of Cimetidine and 
ranitidine were 5.9 and 7.6 min, respectively. Peak height ratios were measured and 
linear calibration curves were obtained for concentrations ranging form 0.025 - 5 
pg/ml (r2 > 0.9994). The absolute recovery of Cimetidine and ranitidine was 90% 
with a coefficient of variation less than 2.3%. The mean precision of analysis in 
spiked samples ranged from 4.0 - 0.7% over a concentration range of 0.063 - 2.5 
pg/ml. The lower limit of detection (four times baseline noise) was 10 ng/ml. 
Pharmacokinetic analysis 
For each subject, plasma concentration curves of piroxicam and Cimetidine and 
ranitidine were analysed according to model independent methods. The following 
pharmacokinetic parameters were calculated: elimination rate constant (K.,), 
calculated by log-linear regression analysis of the terminal phase of the curve (of 
periods 1 and 4); half-lives (tM); areas under the plasma concentration time curves 
(AUC), determined by the linear trapezoidal rule; volumes of distribution (Vjj/F = 
Dose/k.|*AUC; F = bioavailability). Time to peak concentrations (t„,„) and peak 
concentrations (C
m
„) were calculated by using the first peak for C
m m i, and !„,„_, 
and the second peak for С
ш
„
 2 and t , ^ 2. Oral clearance of piroxicam was cal­
culated as CLR = Dose/AUC. Renal clearance (CLR/F) of the H2-receptor an­
tagonists was calculated from the average value of the renal excretion rate divided 
by the midpoint plasma concentration of three different urine collection intervals, in 
the descending phase of the curve. 
Furthermore, the mean residence time in steady state (MRT = (AUC*t + T* 
(C
m
)ss/k
el)/AUC; T=dosing interval; (Cm)„=concentration of the last sample of the 
dosing interval)45 and the steady state volume of distribution (V„/F) of piroxicam 
for each period were calculated, applying statistical moments theory44. 
Cumulative urinary excretion and the percentage of the dose excreted were 
calculated for piroxicam and 5-OH-piroxicam. Creatinine was measured in all 24 
hours urine portions to check completeness of urine collection. 
Statistical analysis 
A number of pharmacokinetic parameters calculated for piroxicam in plasma and 
urine and for 5-OH-piroxicam in urine were mutually dependent. Therefore, a 
subset of parameters was selected for statistical analysis in order to avoid multiple 
testing, and thus reduce the probability of false significancies. 
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Figure 2a. Plasma concentration time course 
Piroxicam (mg/l) 
ί a. . Ν 
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The plasma concentration time course of one volunteer is shown in this figure. The dotted lines, 
calculated by log-linear regression, are used for determination of k^  for the plasma half life 
Figure 2b. Pharmacokinetic profile of piroxicam 
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For evaluation of the interaction between piroxicam and the two H2-receptor 
antagonists paired t-testing was applied to the following parameters of all 16 
volunteers: periods 1 and 2: AUC, the percentage of the dose in urine of piroxicam 
and 5-OH-piroxicam; periods 2 and 3, periods 3 and 4, and periods 2 and 4: AUC, 
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C„,„,i, Cma2, t^^, ^ ¿ , and the percentage of the dose in urine of piroxicam and 
5-OH-piroxicam; and of periods 1 and 4: t^, MRT, and Vjj/F. 
To evaluate the differences between the influence of the two H2-receptor 
antagonists on piroxicam pharmacokinetics, the increments of the same subgroup of 
parameters were analysed using t-tests. Calculation of these increments reduces the 
influence of intersubject variability. 
Results 
Figure 2a shows a representative pharmacokinetic profile of piroxicam in plasma of 
a volunteer over the whole study period. The profiles of the 24 hour curves of 
piroxicam - in total 64 curves - showed two to four peaks (Figure 2b). For all 16 
volunteers, the pharmacokinetic parameters of the four periods are shown in Table 
2. 
Paired t-testing revealed only statistical significant changes in the AUC from 
period 1 to 2, and of t,,,,,
 2 from period 3 to 4 (marked in Table 2). The comparison 
of the influence of the two H2-receptor antagonists on the piroxicam pharmacokine-
tics, analysed by using the increments between the different periods in a subset of 
parameters, 
For analysis of the influence of the two H^receptor antagonists on piroxicam 
pharmacokinetics, the increments between the different periods were calculated and 
showed large ranges of most parameters (see Table 3). None of the parameters, 
selected for statistical analysis, were significantly different, and p-values found 
varied from 0.11 to 0.98. 
Pharmacokinetic parameters of Cimetidine and ranitidine are shown in Table 4. 
Half of the volunteers showed pharmacokinetic plasma profiles with two peaks. 
Pharmacokinetic parameters calculated were consistent with literature33'34'47'52. 
Discussion 
The interaction between ß-cyclodextrin-piroxicam and two H2-receptor antagonists, 
Cimetidine and ranitidine, has been studied under steady state conditions of both ß-
cyclodextrin-piroxicam and the H2-receptor antagonists in healthy volunteers, thus 
mimicking clinical practice. The study design allowed intrasubject comparison of 
parameters of piroxicam, eliminating the effects of the known large variability in 
piroxicam pharmacokinetics between subjects. Changes in the pattern of metabolite 
formation were determined by measuring 5-OH-piroxicam in urine over regular 
time intervals before, during and after administration of the H2-receptor antagonist. 
Pharmacokinetics of piroxicam in plasma were consistent with those reported in 
other studies with healthy volunteers. The percentage of the dose of piroxicam 
excreted unchanged has been reported previously and estimated to be 2 to 5%15. In 
64 
Cimetidine 
8.41 ± 1.40 
2.4 ± 0.7 
160 ±35 
9 ±14 
2.8 ± 0.5 
13 ± 0.2 
1.7 ± 0.9 (n-4) 
2.7 ± 0.6 
6 4 ± 8 
ranitidine 
2.80 ± 0.57 
2.9 ± 0.6 
234 ±75 
29 ± 6 
0.46 ± 0.07 
2.0 ± 0.7 
0.51 ±0.09(n=5) 
4.0 ± 0.6 
45 ± 10 
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Table 4. Phannacokinetíc parameters Cimetidine and ranitidine 
parameter 
AUC (mg.h.r" 
V F ( 1 ) 
CU (l.h') 
C„ b l (mg.11) 
t^., (h) 
C „ j (mg.r') 
«™л (h) 
% of dose excreted in urine 
our study this percentage was even less than 1% over a period of 24 hours after 
dosing. 5-OH-piroxicam, measured after de-glucuronidation with ß-glucuronidase, 
was excreted in urine for about 20 to 25% and this was in line with the percentages 
published recently by Milligan et al.37. 
Pharmacokinetic parameters are mutually dependent, although a subset of 
primary parameters can be identified. In this way multiple testing can be avoided, 
and the probability of false significance reduced. To eliminate intersubject variab-
ility in pharmacokinetics of piroxicam, influences of the Hj-receptor antagonists 
were evaluated by applying t-tests to increments between the different periods. 
The AUC showed a significant difference between periods 1 and 2 (see Table 2), 
although volunteers were loaded with a double dose of ß-cyclodextrin-piroxicam 
during the first two days. Probably steady state has not been reached at day 7 in 
period 1, however as calculated from the volume of distribution, steady state 
concentrations should have been approximated closely by the loading dose. There is 
no reason to doubt that all volunteers were less or non-compliant in the period 1 
than later in the study. The statistical difference found, however, does not interfere 
with the analyses and conclusions of the study. The comparison between periods 2 
and 3, and between periods 3 and 4 are the most important. 
Absorption kinetics of ß-cyclodextrin-piroxicam was not altered significantly 
due to Cimetidine or ranitidine administration. The time of the second peak ( t ^
 2) 
of piroxicam follows about one hour after volunteers had their breakfast, probably 
related to emptying of the gallbladder and the supposed enterohepatic re-circulation 
of piroxicam. The drop in t ^
 2 in period 3 might be attributed to an interaction as 
a result of a changed gastric motility due to an increased gastric pH. It might be 
suggested that the subsequent increase in !„,„,
 2 after discontinuation of the H2-
receptor antagonists points out a possible rebound phenomenon in gastric acid 
production, which could accelerate gastric motility. 
Glucuronidation of a drug can take place in the liver and in the kidney. To 
study the interaction of the I^-receptor antagonists on glucuronidation in the liver 
as well as in the kidney, concentrations of 5-OH-piroxicam in urine were measured 
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after de-glucuronidation. Measurement of the concentration of 5-OH-piroxicam in 
plasma separately would give no additional information concerning the route, i.e. 
liver of kidney, of glucuronidation. In this study the percentage of the dose of 5-
OH-piroxicam excreted in urine was not influenced by the H2-receptor antagonists. 
It can be concluded that both Cimetidine and ranitidine do not give a clinically 
relevant interaction with piroxicam. The 95% confidence intervals of the increments 
calculated between the different periods of pharmacokinetic parameters are large 
and, therefore, differences between the two Hj-receptor antagonists have to be quite 
large to reach significance. Previously an increase in the half-life35 3B and of the 
AUC38 has been found due to Cimetidine administration. The increase in the AUC 
has not been confirmed by Milligan et al37, although in this study the ratio of the 
AUCs of 5-OH-piroxicam and of piroxicam in plasma changed significantly for 
both Cimetidine and nizatidine37. Nizatidine has an inhibitory effect on the enzyme 
cytochrome ¥4X about ten times less potent compared to Cimetidine31. Therefore, it 
is surprising that both drugs showed significance as only influence of Cimetidine 
might be expected. 
The lack of an interaction might be explained by the fact that cytochrome P^, 
is known to comprise multiple isoenzymes53,54. The isoenzymes inhibited by 
Cimetidine53 differ from the isoenzyme responsible for the oxidation of NSAIDs55,56. 
Therefore, piroxicam might be oxidated by an isoenzyme for which Cimetidine has 
a low affinity, resulting in a lack of interactioa 
In this study healthy volunteers have been studied, and results apply for patients 
with a normal liver and kidney functioa The only study available in patients 
included arthritic patients which apparently not had a very active disease reflected 
in albumin concentration of on average 40 g.l"1 37. Additional information about 
liver and kidney function was not provided in this study37. In summary, our study 
satisfactory ruled out the possibility of an effect in man of the two Hj-receptor 
antagonists, Cimetidine and ranitidine, on the kinetics of piroxicam and the ab-
sorption kinetics of ß-cyclodextrin-piroxicam. 
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2nd-line treatment in SSpA 
Summary 
The literature concerning second-line treatment of seronegative spondylarth-
ropathies (SSpA) from 1940 to August 1993 has been reviewed. Sulfasalazine 
(SASP) appeared to be effective in the treatment of ankylosing spondylitis, and 
promising in reactive arthritis (ReA) and Reiters' syndrome (RS). Methotrexate and 
azathioprine were associated with a remarkable improvement in some cases of AS 
and RS. Methylprednisolone and levamisole were both efficacious in AS, but 
levamisole was associated with occasional severe side effects. Radiation therapy 
led to short-term improvement in AS, but was abandoned because of severe long-
term side effects. Only sulfasalazine has been studied in sufficient detail to allow 
definitive conclusions, but methotrexate and azathioprine may be promising drugs. 
Introduction 
The seronegative spondylarthropathies (SSpA) include a broad spectrum of 
diseases, such as ankylosing spondylitis (AS), Reiters' syndrome (RS), reactive 
arthritis (ReA), psoriatic arthritis (PsA), arthritis related to inflammatory bowel 
disease (IBD), Whipples' disease and Behçets' syndrome1. Overlap syndromes also 
occur, and some cases cannot be classified. As present classification criteria are 
limited, new criteria are currently being developed1. 
In general, patients with SSpA can be divided into two major groups; a. 
patients with inflammatory spinal disease (sacroiliitis and spondylitis) and b. 
patients with primarily peripheral, asymmetric synovitis1,2. A high prevalence of 
HLA-B27 is seen in both groups1,3·4. Psoriasis, acute anterior uveitis (AAU), 
enthesopathies3'4, balanitis, urethritis and oral ulcers are common extra-articular 
features. 
SSpA is generally not associated with systemic malaise, fatigue and disability 
as seen in rheumatoid arthritis (RA). Hence, the administration of second-line drugs 
are used less common in SSpA. Nonetheless, second-line drugs have been adminis-
tered to some patients with a severe SSpA over the last three decades. It is most 
likely that this drug regimen partly reflects the natural course of this group of 
diseases; in a minority of cases the disease will have a continuous and unremittent 
course of SSpA, leading to a need for almost continuous drug administration3. 
In this article we summarize the literature concerning use of second-line 
treatments, including second-line drugs and radiation therapy in AS, RS, ReA and 
EBD-related arthritis. Because most studies in PsA6"17 include only patients with 
active peripheral arthritis, in whom only 20% have sacroiliitis1''21, PsA is not 
included in detail. Each treatment will be reviewed separately, starting with the 
results of double-blind studies, followed by open studies and case reports. When-
ever possible the type of arthritis, disease duration and the variables in which 
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improvement was seen are indicated. Finally, we conclude with suggestions for 
further studies of SSpA. 
Materials and methods 
A literature search was conducted to identify all reports concerning use of second-
line drugs - hydroxychloroquine, gold, d-penicillamine, sulfasalazine, methotrexate, 
cyclophosphamide, 6-mercaptopurine, azathioprine, cyclosporine and levamisole as 
well as radiotherapy, methylprednisolone and coiticotrophin - in seronegative 
spondylarthropathies. Our search included AS, RS, EBD-related arthritis, ReA, 
unclassified SSpA and not PsA. 
All general articles on SSpA in English, French and German were reviewed, 
and relevant references, dating from 1940 up to August 1993, identified. Further 
search was undertaken using Medline on CD-ROM from 1966 to July 1993. We 
excluded editorials and papers based only on retrospective data collection. If the 
same set of data was published by the same authors in different journals, we chose 
only the article which appeared in the journal having the greatest impact factor22. 
Papers were included only if patients, methods and results were described, with 
sufficiently detailed data on patient characteristics and on the method of data 
collection; i.e. whether the paper concerned case reports, open uncontrolled studies 
or clinical trials, and the duration of follow-up. In the case of an open study or a 
clinical trial, we required enumeration of inclusion and exclusion criteria as well as 
the statistical methods used for data analysis. 
Results 
Hydroxychloroquine 
This drug has not been studied in relation to SSpA. Only Giordano23 described two 
AS patients with frequently recurring acute anterior uveitis (AAU) in whom attacks 
of AAU did not recur for at least 10 months and whose AS symptoms improved 
after starting hydroxychloroquine 400 mg daily. Side effects were not reported. 
D-penicillamine 
Conflicting reports have been published concerning the efficacy of d-penicillamine 
in AS. In a double-blind placebo-controlled trial, carried out over a six-month 
period on 17 AS patients, 13 of whom had peripheral AS, d-penicillamine was 
reported to be ineffective24. The drug was begun at a dose of 125 mg per day and 
increased monthly up to 750 mg per day. Objective and subjective variables of 
disease activity were assessed monthly. Despite randomization, the placebo group 
had less severe disease upon entering the trial, reflected in the number of inflamed 
joints and morning stiffness. The mean duration of the disease in the group treated 
with d-penicillamine was 16 years (range 8-28 years) versus nine years in the pla-
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cebo group (range 1-26 years). 
In a nine-month-long open study of 49 AS patients (17 with peripheral AS) 
Bemacka et al found a significant improvement in spinal mobility and the number 
of swollen joints, but not in the ESR. The results are in marked contrast to the 
double-blind study, although interpretation is complicated by hospitalization and 
physiotherapy2"6. All 17 patients with peripheral arthritis improved. 
In these two studies three patients experienced side effects, consisting of an 
allergic reaction, a blistering rash and diarrhea with abdominal pain. Similar 
contradictory results have been found in many case reports of patients with axial as 
well as peripheral AS27"31. 
In a case report d-penicillamine proved to be an effective treatment in two 
patients with IBD-related sacroiliitis, both of whom unable to tolerate treatment 
with NSAIDs28. 
Gold 
No placebo-controlled studies with intramuscular gold salts in SSpA are available. 
In a clinical report of 128 AS patients, six out of 18 patients with peripheral 
arthritis, who were treated with intramuscular gold salts, experienced major benefit, 
and two others minor benefit32. One RS patient was successfully treated with 
intramuscular gold up to a cumulative dose of 2.835 mg33. No side effects were 
reported. 
The oral gold compound auranofin was studied a placebo-controlled multi-
center trial, double-blind for six months and single-blind for six additional months. 
In the final six months the auranofin dosage could be increased from 6 mg to 9 mg 
daily. Of the 60 patients, 55 could be evaluated. No difference could be found 
between treatment with auranofin or placebo in clinical or laboratory variables, 
although an improvement could be seen in all ten AS patients with peripheral 
arthritis, termination of treatment because of side effects was seen in 11.6% of 
patients34; the most frequently reported side effects were diarrhea and soft stools. 
Sulfasalazine 
Sulfasalazine (SASP) has been shown be effective in placebo-controlled double-
blind studies in both axial and peripheral AS (see Table la). Dougados et al 
performed a trial in 60 patients, nine of whom had peripheral AS, using a daily 
dose of 2 g of SASP. The two treatment groups showed distinct differences from 
the third month of treatment. At the end of the study improvement in a functional 
index, daily NSAID dose and immunoglobulin levels was seen in 15 of the 25 
SASP-treated patients who were available for evaluation. SASP treatment was 
discontinued in eight patients as a result of side effects39. Another double-blind 
placebo-controlled 12-week study of 37 patients revealed improvements in the 
SASP-treated group after eight weeks36. Five almost similar trials were published 
using average doses of 2 g37"41. All studies lasted at least 12 weeks, and all but 
one41 study indicated efficacy, although the mean disease duration in this study was 
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Table lb. Nature of side effects during S ASP treatment* 
symptoms/number of patients 
rash 
rash + fever 
oral ulcers 
gastrointestinal complaints 
liver function disturbances 
diarrhea 
anemia 
leucopenia 
headache 
dizziness 
headache + dizziness 
depression 
pruritus 
total number of patients 
withdrawal of SASP 
3 
3 
1 
11 
2 
1 
1 
3 
8 
2 
0 
1 
1 
37 
continuation of SASP 
0 
0 
0 
23 
0 
0 
0 
0 
5 
1 
2 
1 
0 
32 
* references 35 to 42 
total number of patients: 430 
relatively long (20 years)41. Only Nissila included a large number of patients with 
peripheral AS (55 out of 85); no significant difference in efficacy was found 
between axial and peripheral AS3*. A 24-week interventional study of 20 patients 
with peripheral AS indicated relapse after withdrawal of SASP in the majority of 
patients (60%)42. Improvement in a reduction of pain, stiffness, sleep disturbance, 
fingertip-to-floor distance and chest expansion was observed in almost all studies. 
Quite different measurements were used for spinal mobility. Peripheral arthritis and 
laboratory variables also were improved. The mean time interval between the 
initiation of SASP treatment and significant improvement was not specified in most 
of the studies. The prevalence of side effects was relatively low: 10% of patients 
had to terminate treatment and another 10% of patients experienced dose-dependent 
and/or transient side effects (see Table lb). 
A meta-analysis of five randomized, double-blind, placebo-controlled trials33'39 
demonstrated that SASP can be a safe and effective drug in the short-term treat-
ment of AS and they found no evidence of a different response between axial AS 
and peripheral AS43. In two open studies44,45 and 10 reported cases46,47 the majority 
of patients experienced benificial effect to SASP treatment 
Two placebo-controlled studies, one open study and several case reports were 
available on use of SASP in ReA. Both placebo-controlled studies reported 
beneficial effects due to SASP treatment*8,49; joint pain, number of swollen joints, 
spinal pain, ESR, CRP and immunoglobulins improved in the SASP-treated group 
compared to the placebo-treated group, although differences were statistically 
significant in only one study49. 
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Two open studies44"50 and the three case reports47 indicated efficacy and toxicity 
of SASP in ReA similar to those in the placebo-controlled studies. 
A group of 15 HLA-B27 positive ReA patients (12 men, 3 women, mean age 
13 years; range 10-25 years), were treated for an average of 13 months (range 3-36 
months). After 3-6 months, all patients showed significant improvement in objecti-
ve and subjective variables. Within 3-12 months 11 patients went into remission 
and all the remaining patients improved. No significant adverse reactions were 
encountered51. 
In an open uncontrolled study of 16 patients with RS greater improvement was 
seen than in a group of AS patients studied simultaneously. None of these RS 
patients experienced side effects47. 
One 6-month placebo-controlled double-blind study (n=351)52 and one open 
study with a follow-up of 28 months (n=37)53 were performed of SASP, 2 to 3 g 
daily, in SSpA. Greater efficacy was seen in the group treated with SASP, although 
the changes were not statistically significant in the double-blind study. Side effects 
were observed in 28 and five patients, respectively, in the two studies. 
Methotrexate 
A one-year open study of 10 AS patients (mean age 32 years, mean disease 
duration 11 years) with active axial arthritis treated with MTX 12.5 mg i.m. weekly 
indicated favorable results54. Nine patients completed the study and one dropped out 
due to a lack of effect. It was possible to either reduce or terminate NSAID 
treatment in most patients. Dose dependent side effects were observed in eight 
patients, including elevated liver function tests (n=4), dizziness (n=4) and dyspeptic 
syndrome (n=5). Prior to this study, four other patients (two axial AS, two periphe-
ral AS) were reported to have been treated succesfully with weekly doses of MTX 
(7.5-15 mg)55Jí. Nausea and headache were observed as side effects (n=l) which 
resolved after treatment with leucovorin. 
During the period covered by this review 33 patients with RS who were treated 
with MTX were reported57'73. Most of these patients had experienced failure of 
treatment with NSAIDs or corticosteroids. The MTX dose varied from 2.5 to 25 
mg daily during six to seven days in total or from 7.5 to 50 mg weekly for at least 
three months. Administration was oral, i.v. or i.m. Treatment with NSAIDs, 
etrenitate (Tigason*: a synthetic analogue of retinoid acid, of which acitretine 
(Neotigason*) is its free acid and main metabolite) or steroids was usually continu-
ed. Significant improvement in arthritis was observed in 25 (78%) patients (n=32: 
one patient could not be evaluated). A good or even dramatic response of mucocu-
taneous lesions to MTX treatment was seen in all patients, generally observed 
within two weeks of onset of treatment No improvement of arthritis was observed 
in seven of the 32 patients, and one patient temporarily relapsed within six weeks, 
after which treatment with azathioprine was commenced. In reports indicating the 
time-course, improvement began within six weeks, but many case reports did not 
specify the interval from treatment onset to improvement. The prevalence of MTX 
side effects was low; four (12%) patients had to terminate MTX due to oral ulcers, 
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liver function disturbances and anemia combined with leucopenia. All side effects 
resolved after withdrawal of treatment One patient experienced peripheral neuropa-
thy, which was not improved after discontinuation of MTX*'. Two other patients 
had transient liver function disturbances, but treatment could be continued. 
Cyclophosphamide 
No controlled studies are available on cyclophosphamide (CCP) in SSpA, and the 
results of open studies are conflicting. In one study in 12 hospitalized patients with 
peripheral AS who had a high disease activity and failure of treatment with 
NSAIDs, 200 mg CCP was administered intravenously every other day during the 
three weeks of hospitalization, followed by 100 mg weekly orally. Within the first 
three weeks of treatment, significant improvement was seen in pain, swelling of 
peripheral joints and ESR (90.3 to 50.6 mm/lst hour). The least satisfactory results 
were obtained with three patients who had amyloidosis. Side effects included 
erythrocyturia (n=l) and leucopenia (n=l)74. Similar efficacy was observed in six 
patients (5 AS, 1 RS), treated with 200-400 mg CCP daily75. However, a lack of 
efficacy was found in another study of seven AS patients, treated with CPP 200 mg 
daily up to a total dose of 6 to 8 g, followed by 100 mg daily for 40 weeks76. CCP 
was used as a local intraarticular treatment for ten patients with peripheral AS. 
Joints were injected on average 2.6 times. Efficacy was seen in eight patients, 
although 4 of them relapsed77. CCP combined with steroid treatment was found to 
be beneficial for articular and extraarticular symptoms, in a 29-year old male AS 
patient with progressive cardiac failure due to aortitis78. 
6-Mercaptopurine 
A short course of 6-mercaptopurine was efficious in one RS patient with extensive 
skin lesions33. 
Azathioprine 
A 16-week placebo-controlled cross-over study was performed of treatment with 
azathioprine (AZA) of eight patients with RS, using AZA 1 mg/kg in the first 
month and 2 mg/kg in the second month. The joint score was reduced during the 
AZA treatment and increased during the placebo period. NSAJD use could be 
reduced during AZA therapy. Two patients withdrew, one because of nausea and 
one because of a lack of effect (placebo)79. In one open uncontrolled study of nine 
patients with AS who had not responded to NSAIDs, AZA, administered at 200 mg 
per day up to a total dose of 6 to 8 g, followed by 100 mg daily, was effective. All 
variables improved. No side effects were mentioned75. 
In two cases of RS treatment with AZA has been reported, both were fatal due 
to complications of the disease (amyloidosis) and treatment (infections)64,67. 
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Levamisole 
Randomized placebo-controlled studies of treatment with levamisole of 22 patients 
with AS and 31 patients with RS have been reported. Both studies were conducted 
over 24 weeks. The dose of levamisole varied from 50 to 150 mg on 2-3 consecuti-
ve days weekly. Early morning stiffness and pain were improved significantly 
within three months in the group treated with levamisole, as was spinal mobility in 
a minority of patients80·81. Nine of 53 patients had to terminate treatment due to a 
rash and gastrointestinal symptoms, liver function disturbances, severe leucopenia 
(n=2), and agranulocytosis (n^)80,81. Results were contradictory in two open 
studies, in which leucopenia and allergic skin reactions were observed as side 
effects'2·". 
Levamisole was used to treat three patients with RS: the dose was 50 mg on 
two consecutive days per week in two patients and 150 mg daily in the third. All 
three patients experienced an almost complete remission of arthritis, ocular, 
mucocutaneous and urethric symptoms"4. 
A relation between agranulocytosis and HLA-B27 during levamisole therapy 
was observed in one study in RA", which was not confirmed by another study86. 
The high frequency of HLA-B27, on average 75-80%87'89, might suggest an 
increased risk of severe side effects. However, agranulocytosis was seen only once 
in the reports available. 
Other treatments 
Methylprednisolone 
Recently a double-blind study was published in which 17 AS patients were treated 
with two different doses of methylprednisolone (MTP) i.V.: 375 and 1000 mg. MTP 
was administered on three consecutive days and patients were monitored for up to 
180 days. No significant differences were observed between the two treatment 
groups, although there did appear to be a trend to a more marked and longer effect 
in the high-dose group88. 
Four open uncontrolled studies with MTP on a total of 21 AS patients (5 
peripheral AS) have been reported89"92. In general, a reduction of pain and stiffness 
was seen after one pulse lasting for up to six weeks. Treatment with several pulses 
led to improvement in most variables, including pain, stiffness, spinal mobility, 
ESR, acute phase proteins, IgA and IgM, although not all changes were statistically 
significant. Efficacy was not influenced by more than three pulses in one course90. 
One patient with peripheral AS withdrew due to a lack of efficacy91; the effects on 
peripheral joint activity was not described separately in those patients. 
Overall, no serious side effects were observed, although one patient developed 
melena six weeks after MTP treatment with concomitant administration of indome-
thacin'8, and two patients experienced attacks of tachycardia, not related to dose88. 
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Table 2. X-ray treatment in ankylosing spondylitis 
η % of patients 
improved 
follow-
up 
(years) 
duration of improve­
ment 
remarks 
Smyth 
1941"" 
Kuhns 
1946107 
Toone 
1948"" 
Richmond 
1950"" 
Desmarais 
1953'°° 
Sharp 
19541И 
Wilkinson 
1958"" 
52 
98 
28 
160 
70 
332 
200 
72% 
85% 
68% 
96% 
64% - 95% 
70% 
84% 15 
only 20 patients of 
370 relapsed 
56 patients(± 20%) 
relapsed within 6 
years 
after б months: 84% 
after 1 year 43% 
after 10 years: 22% 
'placebo-controlled' 
case-control study of 
370 arthritic patients 
early AS best results 
'placebo-controlled', 
different doses used 
study in 102 arthritic 
patients 
atypical AS did not 
respond well 
spondylitics with more 
extensive disease and 
especially peripheral AS 
did not respond well 
Fulton 
1961'" 
Rosen 
1962" 
Sambrook 
1963"2 
Mason 
1964'04 
Kinsella 
1966'» 
Hohl 
1969"° 
Schuler 
1969"" 
Sinclair 
1971'" 
573 
68 
110 
243 
14 
33 
200 
157 
63% 
58% 
76% 
90% 
the majority 
93% 
90% 
95% 
> 5 
> 4 
> 10 
> 5 
1 
> 11 
2 - 2 2 
after 5 years: 
high dose: 62% 
low dose: 31% 
after 1 year: 62% 
after 3 year 25% 
< 10 year 50% had to 
be treated again 
1 - 5 years: 88% relief 
of symptoms 
less than 2 years 
88% 
> 1 year 74% 
> 2 years: 34% 
> 3 years: 12% 
different doses used, 
different sizes of radia­
tion fields 
early AS best results 
cross-over with drug 
treatment 
matched controls were 
studied 
a subgroup of 22 pa­
tients was studied for 
up to 2 years before 
starting radiation 
therapy 
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Corticotrophin 
Coiticotrophin (ACTH) has been reported not to be effective in a placebo-control­
led study of 21 patients with AS93. Patients were admitted for two weeks of 
bedrest, postural and mobilizing exercises and daily i.m. injections of ACTH (20 
ГО for seven days, 10 Ш for five days) or placebo (0.5 ml normal saline). Clinical 
assessments on admission, immediately after discharge and two months thereafter 
furnished no evidence of advantage to ACTH administration. Side effects were seen 
in five patients, comprising a weight gain of at least 2.5 kg (n=l), acne (n=l) and 
reactivation of genital herpes (n=l). The drug treatment could be maintained 
throughout the study. 
Radiation therapy 
Several forms of radiation have been used therapeutically in AS, i.e. roentgen 
therapy, Thorium X, and local radiation therapy. These treatments will be discussed 
briefly below (we will not discuss use of radioactive baths). 
Roentgen therapy 
Use of radiotherapy in AS was quite frequent in the 1940s, but has been replaced 
by analgesics and anti-inflammatory drugs. Only open uncontrolled studies have 
been published. Roentgen therapy was finally abandoned because of serious long-
term side effects, particularly an increased risk of malignancies'4'9'. Most studies 
are thus somewhat dated and describe patients, methods and results in a different 
way than is common today. All studies report a general improvement, defined by 
reduction of pain and stiffness, improvement of spinal mobility and chest expansi­
on, a drop of ESR and a reduced consumption of analgesics (see Table If2·100·113. 
Thorium X (224Radium) 
Thorium X, a disintegration product of thorium, has been used in the treatment of 
AS. Its half-life is 3.85 days and the emitted radiation is largely made up of alpha 
particles (92%), the remainder being beta and gamma rays114. Hemaman-Johnson 
reported two AS cases which were treated successfully with i.v. Thorium X115. 
In Germany the isotope has played an important role in the treatment of AS. 
Koch found an improvement in 120 patients with AS, including a decrease in ESR 
and increase of chest expansion. One year after treatment 75% of patients were still 
free of symptoms"6. Twenty years after treatment these patients were studied 
retrospectively. Compared with a group of patients who had not received thorium X 
treatment, efficacy seemed to favor the Thorium X-treated group117, confirmed in 
other studies on a total of 247 AS patients118'123. No data are presented concerning 
long-term side effects, and treatment was abandoned. 
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Local radiation therapy 
Local irradiation has been used as therapy in SSpA and HLA-B27 related arthropa­
thies. Improvement was observed in IS out of 21 patients treated; 13 patients 
experienced complete remission, with two partial responders. Follow-up ranged 
from two to 43 months124,125. 
Discussion 
Our review of the literature on second-line treatment in seronegative spondyl-
arthropathies has yielded a large number of case reports, but only a few double-
blind (placebo-controlled) clinical trials. No definite conclusions can thus be drawn 
from the available literature, other than the established efficacy of SASP in AS. 
Furthermore, many of the reports have been biased, as unsuccessful treatments 
('negative results') often remain unpublished. In addition, many studies may 
include a type Π statistical error as the number of patients often was small126. 
Of all the treatments, only SASP has been studied in sufficient detail to allow 
conclusions to be drawn. Most35"3*'*0 placebo-controlled double-blind studies of AS 
indicated improvement in the SASP-treated group. In general no significant 
difference was seen between peripheral and axial AS, although efficacy was more 
obvious in peripheral AS. In the studies performed by Kirwan et al41 and Corkill et 
al38 no beneficial effects in spinal mobility were found during a three-year study, in 
contrast with an improvement observed in peripheral arthritis; however, all patients 
had long-standing AS (mean disease duration 20 years). Improvements were 
primarily observed mainly in pain and severity and duration of morning stiffness. 
Chest expansion was the only objective variable which was improved in most 
studies. A meta-analysis43 of five placebo-controlled double-blind studies35'39 allows 
the conclusion to be drawn that SASP is a safe and effective treatment for AS, 
albeit disease duration was not evaluated in this meta-analysis. In RA it was found 
that responders to SASP therapy had significantly shorter disease duration than 
nonresponders127. Although this observation has not been firmly demonstrated in 
AS, a trend was seen in that patients with early AS were more likely to respond to 
SASP than patients with longstanding AS12". 
In severe RS, methotrexate was found to induce an improvement in arthritis and 
in mucocutaneous lesions58'73. In AS, MTX was reported to be effective in 13 
severe cases
54
"
56
. Only a small number of side effects were reported, all resolving 
after discontinuation of the drug or dose reduction. 
Methylprednisolone pulse therapy, when administered as three pulses, was 
reported to be effective in AS88"92. 
Levamisole was beneficial in AS, but led to intolerable number and severity of 
side effects8*82. 
It can be concluded that the efficacy of SASP has been sufficiently established 
in the treatment of AS, that this will be the drug of first choice, if treatment with 
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NSAIDs fails. Among other second-line drags in the treatment of SSpA, MTX and 
AZA show promise, but no other conclusions can be drawn. Due to its severe long-
term side effects, radiation therapy has been abandoned, but it might perhaps play a 
role as a local therapy for refractory entheseopathies124,125. In view of the findings 
in respect of radiation therapy, local radiation therapy should be reserved for cases 
of severe complications of SSpA, e.g. spondylodiscitis or enthesitis, which fail to 
respond to all other treatments. Арал from this, radiosynovio-orthesis in chronic 
and refractory peripheral arthritis may be introduced in the same way as it is used 
in RA. 
Some goals of the treatment of chronic diseases, including the reduction of 
symptoms and joint destruction, improvement of functional capacity and quality of 
life, might be achieved using second-line treatment in SSpA. The final balance 
between efficacy and toxicity can only be determined by studies which still remain 
to be performed. 
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Methotrexate in severe ankylosing spondylitis: 
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MTX in severe AS 
Summary 
Efficacy and toxicity of methotrexate (MTX) in ankylosing spondylitis (AS) were 
studied in a 36 week open, single observer study. Patients were seen 4-weekly and 
variables were assessed for disease activity and toxicity. Patients, included, had to 
have evidence for an active disease and failed to response to nonsteroidal antiin-
flammatory drugs (NSAIDs) and sulfasalazine (SASP). MTX was administered 
weekly at an oral dose of 7.5 to 15 mg. Patients were treated with MTX for at least 
24 weeks, while NSAIDs were kept at a stable dose. Efficacy was evaluated in two 
ways: by calculating the relative difference of assessed variables between weeks 0 
and 24; and by asking the patient at week 24 whether he or she would like to 
continue treatment with MTX. In total, 11 patients entered the study and nine were 
évaluable at week 24. A large part of assessed variables showed a good rehtive 
improvement. Four patients decided to continue MTX; three of them could lower 
the NSAID dose, and one could stop NSAID treatment. The remaining five patients 
discontinued MTX treatment, of whom three showed a flare and opted to restart 
MTX. Side effects seen were mild and reversible: abdominal discomfort (n=2), 
nausea (n=l), transient oral ulcers (n=l) and reversible liverfunction disturbances 
(n=3). 
Introduction 
Ankylosing spondylitis (AS) is a chronic inflammatory condition of the axial 
skeleton and sacroiliac joints that may lead to spinal ankylosis. Peripheral arthritis 
and extra-articular features occur in a small proportion of cases and are bad 
prognostic factors1. Up to now treatment of AS mainly comprises nonsteroidal 
antiinflammatory drugs (NSAIDs). Of second-line drugs, only of sulfasalazine 
(SASP)2 efficacy has been established in AS. Clinical significant improvement with 
weekly administered methotrexate (MTX) has been reported in sixteen patients with 
severe AS3-*. Aim of this study was to determine the efficacy and toxicity of MTX 
in patients with severe AS in an open, single observer 36-week interventional 
study. 
Patients and methods 
The study was conducted at the rheumatology departments of the University 
Hospital Nijmegen St. Radboud and the St Maartenshospital Nijmegen, the Nether-
lands, and was started after full approval of both ethical committees. 
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Patients 
Patients with severe AS, fullfilling the modified New Yoik criteria', of either sex, 
aged between 18 and 60 years, were selected. They were excluded in case of: 1. 
serious systemic disease, malignancies, impaired organ function or serious infec­
tions like tuberculosis; 2. mental disorders; 3. alcohol or drug abuse; 4. pregnancy 
or breast feeding; 5. history of intestinal disease, Reiters' disease. Severe or 
refractory AS was denned as a failure on treatment with NSAIDs and SASP; 
besides, active disease had to be present defined as the presence or persistence of at 
least two of the following features: a. morning stiffness of at least 30 minutes; b. 
disturbed sleep due to pain and stiffness; с peripheral arthritis; d. ESR £ 30 mm 
or CRP ¿ 20 mg/L or IgA ¿3 ,9 mg/L; e. spinal pain; f. stiffness and pain of 
thorax at movement or during normal breathing; g. pain in both buttocks during the 
night or the day. A stable NSAID dose and discontinuation of SASP were required, 
both for at least four weeks at study entry. Adequate anticonception during and six 
months after MTX treatment was recommended. 
Study design 
The study was an open, single observer, 36-week study in which MTX was studied 
for efficacy and toxicity. Patients were seen 4-weekly for 36 weeks and variables 
for disease activity and toxicity were measured every visit. Medication for non-
rheumatic chronic conditions and intercurrent acute illnesses was allowed, except 
for anti-folate drugs (such as sulfonamide derivatives), allopurinol, immunosuppres-
sive treatment and second-line drugs. MTX was administered orally 7.5 mg/week. 
At week 12 MTX dose was increased to 15 mg/week in case of lack of response. 
At week 24 efficacy was evaluated based on patients' global assessment: a. if 
patients judged that MTX was clearly effective, MTX was kept at a stable dose and 
the NSAID dose was reduced, and b. if patients judged efficacy of MTX moderate 
or absent (see below), MTX was discontinued and NSAIDs kept at a stable dose. 
In case of severe side effects MTX was stopped, in milder cases the dose was 
decreased or 1 mg folic acid was administered1"10. 
Measurements 
Every visit the following variables were assessed: a) Objective clinical variables: 
occiput-wall-distance, chest expansion, Schober's 10 cm test", fingertip-to-floor 
distance, an enthesis index (EI)12, the number of swollen joints, Ritchie Articular 
Index (RAI)13. Extra-articular manifestations were carefully sought for, b) Subjec-
tive variables: Visual Analogue Scales (VAS) ranging from 0 to 100 mm, corres-
ponding with 'none', c.q. 'very good' to 'has never been worse' were used for 
spinal pain, chestpain, general wellbeing and tiredness. Next to this, duration of 
morning stiffness after arising was assessed; c) Functional assessment: a Dutch 
Functional Index (DFI) for AS14, in essence a modification of the Functional Index 
of Dougados et al1516; d) Laboratory variables: HLA-B27, ESR, C-reactive protein, 
complete blood cell count, serum Creatinin, liverfunction tests, albumin, immuno-
globin A, G and M, Creatinin Phosphokinase; e) Every visit side effects related to 
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Tabel 1. Patients' characteristics at start of study 
number of patients 
male : female 8 : 3 
HLA-B27 positivily 11 
peripheral arthritis 3 
enthcsitis S 
iridocyclitis 2 
years* 
age 35 ± 8 (21-47) 
disease duration 14 ± 9 (3-26) 
*: mean ± standard deviation (range) 
study medication were assessed by direct questioning or as spontaneously reported 
complaints. 
Response 
The relative difference between weeks 0 and 24 was calculated, and response was 
defined as follows: good, if improvement ~¿ 50% was present in the majority of 
variables; moderate, if this improvement was between 15 to 50% and no response 
in case changes were smaller or absent. 
Results 
In total, 11 patients were enrolled to the study; all had NSAID failure, nine failed 
to respond on S ASP treatment and 2 patients could not tolerate S ASP. Patients' 
characteristics at start of the study are shown in Table 1. After 12 weeks of 
treatment in nine patients MTX was increased to 15 mg weekly. Generally, 
response, if present, could be observed between four to 12 weeks of MTX treat-
ment. Two patients dropped out at week 16 because of protocol violating changes 
in treatment: one due to a flare of the disease, the other due to development of a 
peptic ulcer, for which oral steroids were stopped as well. 
After 24 weeks nine patients were évaluable with a mean weekly dose of MTX of 
13.3 mg over a period of 24 weeks. Improvement could be seen in most assessed 
variables (see Table 2 and Figure 1). C-reactive protein and ESR improved equally. 
Immunoglobin A, elevated in 4 patients, decreased. Anaemia (hemoglobin = Hb: 
5.7 to 6.7 mmol/L), present in all three patients with peripheral arthritis, improved 
at least 1.0 mmol/L. The course of iridocyclitis (3 episodes) appeared not to be 
influenced by MTX. Efficacy was good in 5 patients: four of them continued MTX 
treatment and the dose of the NSAID could be reduced (n=3) or stopped (n=l). 
The fifth patient stopped MTX treatment despite good clinical response, but 
deteriorated within four weeks for which MTX was readministered. In the remain-
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Figure 1. Response of the 9 évaluable patients 
spinal pain (VAS) chest expansion 
pain (mm VAS)_ 
lune (weeks) 
functional index ritchie articular index 
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Table 2. Objective evaluation of MTX treatment: relative improvement in variables* 
variables patients' number 
disease characteristics* 
spinal pain 
chest pain 
general wellbeing 
tiredness 
morning stiffness 
occiput-to-wall distance 
fingertip-to-floor distance 
chest expansion 
Schobers' 10 cm test 
Ritchie Articular Index 
number of swollen joints 
enthcsis index 
Dutch Functional Index 
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ing four patients MTX was stopped, because of moderate or absent efficacy, and 
two of them deteriorated within four weeks. 
Side effects were abdominal discomfort (n=2), nausea (n=l), transient oral ulcers 
(n=l), reversible liverfunction elevations (n=3), for which two patients experienced 
benefit of folic acid 1 mg. 
Discussion 
MTX was studied in severe ankylosing spondylitis (AS) in a 36 week open study. 
Regarding enthesitis, peripheral arthritis and duration of the disease patients were 
quite different. Data were not analysed statistically because of this heterogeneity 
and the small sample size. Evaluation of efficacy was evaluated in two different 
ways: objective, i.e. the relative difference of assessed variables between weeks 0 
and 24 (see Table 2), and subjective by deciding at week 24 to either continue 
(n=4) or stop MTX (n=5) based on patients' global assessment. One patient could 
stop NSAID treatment, three could reduce the dose of NSAIDs, and four patients 
deteriorated after discontinuation of MTX and opted to restart. Side effects were 
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reversible or transient, and no severe side effects were seen. There was no obvious 
difference in response between patients with peripeihal arthritis and patients with 
only involvement of the axial skeleton. Thus, although numbers were small, this 
study provides circumstantial evidence that the majority of patients experienced 
beneficial effects due to MTX. In the future, a double-blind placebo-controlled 
study should further corroborate these data. 
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Dutch functional index for AS 
Summary 
A Dutch Functional Index (DFI) for ankylosing spondylitis (AS) has been develo­
ped, containing 37 questions in essence this is a modification of a French Index 
with additional questions. Internal consistency, reproducibility, criterion and 
construct validity and sensitivity to change were studied in different groups of AS 
patients. In a group of 149 patients the questionnaire was completed and internal 
consistency calculated (Cronbach's α = 0.94) after exclusion of three items. 
Reproducibility was studied in 39 patients with stable disease; Pearson correlation 
was 094. Criterion validity, against a 'gold standard' i.e. experts' observation of 
25 items, was studied in 19 patients; r = 0.85. In a 48-week NSAID study patients 
were enrolled after a washout period: DFI scores before and after treatment 
showed significant improvement (p<0.02). There were 187 DFI with corresponding 
clinical measurements, correlations varied from -0.30 to 0.68. Estimated measure-
ment-remeasurement correlation was 0.87. The DFI is, thus, a potentially useful 
instrument, which is valid, reliable and sensitive to the effects of NSAID treatment. 
Introduction 
In addition to measuring disease activity, assessment of functional status can be a 
useful evaluative technique for arthritis outcome. In RA questionnaires have been 
developed1"3, focusing on the impairment caused by peripheral arthritis. These 
questionnaires proved to be valid, reliable and sufficiently sensitive to detect 
functional change and they have therefore been used to evaluate treatment effects in 
clinical trials4. Questionnaires for RA cannot be used in AS, as the latter affects 
mainly the axial skeleton with only a minority of cases experiencing peripheral 
arthritis. This prompted us to search for a questionnaire dealing specifically with 
problems experienced by AS patients. 
A literature search for questionnaires already available and evaluated revealed 
three approaches in this field: 1. the Ankylosing Spondylitis Assessment Question­
naire (ASAQ), a self-administered questionnaire focusing on spinal mobility and 
pain9; 2. a Functional Index (FI) based on activities of daily living and scored by 
the investigator after verbal response by the patient6,7; 3. the Health Assessment 
Questionnaire for Spondylarthropathies (HAQ-S), in essence the HAQ for RA with 
five additional questions about driving a car, sitting and carrying heavy loads'. The 
FI of Dougados et al.6,7 was most in agreement with the guidelines for the develop­
ment of measurement scales910, but was not a self-administered questionnaire, and 
criterion validity and sensitivity to change over the long-term had not been studied. 
Since the French FI had to be translated and subsequently validated for the Dutch 
situation, items concerning static activities and riding a bike were added in order to 
improve its completeness. 
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Table 1. Items of the Dutch Functional Index 
Can you: 
put on shoes # * pull on a pair of trousers # * 
pull on a pullover # * get into a bath # @ О 
get out of a bath # @ О wash yourself or take a shower 
cough or neezc # breath deeply # * 
turn your head to the left and to the right * • remain standing for 10 minutes # * О 
sleep on your back # sleep on your stomach # • 
walk up one flight of stairs # * remain standing for 30 minutes О 
run # * go Bitting # * 
get out of a chair # * get into a car # * О 
creep # * bend to pick up something from the floor # * 
lie down # * tum in bed # * 
get out of bed # * perform your housework # @ 
do your job # @ go shopping 
get out of a car * О remain sitting for 10 minutes * О 
remain sitting for 30 minutes О kneel down * 
squat * ride on your bike a slight hill * 
ride a bike for 10 minutes * О ride a bike for 30 minutes О 
lift up a weight of 10 kg to shoulderheight * О lift up a weight of 10 kg above shoulderheight * 0 
tum left on a bike without getting off the bike * φ 
explanation of symbols: 
#: item out of the French FI 
@: item out of the French FI, split up into two separate items 
*: item observed by professionals (group V) 
• : item excluded after calculation of internal consistency (group I) 
O: item checked for inconsistency (group I) 
Patients and methods 
Construction of the questionnaire 
The FI of Dougados et al.6,7 was translated into Dutch. The back-translation from 
English into Dutch was without mistakes and the translation was therefore deemed 
satisfactory. Two questions from the FI, 'to get into and out of a bath' and 'to do 
your job and perform your housework', were split up into four separate questions 
(marked in Table 1). Interviews were held with 12 AS patients, two rheumatolo-
gists, three physical therapists, an occupational therapist, a nurse and a psycholo­
gist, all professionals were familiar with the problems specific to AS. From this 
information new items, covering the total field of problems in AS in daily life, 
were added to the questionnaire: firstly, activities with a specific duration of time 
such as to remain sitting for 10 and 30 min as AS patients are known to experience 
increasing difficulties over time in remaining certain postures; secondly, questions 
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to make the FI moie relevant to the Dutch situation, e.g. to ride a bike. In total, 15 
items were added The content validity was optimized by the two rheumatologists, 
the physical therapists and ergotherapist by seeing whether important areas of 
problems in AS were missing. The final Dutch Functional Index (DFI) was self-
administered, in contrast to the FI6,7, so it would be less time-consuming and avoid 
interobserver variability. The questionnaire then comprised of 37 items (see Table 
1). Response options were as follows: 'possible' (score = 0), 'possible but with 
difficulty' (score = 2) and 'not possible' (score = 4). If patients selected more than 
one answer, scores were adapted as follows: 1 = 'possible' plus 'possible but with 
difficulty' and 3 = 'possible but with difficulty' plus 'not possible'. At the most 
three items were allowed to be ommitted, and the score of the final index was 
calculated as the mean of the item scores, thus correcting for missing items. 
Questionnaires missing more items were not considered for further calculations. 
Patients 
AS patients, selected for a 48-week clinical trial, comparing naproxen and ß-
cyclodextrin-piroxicam (Brenn), and AS patients participating in an AS-exercise 
group, were used for the validation of the DFI. 
From the available files at two rheumatology departments 234 AS patients, of 
either sex, aged between 16 and 60 yr, rullfilling the modified New York criteria11 
were selected. They were excluded if they had any evidence of: 1. previously 
experienced side effects on NSATDs; 2. serious systemic disease; 3. impaired organ 
function, mental disorders; 4. alcohol or drug abuse; 5. pregnancy or breast feeding. 
Additionally, there had to be active disease after a washout period, evidenced by 
pain and stiffness requiring use of NSATDs. 
The following groups were identified: 
Group ¡internal consistency): patients at one centre (n = 113) who decided not 
to participate in the clinical trial were asked to complete the DFI once by return 
post and to register the time required to complete the questionnare. These question-
naires (n = 100) together with those DFI completed after the washout period in the 
clinical trial (n = 55) were the basis for a study on (internal) consistency of the 
questionnaire (n = 15S); 
Group Rfeproducibility): in addition to the clinical trial, patients from the 
Nijmegen Region participating in an AS-exercise group (n = 67) were also asked to 
complete the questionnaire twice if they considered their disease to be stable. From 
39 of these patients duplicate questionnaires were received. This group was used to 
study reproducibility of the questionnaire group (n = 39); 
Group V(alidity): a subgroup of R agreed to actually perform the activities of 
the questionnaire for a professional judgement in order to study criterion validity of 
the questionnaire (n = 19); 
Group Lfongitidunal study): the 55 patients who entered the clinical trial served 
as a longitudinal follow-up group to study the sensitivity to change (group L, η = 
55), to calculate correlations with other clinical variables and for estimation of 
measurement-remeasurement correlation. 
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Table 2. pairs of items checked for inconsistency (group I) 
activity/classification of answers 
to get into and out of a bath 
remain standing for 10 and 30 minutes 
lift up a weight of 10 kg to an above 
shoulderheight 
remain sitting for 10 and 30 minutes 
to get into and out of a car 
to rìde a bike for 10 and 30 minutes 
% correct* 
18 
40 
26 
31 
13 
15 
% equal* 
76 
60 
73 
69 
83 
85 
% misclassifìcation 
6 
0 
1 
0 
4 
0 
correct = an increasing score similar to expected increasing difficulty 
equal = the same score in the pairs of items 
misclassified = a decreasing score 
Measurements 
Group I: 112 men and 37 women (mean age 40 ± 9 yr, mean disease duration 11 ± 
9 yr) completed the DFI sufficiently well, six questionnaires were incorrect. 
Group R consisted of 24 men and 15 women (mean age 40 ± 9 yr, mean 
disease duration 10 ± 8 yr) and these patients completed the DFI twice. Thirty 
patients completed the DFI between 7 to 28 days and nine patients between 29 to 
42 days. 
Group V was a subgroup of R and consisted of six men and 13 women (mean 
age 39 ± 7 yr, mean disease duration 7 ± 5 yr). Activities related to 25 items (see 
Table 1) were performed and observed in this group by three rheumatologists and 
three physical therapists, who served as a 'gold standard'. Before observation of 
group V, several standardization meetings were held in which patients performed 
the 25 selected items, observed simultaneously by all observers. In case of disag-
reement of item score between the observers these were discussed and a consensus 
was reached. For the observation of group R the 25 performances were divided into 
four separate parts and each part had an almost equal degree of difficulty and 
required similar physical effort. At least two rest periods of 15 min were between 
these four parts. The entire observed performance took about 1.5 h for each patient. 
Patients completed the DFI no more than 10 days before the observation. For blind 
validation, patients were asked to participate in group V without knowing that the 
procedures were used for the validation of the DFI. Observers did not know DFI 
scores of these 19 participating patients. 
Group L consisted of 55 patients, the DFI being completed every 12 weeks. 
Repeated measurements were obtained from 51 patients (40 men and 11 women, 
mean age 39 ± 9 yr, mean disease duration 9 ± 7 yr); 38 patients adequately 
completed the DFI at weeks 0 and 12 and 29 patients completed the whole study 
(see Table 3). In addition to the DFI, the following variables were measured; i.e. 
the modified Schober, fingertip-to-floor distance, chest expansion and pain in the 
spine and sacroiliac region reported during physical examination, duration of mor-
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Table 3. Correlations of DFI with clinical measurements (group L) 
(n varying from 31 to 46) 
variable/week 
spinal pain 
during the day 
spinal pain 
during the night 
morning stiffness 
general well-being 
reported by the 
patient 
pain of the back 
and sacroiliac region 
general well-being 
reported by the 
investigator 
chest expansion 
fingertip-to-floor-
dis tance 
modified Schober 
week 0 
0.56 
0.50 
0.19 
0.60 
0.45 
0.00 
0.11 
0.26 
-0.13 
week 12 
0.67 
0.58 
0.33 
0.62 
0.45 
0.51 
0.19 
0.39 
-0.21 
week 24 
0.54 
0.54 
-0.04 
0.68 
0.66 
0.47 
0.02 
0.48 
-0.02 
week 36 
037 
0.70 
0.34 
0.55 
0.34 
0.23 
-0.17 
0.58 
-0.32 
week 48 
0.59 
0.60 
0.21 
0.64 
0.68 
0.26 
-0.30 
0.74 
-0.69 
(Standard error in г < 0.18) 
rung stiffness and 100-mm visual analogue scales about backpain at night, backpain 
during the day and general well-being. 
Statistical analysis 
Group I: principal component analysis10 was applied to identify any homogenous 
subgroups of items. Cronbach's α for internal consistency and item evaluation was 
performed12. The interpretation of Cronbach's α is comparable to the measurement-
remeasurement correlation. Pairs of items dealing with the same activity but 
differing in difficulty, e.g. to sit for 10 and for 30 min (see Table 2), were analysed 
for inconsistency. The hypothesis was studied that 'in general the more difficult the 
action was, the higher the item score would be', and the following definitions were 
used: equal = the same score in the pairs of items, correct = an increasing score, 
misclassified = a decreasing score. 
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Group R: for reproducibility correlation between mean score of two series of 
measurements was calculated. The mean difference between both measurements 
was used to test for learning effects (paired t-test) and the corresponding standard 
deviation (S.D.) was used to calculate measurement errors (S.D.//2). 
Group V: two scores were calculated of the DFI completed by the patient; a 
mean total score (patients' total DFI score) and a partial score (patients' partial DFI 
score) being the mean of the sum of the 25 observed items (as indicated in Table 
1). Apart from this, scores assessed by the observer were calculated also as the 
mean of the sum of the 25 observed items (observers' DFI score). Criterion validity 
was evaluated using these correlations. 
Group L: paired t-test was used to test the difference in score between week 0 
and 12 for determining sensitivity to change. 
Construct validity was analysed using Pearson correlations of the DFI with 
clinical variables. Clinical variables which were statistically significant associated 
with the DFI were analysed using a multiple regression analysis, the DFI score 
being the dependent variable and the clinical variables being the independent 
variables. Multiple R and squared R were calculated. 
In longitudinal studies quality of variables can be determined by calculation of 
interperiod correlations. These intercorrelations can be plotted against time interval 
and a regression line can be calculated. The intersection of this line with the 
vertical axis (intercept) is an estimation of the direct measurement-remeasurement 
correlation (r0) and this may be interpreted as a quality measure of a variable13. The 
DFI scores of weeks 12, 24, 36 and 48 were used for this estimation and time 
intervals were 12 weeks. 
Results 
Group /: Principal component analysis on the correlation matrix of the 37 items (n 
= 149) resulted in 10 factors (Eigenvalue > 1). Almost all items loaded strongly on 
the first factor (explained variance 32%). The other factors, also after rotations only 
comprised a small number of items. Therefore it was decided to consider the 
questionnaire as unidimensional. Internal consistency of the DFI (n = 149) was 
analysed using reliability analysis leading to a Cronbach's α = 0.93. Three items 
decreased the reliability of the questionnaire (indicated in Table 1) and were 
excluded, leading to a Cronbach's α = 0.94. One of these three originated from the 
French FI (marked in Table 1). The median total score on 34 items was 1.0 (range 
0 - 2.45, S.D. 0.62). 
The questionnaire included six pairs of items dealing with the same activity but 
differing in difficulty and physical effort (see Table 1). Inconsistency was counted 
as described above. Very few misclassificatìons were seen; 2% on average (see 
Table 2). The time required to complete the questionnaire was on average less than 
five minutes. 
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Figure 1. Inteiperiod correlations and regression line 
correlation 
1 
0.9 
0.8 
0.7 
0 . 6 ' 
0 1 2 3 
lime interval [12 weeks) 
legend: con-elations shown in Table 4 have been plotted against intermediate time, where one time 
interval was defined as 12 weeks. The corresponding regression line is calculated and extrapolated to the 
intersection with the Y-axis. This point of intersection can be interpreted as the measurement-remeasure-
ment correlation (r0) 
Group R: Patients of this group (n = 39) could be divided into two groups, 
namely those who completed the DFI twice within 4 weeks and those who 
completed it twice between 4 to 6 weeks. Pearson correlations of these groups were 
0.95 (n = 30) and 0.94 (n = 9) respectively. The correlation of the whole group (n 
= 39) was 0.94. The mean difference in item scores was -0.02 and 0.12, respective-
ly and measurement errors were 0.16 and 0.18 respectively. Paired t-testing for any 
learning effect was not significant. 
Group V: Correlation between patients partial DFI score and observers DFI 
score was 0.85, being criterion validity of the DFI. The mean observers DFI score 
was 0.68 (S.D. = 0.06) and the mean patients partial DFI score was 0.82 (S.D. = 
0.30). The mean difference between the two scores was 0.10 (S.D. = 0.14). 
Group L: sensitivity to change was tested using the mean scores of weeks 0 and 
12, being 1.01 (S.D. = 0.59) and 0.85 (S.D. = 0.63) respectively. The mean 
difference between weeks 0 and 12 was 0.31 (S.D. = 0.43, range -0.45 to 0.99). 
Paired t-testing showed significant effect (P < 0.02), meaning that important 
clinical changes can be measured using the DFI. 
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Correlations between the DFI and clinical variables were calculated for 
construct validity (see Table 3). There were 187 DFIs adequately completed with 
all corresponding clinical measurements. The multiple correlation (multiple R) was 
0.68 and R2 was 0.47. Fingertip-to-floor distance, pain and general well-being were 
significantly associated in this analysis. 
Interperiod correlations were calculated (see Table 4), and the corresponding 
regression line was calculated. Extrapolation of the intersection with the Y-axis of 
this regression line resulted in the estimation of the measurement-remeasurement 
correlation (r0) of 0.87 (see Fig. 1). 
Discussion 
Three different questionnaires claiming to assess functional status in AS have been 
published in the literature. In our opinion the FI of Dougados et al.6,7 approached 
most closely the guidelines for development of measurement scales'10, but it was 
not available for Dutch AS patients and was not self-administered. Therefore, this 
questionnaire was translated, modified into a self-administered questionnaire and 
items concerning activities lacking in the French FI were added. The modified DFI 
was subsequently validated, similar to the French FI, but with additonal criterion 
validity and sensitivity to change over the longterm. 
Measurement errors in group R being 0.16 and 0.18 on a range from 0 to 4, 
and the accompanying measurement-remeasurement correlations 0.95 and 0.94 
respectively indicate good reproducibility. Despite the fact that the time interval 
between completion of the DFI varied from 7 to 42 days, in patients with stable 
disease (group R) reproducibility was satisfactory, and it can be concluded that 
daily fluctuations in disease activity do not influence the score of the DFI in 
patients with stable disease. 
The lack of a 'gold standard' of a functional status instrument makes it 
necessary to test criterion validity in a broader term, as other investigators have 
done before14"16. Criterion validity was, therefore, tested against a 'gold standard' 
(expert observation) and compared with reproducibility contained smaller albeit 
satisfactory correlations. Patients' partial DFI score and observers' DFI score did 
not differ significantly, although, observers' DFI score was slightly lower. An 
observer bias may cause this difference in DFI score; pain and difficulty experien-
ced by the patient during performance cannot always be observed. An attempt was 
made to reduce measurement bias by standardizing observation. 
Sensitivity to change was studied in the clinical trial. A statistically significant 
decrease was found in DFI scores at the end of a washout period and after 12 
weeks of NSAID treatment. It can be concluded that the DFI is a sufficiently 
sensitive instrument to detect the effects of NSAID treatment. This is in agreement 
with the studies of Dougados et al.6,7, who found significant improvement in scores 
in their 2-week clinical trials. 
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Table 4. Correlation matrix of DFI scores* (Group L) 
week 12 
week 24 
week 36 
week 48 
week 12 
1.00 
(41) 
0.80 
(34) 
0.70 
(28) 
0.79 
(28) 
week 24 
1.00 
(41) 
0.87 
(28) 
0.83 
(29) 
week 36 
1.00 
(33) 
0.86 
(29) 
week 48 
1.00 
(36) 
* the number of questionnaires adequately completed is placed between brackets 
Correlations of DFI scores with clinical variables varied from poor to moderate 
(see Table 4); this was also found by Dougados et al.6,7 as well. Spinal pain, well-
being and fingertip-to-floor distance showed moderate correlations. In a multiple 
regression analysis general well-being, finger-tip-to-floor distance and pain during 
physical examination were significant and about 47% of variance in the DFI could 
be explained by these three variables. 
It can be concluded that the DFI is a potentially useful instrument, which is 
valid, reliable and sensitive to the effects of NSAID treatment, is easy to administer 
and requires little time for completion. 
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Disease activity in AS 
Summary 
For assessment of disease activity in ankylosing spondylitis (AS) a large number of 
variables are available. The aim of this study was to evaluate validity of commonly 
used variables, to select a core set of valid variables for disease activity, and 
finally compute an AS disease activity score (AS-DAS). Data of two longitudinal 
studies were used. Principal component analysis and reliability analysis resulted in 
11 factors: cervical mobility, lumbar flexion, subjective complaints, functional index 
(FI), enthesis index (EI), inflammatory response, IgA, IgM, root joints, swollen 
joints and spinal mobility. Based on discriminating power, reproducibility and 
correlation with disease duration, seven single variables were selected. In a 
subsequent discriminant analysis an AS-DAS was computed of five variables, i.e. 
subjective complaints, FI, EI, root joints and C-reactive protein, which should be 
validated in the future. A core set of process variables solves the problem of 
multiple testing in clinical trials, and improves comparability. 
Introduction 
The evaluation of disease activity in ankylosing spondylitis (AS) is a complex and 
multifactorial problem. Therefore a large number of different variables are being 
used for evaluation of patients with AS. Guidelines of the ARA1 and EULAR2 for 
clinical trials in AS have been developed. However, of this large number of 
variables validity, reproducibility and their mutual relation has not been studied3,4, 
with the exception of some variables3. Laboratory variables, for example C-reactive 
protein (CRP), ESR and IgA are not abnormal in every patient with active dis-
ease4'1*, and primarily appear to be associated with peripheral arthritis15'16 and extra-
articular features17. Another major problem is the lack of sensitivity to change, 
especially in those variables measuring spinal mobility2, possibly caused by the fact 
that commonly used variables are a combination of momentary disease activity, i.e. 
process of the disease, and of the result, i.e. outcome of the disease. As a result of 
these problems, in clinical trials in AS a wide variety of variables is used, making 
comparison between different studies difficult. 
The aim of this study was to evaluate the validity of commonly used variables 
for the assessment of disease activity in AS. Data of two clinical longitudinal 
prospective studies, in which patients had to have a high disease activity upon 
study entry, have been used for this. The results of this evaluation brings within 
reach the selection of a core set of variables, wich are reliable, reproducible and 
sensitive to change. Finally, this might lead to the development of a disease activity 
score for AS. 
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Table 1. Patients' characteristics at baseline 
NSAID study MTX study 
(n=59) (n=ll) 
age (years)* 39 ± 9 35 ± 8 
sex ratio male : female 45 : 14 (76% : 24%) 8 : 3 (73% : 27%) 
disease duration (years)* 10 ± 8 14 ± 9 
number of patients with: 
HLA-B27 55 93% 11 100% 
peripheral arthritis 3 5% 3 3% 
iridocyclitis 2 3% 2 18% 
* : mean ± standard deviation 
Patients and methods 
Patients 
AS patients, fulfilling the modified New York criteria", of either sex, aged between 
18 and 60 years, were selected. Study I was a 48-week NSAID study (n=59), 
comparing ß-cyclodextrin-piroxicam and naproxen. In study II patients with severe 
AS (n=ll) were treated with low-dose methotrexate (MTX) for at least 24 weeks. 
Exclusion criteria of both studies were: 1. serious systemic disease and or impaired 
organ function; 2. depression or other mental disorders; 3. alcohol or drug abuse; 4. 
pregnancy and breast feeding. Additional exclusion criteria for study I were major 
side effects caused by NSAEDs and active peptic ulcer disease in the past, and for 
study Π a history of intestinal disease, Reiters' disease or chronic infection. 
Patients' characteristics of both clinical studies are presented in Table 1. 
Active disease had to be present at the start of both studies: in study I, after a 
washout period of NSAIDs, a clear need for the use of analgesics or NSAIDs had 
to be present, next to at least two of the following features: a. back pain during the 
night and/or the day; b. morning stiffness of at least 15 minutes; с pain and stiff­
ness in both buttocks; d. pain and stiffness of the chest. In study П, additional to 
failure to treatment with NSAIDs and sulfasalazine, patients had to have at least 
two of the following features: a. morning stiffness of at least 30 minutes; b. 
disturbed sleep due to pain and stiffness; с peripheral arthritis; d. ESR ¿ 30 mm 
or CRP S 20 mg/L or IgA > 3,9 mg/L; e. spinal pain; f. stiffness and pain of the 
chest at movement or during normal breathing; g. pain in both buttocks during the 
night and/or the day. 
Measurements 
Patients were seen at weeks 0, 2, 4, 8, 12, 18, 24, 30, 36, 42 and 48 for study I 
and 4-weekly for study П. For measurement of disease activity the following varia-
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Table 2. Median, percentiles 10 and 90 of assessed variables 
Variable 
spinal pain night (VAS) 
spinal pain day (VAS) 
general wellbeing (VAS) 
morning stiffness (minutes) 
fingertip-to-floor distance (cm) 
lumbar flexion index (cm) 
modified Schober index (cm) 
Schober 10 cm index (cm) 
lateral flexion good side (%) 
lateral flexion bad side (%) 
occiput-to-wall distance (cm) 
chest expansion (cm) 
cervical mobility (degrees) 
anteflexion 
retroflexion 
lateral flexion good side 
lateral flexion bad side 
rotation good side 
rotation bad side 
enthesis index 
root joint index 
plO 
6 
6 
10 
0 
0 
17.0 
17.0 
11.0 
1.75 
2.20 
0 
2.0 
16 
20 
13 
14 
30 
40 
0 
0 
median 
37 
46 
46 
60 
16 
20.0 
20.0 
14.0 
4.17 
5.14 
1 
3.5 
52 
42 
32 
40 
62 
70 
7 
0 
p90 
82 
82 
84 
144 
41 
22.0 
21.5 
15.0 
9.38 
10.17 
10 
6.0 
71 
68 
48 
58 
80 
4 
29 
2 
skewness 
0.19 
0.04 
0.14 
2.34 
0.62 
-0.40 
-0.25 
-0.37 
0.83 
0.69 
1.75 
1.02 
-0.30 
0.11 
0.05 
-0.04 
-0.69 
-1.08 
1.97 
3.28 
skewness after 
transformation 
-
-
-
0.08 (sqrt) 
-
-
-
-
-
-
0.62 (sqrt) 
-0.76 (In) 
-
-
-
-
-
-
0.34 (sqrt) 
1.29 (d-sqrt) 
Dutch functional index 
number of swollen joints 
0.24 1.12 2.17 0.20 
5.40 2.26 (d-sqrt) 
ESR (mm/lst hour) 
C-reactive protein (mg/L) 
platelets (lO'/L) 
IgA (mg/L) 
IgO (mg/L) 
IgM (mg/L) 
6 
4 
217 
1.61 
8.50 
0.80 
15 
19 
274 
2.74 
11.28 
1.74 
53 
51 
405 
5.15 
17.60 
2.74 
1.92 
3.61 
1.53 
0.77 
3.19 
0.72 
-0.09 (In) 
-0.20 (In) 
0.26 (In) 
-
1.04 (In) 
-
VAS ш visual analogue scale; ESR = erythrocyte sedimentation rate; (In) = logaritimic transforma­
tion; (sqrt) » square root transformation; (d-sqrt) = double square root transformation 
bles were assessed at every visit: 
a) Clinical variables: 
* occiput-to-wall distance, measured in cm with the patient standing as erect as 
possible with heels and back against the wall; 
* chest expansion: the difference in cm between the circumference of the chest at 
nipple line on full inspiration and full expiration; 
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* Schober 10 cm index19; 
* Modified Schober 15 cm index5; 
* Lumbar flexion index20; 
* fingertip-to-floor distance: the distance in cm between the third finger and the 
floor with the patient bending forward maximally, without flexing the knees; 
* lumbar lateral flexion21, in the percentage of the body height; 
* the number of swollen joints; 
* enthesis index22, maximal score being 90; 
* root joint index: pain of shoulders and hips by palpation and/or passive move­
ment was assessed with pain graded from 0 to 3. The sum of the scores being 
the index; 
* mobility of the cervical spine (in degrees): rotation using a goniometer, and 
lateral flexion, anteflexion and retroflexion using a hydrogoniometer. 
b) Subjective variables: 
* spinal pain during the day, spinal pain during the night and general wellbeing 
were assessed by using 100 mm VAS; 
* duration of morning stiffness after arising, recorded in minutes with a maximum 
of 360 minutes. 
c) Laboratory variables: 
* ESR, C-reactive protein, complete blood cell count, immunoglobin A, G and M; 
d) Functional assessment: 
A Dutch functional index for AS23, in essence a modification of the functional 
index of Dougados et al24,25 was completed at week 0 and every 12 weeks. Score 
maximally 4. 
Variables which have been measured at both sides, i.e. lumbar lateral flexion, 
cervical rotation and cervical lateral flexion, were reported as a good and bad score 
for each patient irrespective of the side. 
Definition of disease activity and selection of records 
Patients' records were selected guided by the definitions of high and low disease 
activity. Disease activity was defined low, in study I if patients had used a stable 
dose of NSAIDs for at least 24 weeks, and in study Π if patients continued MTX 
after 24 weeks. Disease activity was defined high at week 0 of both studies, with 
the exception that some patients of the NSAID study, of whom pain and stiffness 
did not deteriorate enough after a washout period for NSAIDs, were excluded for 
this study. Finally, 101 records of 65 patients were selected for further analysis: 46 
records with a low disease activity and 55 with a high disease activity. For 36 
patients both a low and a high disease activity record was available. Ranges of 
variables of these 101 records are shown in Table 2. 
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Statistical analysis 
Variables used in multivariate statistical analysis have to be normally distributed. If 
necessary, assessed variables, were, therefore, transformed to obtain normality. To 
find subgroups of variables, principal component analysis was performed on all 
variables. For reliability testing Cronbach's a26 was calculated of the factors. A 
forward stepwise discriminant analysis was performed for determination of factors 
discriminating significantly between a high and a low disease activity. Because the 
number of visits in the two studies was different, resulting in different amount of 
records per patient, only the selected 101 patients' records were used for factor 
analysis and discriminant analysis. Records of patients of whom both a high and 
low disease activity record was available were analysed using paired t-tests. Of 
these paired observations the discriminating power was expressed as the standardi­
zed difference (difference/pooled standard deviation). AU records of the 59 patients 
of the NSATD study were used for analysis of the reproducibility of variables, 
calculated with an interperiod correlation matrix and the corresponding regression 
line was calculated for the estimation of measurement-remeasurement correlation 
(r0)27. Because variables might be a combination of process and outcome of the 
disease, the relation with disease duration was analysed. For this, Spearman rank 
correlations were computed of disease duration and all assessed variables of weeks 
0 and 12 of study I. To separate process and outcome variables, those variables 
having a significant correlation with the disease duration, were considered mainly 
assessing outcome. 
Finally, a set of process variables was then selected and an index for disease 
activity calculated using discriminant analysis. 
Results 
Factor analysis and reliability 
Principal component analysis was performed on 27 variables of the 101 selected 
records. Seven factors were found with eigenvalues larger than 1 (see Table 3) and 
a cumulative explained variance of 76%. After varimax rotation, four variables, i.e. 
fingertip-to-floor distance, occiput-to-wall distance and lumbar lateral flexion 
loaded moderately on factor 1 as well as on factor 2, and were put into a new 
factor (factor ПІ). Factor 3 was composed out of morning stiffness, spinal pain 
during the day and during the night, general wellbeing, the enthesis index and the 
functional index. The first four variables were considered patients' assessed 
variables and were grouped together in factor Ша. The questionnaire (functional 
index) and the 'assessor' variable (enthesis index) were used as separate factor, 
Factor ШЪ and Шс respectively. 
Variables were scaled, and scaling factors were chosen to equalize the standard 
deviations of variables within each factor. Factor values then were calculated as the 
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Table 3. Factors out of prinicipal component analysis and reliability analysis 
Factor analysis Reliability analysis 
Factor 1 
cervical anteflexion 
" retroflexion 
" rotation g 
" rotation b 
" lateralflexion g 
" lateralflexion b 
Factor I 'CERVICAL MOBILITY' 
anteflexion 
retroflexion 
rotation g 
rotation b 
lateralflexion g 
lateralflexion b 
Factor 2 
modified Schober 
lumbar flexion index 
Schober 10 cm index 
Factor II 'LUMBAR FLEXION' 
modified Schober 
lumbar flexion index 
Schober 10 cm index 
Factor 3 
spinal pain day 
spinal pain night 
general wellbeing 
morning stiffness 
functional index 
cnthesis index 
Factor Ша 'SUBJECTIVE COMPLAINTS' 
spinal pain day 
spinal pain night 
general wellbeing 
morning stiffness 
Factor IHb FUNCTIONAL INDEX 
Factor Шс ENTHESIS INDEX 
Factor 4 
ESR 
CRP 
IgO 
platelets 
Factor 5 
IgA 
IgM 
Factor 6 
root joint index 
Factor 7 
swollen joints 
Factor 8* 
fingertip-to-floor distance 
occiput-to-wall distance 
lumbar lateralflexion g 
lumbar lateralflexion b 
Factor IV 
Factor Va 
Factor Vb 
Factor VI 
Factor VII 
Factor ІІГ 
•INFLAMMATORY RESPONSE' 
ESR 
CRP 
IgG 
platelets 
IgA 
IgM 
ROOT JOINTS 
SWOLLEN JOINTS 
'SPINAL MOBILITY' 
fingertip-to-floor distance 
occiput-to-wall distance 
lumbar lateralflexion g 
lumbar lateralflexion b 
g = good side; b = bad side; 
* : variables which loaded moderately both on factor 1 and factor 2 
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mean of the variables corresponding with the factor. 
Cronbacb's α was calculated for the composed factors (1, 2, Ша, 4, S, 8). All 
variables within a factor gave a positive contribution to the reliability, except for 
factor 5 (Cronbach's α = 0.47), which subsequently was splitted up into two single 
factors (factors Va and Vb). Cronbach's α of factors 1, 2, 4, 8 and ΠΙ varied from 
0.82 to 0.97 and may be considered as reliable. Finally there were 11 factors: 
cervical mobility (factor I), lumbar flexion (factor Π), 'subjective complaints' 
(factor Ша), the functional index (factor ШЬ), the enuresis index (factor Шс), 
'inflammatory response' (factor Г ), IgA (factor Va), IgM (factor Vb), the root 
joints (factor VI), swollen joints (factor VI) and 'spinal mobility' (factor Ш). 
Discriminant analysis 
Paired t-testing was performed on the factor values of the records of 36 patients 
with observations both with a high and low disease activity. For further analysis 
factor I was excluded because no significant change was found (p=0.16). The 
number of swollen joints also showed no significant change (p=0.06); as this was 
possibly due to the small number of patients with peripheral arthritis, we did not 
exclude this factor. 
The stepwise forward discriminant analysis showed five significant steps 
entering: 'subjective complaints' (F Ша), 'inflammatory response' (F TV), root 
joints (F VI), enthesis index (F Шс) and IgA (F Va). Table 4 shows the relative 
importance of factors and variables used in the discriminant analysis. Canonical 
correlation was 0.64 and 80% was correctly classified. 
Table 4. Correlations of eleven factors with discriminant score and discriminating 
power 
Factor 
subjective complaints' (F Ша) 
enthesis index* (F Шс) 
functional index (F ¡lib) 
spina] mobility (F ІП) 
root joints* (F VI) 
lumbar flexion(F П) 
inflammatory response" (F Г ) 
IgM (F Vb) 
swollen joints (F П) 
IgA' (F Va) 
cervical mobility (F I) 
correlations with 
discriminant score 
(101 records) 
0.84 
0.63 
0.56 
-0.42 
0.38 
0.30 
-0.24 
0.17 
0.12 
0.10 
standardized difference 
(72 paired records) 
1.17 
0.89 
0.69 
0.46 
0.50 
0.44 
0.33 
0.40 
0.34 
0.25 
0.16 
(F) : Factor (see Table 3) 
*: factors selected stepwise in discriminant analysis 
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The discriminating power, computed as the standardized differences from paired 
t-testing of the 36 patients, and the correlations with the discriminant score (101 
records) gave similar information about the factors used in the analyses (see Table 
4). 
Disease duration 
Variables and factorvalues from the NSAID study of weeks 0 and 12 and corre-
sponding differences were used for calculation of Spearman rank correlations with 
disease duration. Only correlations statistically significant are shown in Table 5. 
Reproducibility 
In longitudinal studies quality of variables can be determined by calculation of 
interperiod correlations. These intercorrelations can be plotted against rime interval 
and a regression line can be calculated. The intersection of this line with the 
vertical axis (intercept) is an estimation of the direct measurement-remeasurement 
correlation (r0) and this may be interpreted as a quality measure of a variable. 
Estimated r0 of variables belonging to composed factors are shown in Table 5. 
Selection of a core set of variables 
The selection of usefull process variables is based on discriminating power 
(standardized difference), reproducibility and a lack of correlation with disease 
duration. Factors and variables correlating with disease duration were considered 
assessing primarily outcome and not selected. For reasons of simplicity and 
practicality, only one single variable out of a composed factor was selected. The 
selection of factor and variables was based on the largest discriminating power 
(standardized difference) and reproducibility (measurement-remeasurement correla-
tion, r0), and variables with standardized differences less than 0.30 were not taken 
into account. Selected process variables are thus (marked in table 5): 1. spinal pain 
during the day (VAS); 2. lumbar flexion index; 3. root joints; 4. enthesis index; 5. 
swollen joints; 6. functional index and 7. CRP. 
Composition of a disease activity score 
A forward stepwise discriminant analysis on the seven selected process variables 
resulted in a correlation with the discriminant score of 0.07 for swollen joints, 
while the remaining six variables had correlations of at least 0.35. Therefore, this 
variable was left out of consideration. The subsequent discriminant analysis showed 
a positive coefficient for the lumbar flexion index and a negative correlation with 
the discriminant score. Because of this discrepancy, this variable was considered 
being unstable, i.e. its discriminating power is completely expressed by the other 
(interrelated) variables. Finally, the Ankylosing Spondylitis Disease Activity Score 
(AS-DAS) was computed with a discriminant analysis using five variables, namely 
spinal pain during the day (VAS), enthesis index, functional index, root joints and 
CRP. Three variables had to be transformed to obtain normality for this analysis. 
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Table 5. Analyses used for selection of variables 
selected discriminating reproducibility correlations with 
for AS-DAS power disease duration 
factors and venables standardized estimated r0 week 0 week 12 
difference (n=36) (n=59) 
'CERVICAL MOBILITY' 
anteflexion 
retroflexion 
rotation g 
rotation b 
lateral flexion g 
lateral flexion b 
'LUMBAR FLEXION' 
lumbar flexion index 
modified Schober index 
Schober 10 cm index 
(X) 
•SUBJECTIVE COMPLAINTS' 
spinal pain day X 
spinal pain night 
general wellbeing 
morning stiffness 
ENTHESIS INDEX X 
0.16 
0.11 
0.01 
0.29* 
0.29* 
0.06 
0.05 
0.44"" 
0.63"" 
0.30"" 
0.35"' 
1.17"" 
1.06"" 
0.83"" 
1.11"" 
0.75"" 
0.77 
0.81 
0.82 
0.80 
0.87 
0.86 
0.88 
0.87 
0.85 
0.65 
0.63 
0.58 
0.55 
-0.32" 
0.89" 0.74 
FUNCTIONAL INDEX 0.69" 0.92 
•INFLAMMATORY RESPONSE' 
ESR 
CRP X 
IgG 
platelets 
0.33"" 
0.17 
0.72 
0.23 
0.02 
0.87 
0.74 
0.86 
0.85 
IgA 
IgM 
ROOT JOINTS 
0.25"" 
0.40"' 
0J0* 
0.94 
0.95 
0.67 
-0.28" 
SWOLLEN JOINTS (X) 0 3 4 H i o 6 0.80 
'SPINAL MOBILITY' 
fingertip-to-fioor distance 
occiput-to-wall distance 
lumbar lateral flexion g 
lumbar lateral flexion b 
chest expansion 
0.46"" 
0.44"" 
0.31'" 
0 .31"" 
0.31"" 
0.34"· 
0.94 
0.89 
0.94 
0.94 
0.86 
-0.30* 
0.27* 
-0.27' 
-0.37" 
0.27* 
-0.33" 
-0.35·' 
p-value:* p<0.05, **· p<0.01; *·*· p<0.005; *»**· p<0.001 
ESR = erythrocyte sedimentation rate, CRP = C-reactive protein; b = bad side, g = good side 
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Correlations with the final score, means and standard deviations of the separate 
variables and coefficients for the final formula are shown in Table 6. The canonical 
correlation was 0.67 and 82% was correctly classified in this final discriminant 
analysis. 
Discussion 
Judgement of disease activity in rheumatic diseases is a complex process and forms 
the basis of clinical decisions. Assessed variables are often a combination of 
process and outcome of the disease. In AS commonly used variables contain a lot 
of interpretation problems as stated in the introduction. In the past, some indices of 
disease activity in AS have been proposed, based on clinical judgement28"32. 
However, the majority of these indices have not been validated. Recently, Salaffi et 
al33 analysed data of 45 AS patients in order to identify groups of variables out of 
the large number available. Three groups of variables were identified, measuring 
disease activity, damage and functional status, the latter being a combination of 
disease activity and disease outcome. 
In our study longitudinal data of AS patients were analysed to identify those 
variables which discriminate for disease activity. Since no 'gold standard' for 
disease activity in AS is available, predefined criteria for high and low disease 
activity were used. Two groups of patients' records were formed; one group with 
high and one group with low disease activity. For evaluation of reproducibility, 
discriminating power and the correlation of variables and factors with disease 
duration, a predefined analysis strategy34, including principal component analysis to 
form subgroups of reliable, interrelated variables, reliability of factors was used. 
This evaluation resulted in a selection of 7 process variables. Finally, a disease 
activity score was computed of five variables, derived from a discrimant analysis. 
The core set of seven process variables encompassed lumbar flexion index, 
spinal pain during the day, enthesis index, functional index, CRP, root joints and 
the number of swollen joints. In a discriminant score for the construction of a 
disease activity score two variables had to be excluded: a. 'swollen joints' because 
of a low correlation with the discriminant score; and b. 'the lumbar flexion index', 
which appeared to be an instable variable, i.e. its discriminating power is com-
pletely expressed by the other (interrelated) variables. The five variables of the AS-
DAS are part of the whole spectrum of clinical, subjective and laboratory variables. 
It is striking that pain assessed in three of these variables, i.e. two, gives most 
weight to the AS-DAS. 
In conclusion, the proposed AS-DAS should be validated further. For standardi-
zation purposes the selected core set of process variables should be used in future 
clinical trials in AS, resulting in improvement of comparability of different studies. 
Additionally, the problem of multiple statistical testing will be solved since only a 
reduced number of variables, and eventually a single composed variable, i.e. the 
AS-DAS, have to be analysed for evaluation of disease activity. 
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A radiographic scoring system in AS 
Summary 
A radiographic scoring system for ankylosing spondylitis (AS) was developed and 
evaluated in a 48-week clinical study, in which ß-cyclodextrin-piroxicam was 
compared with naproxen, comprising a modified lumbar spine score (LSS), a 
cervical spine score (CSS), an enthesis score (ES) and Larsen hip score (HS). 
In study I radiographs of patients with AS, not participating in the clinical 
study, were scored by two observers to study reproducibility. The interobserver 
correlations of the CSS and LSS were larger than 035, corresponding intraobser-
ver errors were satisfactory. In addition, the intraobserver correlation and error 
were studied of ES and HS, and were satisfactory. However there was a statistical-
ly significant difference between the scores of the ES (t-test). 
In study II, radiographs made at week 0 and 48 of 57 patients were scored, 
blinded for treatment and patient, by a single observer in a sequential way. A 
significant change was found from week 0 to 48. There were no differences in 
radiographic scores and change in radiographic score between the two treatments 
(t-test), nor between responders and non-responders. Differences in radiographic 
scores between men and women were evaluated, and no significant differences 
could be found if corrected for disease duration. Pearson correlations of radio-
graphic scores and clinical variables assessed in the clinical study revealed several 
significant correlations, and these variables might be considered variables measu-
ring structural damage. 
This extended radiographic scoring is reproducible and sensitive to change. No 
differences were found between ß-cyclodextrin-piroxicam and naproxen, responders 
and non-responders, and men and women. 
Introduction 
To evaluate outcome in AS radiological scoring systems of the lumbar spine and 
the sacroiliac joints have been published by Taylor et al.1 But next to sacroiliitis, 
the hallmark lesion in AS, the whole axial spine, entheses and root joints are 
frequently involved2"*. Therefore, additional to radiographic scoring of the lumbar 
spine, these other sites should also be taken into account as well in the evaluation 
of outcome in AS. 
The aim of this study was to develop and evaluate a more extensive radiologi-
cal scoring system for AS, in which several entheses, the hip joints and the cervical 
spine were encompassed. This extended radiological scoring system was used in a 
48-week longitudinal study of patients with AS to describe radiographic features, 
and to evaluate sensitivity to change. In addition to this, the relationship with 
commonly used clinical variables was studied. 
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Table 1. Patients' characteristics at the start of the clinical trial 
number of paticns (n«57) 
sex ratio male : female 
HLA-B27 
peripheral arthritis 
age 
disease duration* 
43 : 14 
54 
3 
39 ± 9 
10 ± 8 
*: years, mean ± standard deviations 
Patients and methods 
The study was conducted at the departments of rheumatology of the University 
Hospital Nijmegen, St. Radboud and of the St Maartenshospital Nijmegen, the 
Netherlands, and started after full approval of both ethical committees was obtain­
ed. 
Radiographs 
Study I 
Plain X-rays of the pelvis (anterior-posterior film) and lateral view of the lumbar 
and cervical spine were used for the development of the radiographic scoring 
systems and for standardization of the two observers (MF, MC). Radiographs of 
370 patients (not included in study Π) with AS fulfilling the modified New York 
criteria5, attending the rheumatology departments, were used. To study reproducibi­
lity, a separate set of 95 X-rays of the pelvis, 46 lateral views of the lumbar spine 
and 26 lateral views of the cervical spine were scored. 
Study II 
Plain X-rays of the pelvis (anterior-posterior film), and lateral view of lumbar and 
cervical spine were made at weeks 0 and 48 of patients with AS fulfilling the 
modified New York criteria5, who participated in a nonsteroidal antiinflammatory 
drug (NSAID) trial. This trial was a single observer double-blind randomised study 
in which ß-cyclodextrin-piroxicam (SA Nycomed Christiaens BV, Belgium) was 
compared with naproxen (SA Nycomed Christiaens BV, Belgium). Radiographs of 
both week 0 and 48 were available of 57 out of 59 patients. Patients' characteristics 
are shown in Table 1. All radiographs were scored blinded with respect to the 
patient and treatment in a sequential way by a single observer. 
All patients had to have an active disease after a washout period for NSAIDs. 
Patients were sequentially assigned to one of the treatment groups, balanced* for 
age, sex, peripheral arthritis, extent and duration of the disease. Clinical measure-
ments were performed by a single observer (MC), generally at the same time of the 
day, at start of the medication (week 0) and at weeks 2, 4, 8, 12, 18, 24, 30, 36, 42 
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and 48. The following measurements were assessed at every visit: a. objective 
clinical variables: occiput-to-wall-distance, chest expansion, Schober 10 cm test7, 
lumbal lateral flexion', the number of swollen joints (n=S3), enthesis index', root 
joint index (pain of shoulders and hips by palpation and/or passive movement was 
assessed with pain graded from 0 to 3, the sum of the score being the index), 
mobility of the cervical spine in all three planes; b. subjective variables: duration of 
morning stiffness, and 100 mm Visual Analogue Scales (VAS) for spinal pain 
during the day, during the night and general wellbeing; с laboratory variables: 
HLA-B27, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), 
complete blood cell count, immunoglobin A, G and M; d. functional assessment: a 
Dutch Functional Index for AS10 was completed at week 0 and every 12 weeks 
thereafter. 
Radiographic scoring system 
a. lumbar spine: the scoring system, developed by Taylor et al.4 was applied to the 
lower border of the 12th thoracic vertebra, all five lumbar vertebrae and the 
upper border of the sacrum were viewed on the lateral X-ray. The corresponding 
nominal scoring system: 0 = no abnormality; 1 = erosion, sclerosis or squaring; 
2 = syndesmophyte, and 3 = total bony bridging at each site. Radiological 
abnormalities, which were not related to AS such as osteophytes, were not 
considered for scoring. Sites which were not clearly visible on the radiograph 
were not considered for scoring. If more than three scoring sites were missing, 
radiographs were not taken into account. Additional to the definitions of Taylor 
et al.1 squaring was defined as present if the surface of the vertebra was convex; 
or if a line could Actively be drawn with a transparent ruler, from the upper to 
the lower border of a vertebral body, and if this line overlayed 50% or more 
with the surface of the vertebra. This added definition of squaring approaches 
the method of Ralston et al.11 In order to deal efficiently with missing observati­
ons the total score (range 0-36) of all radiographs was calculated as 12 times the 
mean score of all scoring sites; 
b. cervical spine: this scoring system was identical to that of the lumbar spine. The 
lower border of the 2nd cervical vertebra up to and including the upper border 
of the first thoracic vertebra were viewed for this on the lateral X-ray. Due to 
the original straight shape of the lateral surface of the third cervical vertebra it 
was decided that this vertebra was not scored for squaring, although erosions and 
sclerosis were scored; 
с hip joints: the scoring system of the hips developed by Larsen et al.12 was 
applied. The anterior posterior X-ray of the pelvis was viewed. This scoring 
system uses the overall appearance of each hip was graded from 0 to S accor­
ding to standard radiographs (0 = normal conditions; and 5 = mutilating abnor­
mality and gross bone deformation). The total score is the sum of the grades of 
the two hips (range 0-10); 
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d. entheses: the following 4 entheses were viewed on the anterior-posterior film of 
the pelvis: the ischial tuberosities, the iliac alae, and the minor and major 
trochanter of the femoral bone. They were scored: 0 = no abnormalities; and 1 = 
irregular new bone formation ('whiskering'), or osseous erosions with ill-defined 
bony margins and reactive sclerosis. In order to deal efficiently with missing 
observations the total score was eight times the mean score of the different 
scoring sites, with at most two entheses allowed not to be scored. 
e. pubic symphysis: on the anterior-posterior view of the pelvis both sites of the 
pubic symphysic joint were scored separately: 0 = no abnormalities; and 1 = 
irregular new bone formation ('whiskering'), or osseous erosions with ill-defined 
bony margins and reactive sclerosis, or (sub)luxation. The total score (range 0-2) 
was the sum of the score of the two sites of the joint. 
Radiographs of patients in study I were used for the development of the radio­
graphic scoring systems. After standardization of the two observers, radiographs, 
which had not been used previously, were scored to study reproducibility. 
Statistical analysis 
Reproducibility (Study I) was analysed by calculation of interobserver correlation 
and interobserver duplicate error (VEdj2/2n) of the different scores. To find systema­
tical differences between the two observers t-tests were applied on the scores of the 
two observers. Intra-observer correlation and intraobserver error were only studied 
additionally if the interobserver correlation was less than 0.95. For the intraobserver 
study radiographs were scored a second time, without knowledge of the previous 
score. If necessary variables were transformed to obtain normality. 
To study potential differences in radiographic scores, several groups of patients 
were studied (Study Π): a. the two treatment groups; b. men and women; and с 
patients who completed the whole study, i.e. responders, and patients who dropped 
out because of either inefficacy or side effects, i.e. non-responders. The Wilcoxon 
signed rank-test was used for analysis. In order to avoid multiple testing and thus 
decrease the risk of false significancies, two radiographic scores were composed: 1. 
the spinal score which was the sum of the lumbar and cervical radiographic score 
(range 0 - 72); and 2. a weighted overall score (range 0 - 124) of the spinal score 
(range 0 - 72) + 3.6 times the hip score (range 0-10) + 2 times the enuresis score 
(range 0 - 8). Additionally, to study the cervical spine involvement in the different 
groups, this score was analysed similarly. A 3-way ANOVA has applied additional­
ly to the scores of men and women to correct p-values for disease duration. 
In order to analyse the influence of HLA-B27 positivity, sex and disease 
duration on the scoring systems of the lumbar spine, cervical spine, entheses and 
hips (Study П) a multiple regression analysis has been done. 
Pearson correlations between the spinal score and the overall score and assessed 
clinical variables, which were transformed if necessary to obtain normality, were 
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calculated (Study Π). Those variables which revealed significant correlations with 
the overall and spinal score both at weeks 0 and 12 were considered as variables 
measuring structural damage. 
Results 
Study I 
In total 46 X-rays of the lumbar spine, 26 of the cervical spine and 96 of the 
pelvis have been scored for the evaluation of reproducibility. Table 2 shows the 
means, standard deviations, interobserver correlations, duplicate error and p-value 
of t-testing of the different radiographic scoring systems. Because the hip and 
enthesis score had interobserver correlations less than 0.9S, the intraobserver 
correlation and intraobserver duplicate error of these two scoring systems were 
studied additionally (see Table 2). 
Study II 
Table 3 shows the number of patients at week 0 with radiological involvement 
of the cervical and lumbar spine, the hips and entheses. To get an impression about 
the distribution of the radiological involvement in the cervical and lumbar spine, 
the percentages of the upper and lower border with scores 0 and 3 are shown in 
Table 4. Total bony bridging was mainly present from Cj to Th„ Q to C3, C3 to 
C4, and from Thi2 to L,. The 12th thoracic, the 1st lumbar and the 4th cervical 
vertebrae showed most frequently radiological involvement 
Table 4. Percentages of the presence of score 0 and 3 per vertebra in study Π 
cervical 
vertebra 
Qi 
C311 
C,l 
C4u 
Qi 
CjU 
C,l 
Qu 
Qi 
C,u 
C71 
Th,!! 
0 
84 
74 
75 
25 
30 
65 
68 
74 
72 
60 
60 
50 
score 
3 
5 
5 
5 
5 
2 
2 
2 
2 
2 
2 
7 
12 
Explanations of abbreviations' 
С = cervical; Th = thoracic, L = 
lumbar 
vertebra 
Th„l 
L,u 
L,l 
L,u 
W 
L,u 
L,l 
L4u 
L41 
L,u 
L,l 
S,u 
• lumbar; S » sacral; 
0 
44 
51 
75 
72 
83 
65 
77 
72 
79 
79 
82 
93 
score 
u = upper margin; 
3 
11 
11 
5 
5 
2 
2 
5 
5 
5 
5 
4 
4 
1 = lower margin 
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Table 5. Median (percentiles 10 and 90) of cervical spine, spinal and overall score 
and change in score of men and women and the two treatments at weeks 
0 and 48 
radiographic score 
cervical spine score 
spinal score 
overall score 
spinal score 
overall score 
week 
0 
48 
change' 
0 
48 
change* 
0 
48 
change' 
0 
48 
change' 
0 
48 
change* 
men (n » 43) 
3.3(1.0, 11.6) 
5.0 (2.0, 14.9) 
1.1 (0, 4.5) 
6.0 (1.4, 25.6) 
9.0 (2.0, 30.8) 
2.0 (0, 5.7) 
9.6 (2.4, 29.7) 
13.0 (4.4, 38.6) 
3.1 (0.4, 8.0) 
ß-cyclodextrin-
piroxicam 
5.7 (0.9, 32.3) 
8.0(1.8,33.4) 
1.1 (0, 4.5) 
7.2(1.8,32.3) 
10.2 (3.6, 32.3) 
2.0 (0, 5.7) 
women (n a 14) 
2.2(0, 11.6) 
2.2 (0, 14.4) 
0 (0, 3.7) 
3.6 (0, 16.0) 
4.7 (0, 17.7) 
1.1 (0, 3.8) 
4.6 (0, 17.0) 
7.0 (1.1, 20.2) 
2.1 (0, 4.5) 
naproxen 
6.0 (0, 20.6) 
9.0 (1.1, 22.8) 
0 (0,3.7) 
9.6 (2.0, 22.7) 
12.8 (3.6, 28 J) 
1.1 (0, 3.8) 
p-valuc 
0.31 
0.24 
0.25 
0.09 
0.05 
0.15 
0.02 
0.02 
0.15 
p-value 
0.79 
0.76 
0.89 
0.87 
0.79 
0.47 
corrected 
p-value 
0.70 
0.54 
0.22 
0.15 
0.09 
0.053 
Explanations of symbols: percentiles 10 and 90 are placed between brackets, 
': the change from weeks 0 to 48 
The mean change in scores between week 0 and 48 of all patients was 1.45 
(range 0 - 6.0) in the cervical spine, 1.06 (0 - 5.0) in the lumbar spine, 0.08 (0 -
1.0) in the hips, and 0.32 (0 - 2.0) in the enthesis score. All changes were statisti-
cally significant (p < 0.001). Radiological progression in the cervical spine was 
seen in 23 patients, in the lumbar spine in 24 patients, and in the enthesis score in 
17 patients. 
The spinal score and overall score at weeks 0 and 48, and the change in these 
scores were calculated for the two treatment groups, for responders and non-
responders, and for men and women. No statistically significant differences were 
found between the two treatment and between responders and non-responders. The 
mean disease duration for men and women was 11 years (standard deviation = sd = 
8 years) and six years (sd = 4 years) respectively, which was statistically different 
(p = 0.015). T-testing of the scores of men and women revealed a statistically 
significant difference, which was no longer present after correction for disease 
duration (see Table 5). None of the calculated changes between the different groups 
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Table 6. Clinical variables with significant Pearson correlations (57 patients) 
variables overall score spinal score 
chest expansion 
fingertip-to-floor distance 
occiput-to-wall distance 
lumbar flexion index 
lumbar lateral flexion 
cervical anteflexion 
cervical retroflexion 
cervical lateral flexion 
cervical rotation 
week 0 
-0.47"· 
0.41"· 
-0.42"· 
-0.40*" 
-0.28* 
-0.35* 
-0.45*" 
-0.32* 
Explanation of symbols: p-values: ' 
week 12 
-0.56"· 
0.29* 
0.42"· 
-0.53"· 
-0.45*" 
•0.41"* 
-0.37"· 
-0.48"· 
-0.50"· 
« ρ < 0.05; " = ρ < 0.01; ' 
week 0 
-0.Э6" 
0.37"' 
-0.41"· 
•0.4 Γ* 
-0.37" 
-0.35* 
-0.29* 
" = ρ < 0.005 
week 12 
-0.43"· 
0.28* 
0.36"' 
-0.5 Γ" 
-0.44"* 
-0.40'" 
-0.36" 
-0.41*·· 
-0.49"" 
showed a statistical significant difference. Table S shows the scores and change in 
scores for men and women, and for the two treatments. 
To evaluate the influence of disease duration, sex and HLA-B27 positivity on 
the radiographic scores, a multiple regression analysis was done on all six scores at 
week 48. Long disease duration and male sex showed an unfavourable significant 
influence on the enuresis score. HLA-B27 did not reach significance in any of the 
scores. 
Pearson correlations between all assessed clinical variables at weeks 0 and 12 
and the spinal and overall score were analysed, and those which revealed statistical 
significant correlations are shown in Table 6. 
Discussion 
A scoring method for radiographic assessment in AS has been evaluated in this 
study. Previously published radiographic scoring systems of the hips13 and of the 
lumbar spine4 have been used. The scoring system of the lumbar spine has been 
modified and made applicable for the cervical spine as well. Next to this, a scoring 
system for entheses of the pelvis and femural bone was developed and evaluated. 
During the standardization procedure many difficulties were experienced with the 
pubic symphysis score, reason to exclude this score. The radiological evaluation of 
the sacro-iliac joint was left out of consideration, as the presence of sacroiliitis is 
fundamental to diagnosis of AS. 
The interobserver correlations of the lumbar and cervical spine scores were 
good (r > 0.95). Although the cervical spine score showed a statistically significant 
difference between the scores of the two observers, the interobserver duplicate error 
of 0.55 in a range from 0 to 36 can be considered as relatively small. The enthesis 
and hip scores have been scored twice by the two observers, because interobserver 
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correlations were less than 0.95. The intraobserver correlations of both scores were 
satisfying (see Table 2). As it concerns the enthesis score one observer is obligate 
for this part of the scoring system. 
In our group of patients the thoracolumbar area and the lower lumbar vertebrae 
most frequently showed total bony bridging. In the past Resnick et al.13 have 
reported a predominant involvement of the thoracolumbar area with subsequent 
ascent. The same study13 has found that the upper levels of the cervical spine most 
frequently were involved, together with the cervicothoracic area. AU these findings-
were confirmed by our data. However Braunstein et al.'4 have reported a spinal 
ascend in the cervical spine. Comparison of squaring is made impossible, because 
different definitions for squaring of vertebrae have been used in other studies1115, or 
the frequency of squaring has not been reported1. Pelvic whiskering has been 
reported to be present in 44% of cases13, without reporting patients' characteristics. 
Since it is plausible that radiographic involvement and progression increases with 
disease duration, we cannot compare out data with those published by others. 
The radiographic scores progressed statistically significant during the first year 
of follow-up, although only half of the patients showed changes. However, it 
should be noted that the radiographs have been scored in sequential order with each 
other, so only a positive difference, i.e. progression, is possible. 
In previous studies it has been reported that radiological involvement and 
progression was less severe in women13,14,1', whereas others did not find these 
differences15,17. Apart from the differences in severity, some studies have found an 
increased involvement of the cervical spine in women13,1'. In our study significant 
differences between men and women have been found in the spinal score 
and overall score, but neither in the cervical spine score nor in the change in scores 
over 48 weeks. However, if we corrected for disease duration, no significant 
differences between men and women could be found. Thus, it might be concluded 
that disease progression and radiographic involvement is similar in men in women 
in this study. Kennedy et al.19 recently have reported that onset of disease in 
women is later than in men, previously already reported by Resnick et al.13. Our 
data might confirm this, however we have studied only 57 patients. 
Chest expansion, occiput-to-wall distance, lumbar flexion index, lumbar lateral 
flexion and cervical anteflexion, retroflexion, lateral flexion and rotation revealed 
significant correlations with radiographic scores at weeks 0 and 12 and might be 
identified variables measuring structural damage. 
In future studies evaluation should contain a much longer follow-up time. The 
enthesis score should be evaluated anew, and possibly modified, after extensive 
standardization. The identification of a subset of variables which show highly 
significantly correlations with radiographic scores is important for interpretation of 
results in future studies, since these variables might not be sensitive to change 
regarding disease activity. In conclusion, this extensive radiographic scoring system 
is a very useful method to assess radiographic damage in AS. 
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Summary and conclusions 
Ankylosing spondylitis (AS) is a chronic inflammatory disease mostly affecting the 
sacroiliac joints and the spine. This inflammation may often lead to ankylosis, 
resulting in a limited mobility of the back and eventually in a decreased functional 
capacity. Structural damage, in fact the final result of the inflammatory process, can 
partly be seen on X-rays as ankylosis and syndesmophyte formation. Treatment 
mainly consists of chronic intermittent administration of nonsteroidal antiinflam-
matory drugs (NSAIDs), however a growing interest is seen for 2nd line treatment 
(such as sulfasalazine, methotrexate, hydroxychloroquine), since these drugs might 
influence the course of the disease. 
In this thesis, several aspects of first and second-line treatment in AS were 
studied. In addition, attention was paid to assessment of the disease. 
ß-cyclodextrin-piroxicam versus naproxen 
The comparison of ß-cyclodextrin-piroxicam and naproxen was evaluated in 59 
patients (ß-cyclodextrin-piroxicam: η = 29; naproxen: η = 30) with AS during 48 
weeks. Efficacy and toxicity are described in chapter 2. In general there was no 
difference in efficacy and toxicity between ß-cyclodextrin-piroxicam and naproxen. 
At the end of the study 38 patients still used the study medication (21 patients 
treated with ß-cyclodextrin-piroxicam, 17 patients treated with naproxen). The mean 
drug survival time is 41 weeks (standard deviation = sd = 14 weeks) for ß-cyclo-
dextrin-piroxicam, 36 weeks (sd = 16 weeks) for naproxen, which is not statistical-
ly significant different. Comparison between the two treatments of commonly used 
clinical variables over 48 weeks and the mean change from week 0 to week 2 did 
not reveal any difference in efficacy. 
Gastrointestinal toxicity of NSAIDs 
In chapter 3 gastrointestinal (GI) toxicity of the two NSAIDs is described. For this 
purpose the HemoQuant Assay has been used, a method which measures haem-
derived porphyrins. Advantages of this HemoQuant Assay are that it is a non-
invasive technique, and that it evaluates the entire GI tract. Evaluation of the entire 
GI tract is of crucial importance, because NSAIDs can cause (severe) mucosal 
injury in the small and large intestines, and additional to this, the frequency of 
inflammatory bowel disease is known to be increased in AS. The amount of faecal 
blood loss did not differ between ß-cyclodextrin-piroxicam and naproxen over 48 
weeks, however the amount of faecal blood loss at week 4 was increased compared 
to the other measurement occasions, i.e. weeks 0, 24 and 48. This increase 
indicates a possible mechanism of gastric adaptation, as reported in previous studies 
with aspirin. 
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Pseudoporphyria due to naproxen 
In chapter 4 we describe three cases of pseudopoiphyria due to naproxen, of 
whom two patients participated in the NSAID study. All literature on pseudopor-
phyria due to naproxen has additionally been reveiwed. 
Pharmacokinetic interaction of ß-cyclodextrin-piroxicam 
with H2-receptor antagonists 
The possible interaction between ß-cyclodextrin-piroxicam and the two H2-receptor 
antagonists, Cimetidine and ranitidine, has been studied at steady state conditions of 
all drugs. Two groups of each eight healthy male volunteers were included in the 
study, and during 40 days blood and urine samples have frequently been taken. 
Absorption, metabolism and excretion of ß-cyclodextrin-piroxicam did not change 
during concomitant administration of the two H2-receptor antagonists. Pharmaco-
kinetics of Cimetidine and ranitidine did not change either during ß-cyclodextrin-
piroxicam administration (chapter 5 and appendix). 
Second-line treatment 
In chapter 6 a review of the literature on second-line treatment in seronegative 
spondylarthropathies is reported. Second-line treatment reviewed included hydroxy-
chloroquine, gold, d-penicillamine, sulfasalazine, methotrexate, cyclophosphamide, 
6-mercaptopurine, azathioprine, cyclosporin and levamisole as well as radiothera-
py, methylprednisolone and corticotrophin. Only sulfasalazine has been studied in 
sufficient detail to allow definitive conclusions, but methotrexate and azathioprine 
may be promising drugs. Radiation therapy led to short-term improvement in AS, 
but was abandoned because of severe long-term side effects. 
Methotrexate in ankylosing spondylitis 
Methotrexate (MTX), therefore, was studied in 11 patients with severe AS in an 
open study of 36 weeks (chapter 7). Evaluation of efficacy was evaluated in two 
different ways for objectivity, i.e. the relative difference of assessed variables 
between weeks 0 and 24, and by deciding at week 24 either to continue or to stop 
MTX based on patients' global assessment. In total nine patients were évaluable at 
week 24: one patient could stop NSAID treatment, three could reduce the dose of 
NSATDs, and three patients deteriorated after discontinuation of MTX and opted to 
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restart. Side effects were reversible or transient, and no severe side effects were 
seen. 
Functional assessment in ankylosing spondylitis 
Chapter 8 describes the development and evaluation of Dutch Functional Index for 
the assessment of functional status in patients with AS. For this purpose a French 
Functional Index was translated, and items concerning static activity and bicycle 
riding, typically Dutch, have been added. In 150 patients with AS fulfilling the 
modified New York criteria, reliability has been studied (cronbach's α = 0.95). 
Reproducibility and criterion validity were studied in two other groups of patients 
with AS (n = 39 and η = 19, respectively) and considered good. Finally, in the 
NSAID study the questionnaire was completed at the start of the study medication 
and every 12 weeks thereafter in order to study sensitivity to change on the 
longterm and for evaluation of the measurement-remeasurement correlation. In 
conclusion, the Dutch Functional Index, comprising 34 questions, turned out to be a 
questionnaire, which is reliable, reproducible, valid and sensitive to change for 
assessment of functional status in patients with AS. 
Assessment of process variables of disease activity 
As discussed before, the assessment of disease activity comprises many difficulties. 
Because of this, all data of the two clinical studies, i.e. the NSAID study and the 
MTX study, have been used to evaluate 27 commonly used clinical variables 
(chapter 9). For evaluation of reproducibility, discriminating power and the 
correlation of variables and factors with disease duration, a predefined analysis 
strategy was used, which included principal component analysis to form subgroups 
of reliable, interrelated variables. This evaluation resulted in a selection of seven 
process variables. The core set of seven process variables encompassed lumbar 
flexion index, spinal pain during the day, enthesis index, functional index, C-
reactive protein (CRP), root joints and the number of swollen joints. In subsequent 
discriminant analysis two variables had to be excluded, namely the number of 
swollen joints and the lumbar flexion index for the computation of a disease 
activity score (AS-DAS). The formula for the AS-DAS is: AS-DAS = 
0.238*(Dutch Functional Index) + 1.13*sqrt(enthesis index) + 0.318*(spinal pain 
during the day) + 6.54*ln(CRP) + 5.245*double square root(root joints). This AS-
DAS has to be validated in the future. A core set of process variables for disease 
activity in AS improves standardization in future studies, thus improving 
comparability of different clinical studies. The problem of multiple testing, caused 
by the large number of variables, is solved, especially if in future the validated AS-
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DAS can be used as a single, composed variable for evaluation in clinical studies 
in AS. 
Radiographic scoring systems 
Structural damage, in fact the result of the disease, can be seen on X-rays. To 
evaluate structural damage in AS, a radiographic scoring system is described in 
chapter 10. This radiographic scoring system is composed of: 1. a radiographic 
scoring system of the lumbar spine, in essence a modification of a previously 
published radiographic scoring system for the lumbar spine; 2. a similar system for 
the cervical spine; 3. the Larsen score for the hip; and 4. a radiographic enthesis 
score of the ischial tuberosities, the iliac alae, and the minor and major trochanter 
of the femoral bone. This extended radiographic scoring system has been validated. 
Reproducibility and duplicate errors are satisfactory. Subsequently X-rays made at 
weeks 0 and 48 of the NSAID study have been scored with this system. The 
change in scores from weeks 0 to 48 was highly statistically significant, indicating 
that the radiographic system is sensitive to change. The mean change from week 0 
to 48 as well as the scores at weeks 0 and 48 reveal no statistically significant 
difference between ß-cyclodextrin-piroxicam and naproxen, respondéis and non-
responders, and men and women. 
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Solid-phase extraction of Cimetidine and analysis bij HPLC 
Summary 
An improved method is described for the solid-phase extraction of Cimetidine from 
plasma or serum with subsequent analysis by high-performance liquid chromatog-
raphy (HPLC). New aspects of the method include protein precipitation with 
metaphosphoric acid (5%wlv), followed by selective adsorption of Cimetidine and 
the internal standard ranitidine on the surface of a solid-phase phenyl (PH Bond 
Elut) column, using octanesulfonate as an ion-pairing agent. Separation was 
achieved on a LiChrosorb RP-18 column with a mobile phase consisting of 
acetonitrile - 0.01 M phosphate buffer pH 3.0 containing 0.005 M octanesulfonate 
(22:78 vlv). Intra-assay coefficient of variation varied between 0.7 and 4.0%. The 
procedure provides cleaner and more stable samples and a better recovery (90 ± 
23%) and sensitivity (limit of detection 5 nglml and limit of quantitation 25 nglml) 
as compared to previous methods. 
Introduction 
A large number of high-performance liquid chromatographic methods (HPLC) for 
the quantitation in biological fluids of Cimetidine, an H2-receptor antagonist widely 
used for the treatment of gastric and duodenal ulcers, has been published. For the 
sample clean-up of plasma or serum one of the investigators used acetonitrile for 
the precipitation of protein1. Some investigators employed single or multiple liquid-
liquid extraction procedures2"9, and others made use of solid-phase extraction10"15. 
None of the authors who employed the solid-phase extraction technique for the 
sample clean-up of plasma or serum took account of the protein binding of Cimeti-
dine, which is about 13 to 26%16. This is probably one of the reasons why some 
authors have reported an absolute recovery as low as 59%12 and 73% u . Another 
important reason for the low recovery, and in most papers high coefficient of 
variations, may be heterogeneity and channeling in the solid-phase bed. However, 
when the solid-phase extraction technique is used optimally, an absolute recovery 
of 90% with negligible interferences should always be achievable. The mean 
particle size of the commonly used bonded silica sorbents is 40 urn17. The nominal 
porosity of most of the sorbents is 60 Â, adequate for compounds with molecular 
weights up to approximately 15,000. Molecules larger than this (molecular weight 
of human serum albumin = 69,000) are excluded from the 60 Â pores and are 
exposed to too little of the surface area of the sorbent for sufficient interactions 
with the sorbent functional groups. As a consequence, they pass through these 
sorbents without being retained. Cimetidine bound to albumin will be lost in this 
manner. 
Therefore, we incorporated a precipitation step in our solid-phase extraction 
method using metaphosphoric acid. This does not add much time to the procedure, 
as precipitation of the protein can be carried out in a large series of samples. A 
second new element introduced in our procedure is ion-pair solid-phase extraction. 
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After deproteinizatìon the pH of the resulting supernatant is acidic. Under this 
condition Cimetidine and ranitidine (internal standard) are principally not retained 
by non-polar solid-phase extraction columns. In order to cause retention of both 
compounds on PH (Phenyl) columns we added, octanesulfonate, an ion-pairing 
agent, to the supernatant. Both protein precipitation and ion-pair solid-phase 
extraction provide cleaner samples and a better recovery and sensitivity as compa-
red with previously published methods. 
Experimental 
Reagents and materials 
Cimetidine and ranitidine hydrochloride were purchased from Sigma (St. Louis 
MO, USA). Potassium dihydrogen phosphate, disodium hydrogen phosphate 2-
hydrate, orthophosphoric acid, metaphosphoric acid were all of analytical grade 
(Merck, Darmstadt, Germany). Methanol and acetonitrile were HPLC grade 
(Merck), and 1-octanesulfonic acid sodium salt was from Janssen Chimica (Beerse, 
Belgium). Vac Elut manifold and Bond Elut PH (Phenyl) columns (1 ml capacity, 
to which a 4 ml Bond Elut reservoir was attached using a Bond Elut adaptor) were 
manufactured by Analytichem International (Habor City, CA, USA). Available 
reverse osmosis water (Millipore) was further purified with a MilliQ system 
(Millipore) before use. Human blood samples, stored at -20 °C, were obtained from 
the local blood bank. 
Standard solutions 
Stock solutions of Cimetidine (1 mg/ml) and ranitidine (1 mg/ml) were made with 
0.01 M phosphate buffer pH 3.0. Working standard solutions were prepared each 
time by diluting the stock solutions with the same buffer. A 100 ul aliquot of the 
working standard solutions was used. Stock solutions of Cimetidine and ranitidine 
in 0.01 M phosphate buffer pH 3.0 were stable for at least 6 months when stored in 
the dark at 4 °C. 
Apparatus and chromatographic conditions 
The chromatography system consisted of a Spectra Physics P2000 binary gradient 
pump, a Hewlett Packard S um ODS Hypersil guard column (20 χ 2.1 mm), a 
Hewlett Packard 5 urn LiChrosorb RP-18 analytical column (200 χ 4.6 mm) and a 
Spectra Physics AS 3000 autosampler with a built-in column heater. The mobile 
phase, acetonitrile - 0.01 M phosphate buffer pH 3.0 containing 0.005 M octanesul­
fonate (22:78 v/v) maintained under a helium sparge during use, was delivered at a 
rate of 1 ml/min, the resulting pressure being 8.0 MPa. The column effluent was 
monitored with a Spectra Physics UV1000 variable wavelength detector set at 228 
nm. The signal was processed by a Spectra Physics SP4400 integrator. The column 
heater was set at 40 °C and the injection volume was 10 ul (50 ul at concentrations 
lower than 0.05 ц^ті). 
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Sample pretreatment 
Into a plastic tube were pipetted successively, 0.5 ml plasma, 100 ul internal 
standard (5 mg ranitidine per 100 ml 0.01 M phosphate buffer pH 3.0) and 2 ml of 
a 5% (w/v) metaphosphoric acid solution. The tube was vortex-mixed for 5 s. After 
standing for 5 min at room temperature, the tube was again vortex-mixed for 5 s. 
Therafter, the tube was centrifuged at 2000g and 20 °C for 10 min. The supernatant 
was transferred into another plastic tube, and 0.8 ml 0.3 M NajHPO^ solution 
containing 0.02 M octanesulfonate was added. The tube was then vortex-mixed for 
5 s. The prepared sample was now ready to be loaded onto the PH (Phenyl) solid-
phase extraction column. 
Extraction procedure 
Extraction of Cimetidine and ranitidine (internal standard) from plasma was 
achieved by the use of a bonded silica solid phase extraction column (Bond Elut 
PH, 1 ml capacity). The column was conditioned prior to use by drawing three 
column volumes (appr. 3 ml) of methanol followed by a similar volume of 0.01 M 
phosphate buffer pH 3.0 containing 0.005 M octanesulfonate through the column. 
The prepared sample was loaded onto and subsequently drawn through the column. 
The column was then washed with four column volumes of 0.01 M phosphate 
buffer pH 3.0 containing 0.005 M octanesulfonate. The cover of the manifold was 
then removed and the blunt nose stainless-steel needle of the Vac Elut cover was 
wiped with a tissue to remove drops of washing solution. The Vac Elut rack 
holding a 2-ml glass sampling tube, was placed under the column. Cimetidine and 
ranitidine were eluted from the column with 0.75 ml of an elution mixture, 
acetonitrile - 0.01 M phosphate buffer pH 3.0 containing 0.005 M octanesulfonate 
(30:70 v/v). To make the elution strength of the collected eluate equal to that of the 
mobile phase, 275 ul 0.01 M phosphate buffer pH 3.0, containing 0.005 M octane-
sulfonate, was added. This was done to prevent peak broadening whenever larger 
volumes (50 ul) had to be injected onto the column. The eluate was then analysed 
as described. The eluate was found to be stable for more than 2 weeks at room 
temperature and more than 4 weeks stored at 4 °C. 
Results and discussion 
Chromatography 
Figure 1 shows typical chromatograms for blank plasma and for blank plasma 
spiked with Cimetidine and the internal standard (I.S.) ranitidine. The retention 
times of Cimetidine and ranitidine were 5.85 and 7.57 min, respectively, while an 
endogenous peak had a retention time of 6.37 min. Without the presence of the ion-
pairing agent octanesulfonate retention times of Cimetidine and ranitidine were 2.87 
and 3.28 min. 
The efficiency of the analytical column used to obtain the chromatogram in Fig. 1 
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Fig. 1. Chromatograms obtained for blank plasma and blank plasma spiked with 
1.25 pg/ml Cimetidine (1) and 1.25 pg/ml ranitidine (2). Injection volume = 
10 pi. 
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was 9000 plates/20 cm for the Cimetidine peak. The theoretical plate number 
remained practically the same after 700 samples, but the column pressure increased 
slightly. After renewal of the guard column the system pressure attained its original 
value. 
Calculation 
The Cimetidine concentration in a sample was determined from a standard curve of 
peak height ratio versus Cimetidine concentration. Whenever a sample containing 
Cimetidine was measured, a standard curve was generated by adding different 
amounts of Cimetidine to blank plasma. A linear relationship was found between 
the peak height ratio of Cimetidine to ranitidine (Y) and the plasma Cimetidine 
concentration (X), as given by the equation Y = 0.841X + 0.002 (r = 0.9999, л = 6) 
for the plasma Cimetidine concentration range 0.25 - 5 pg/ml (LS. = 5 pg/ml) and Y 
= 8.472X + 0.009 (r = 0.9997, η = 5) for the plasma Cimetidine concentration range 
0.025 - 0.25 pg/ml (LS. = 0.5 pg/ml). 
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Recovery 
Overall recovery with the extraction procedure was determined by comparing the 
peak heights of Cimetidine and ranitidine obtained after injection of non-extracted 
standard solutions with peak heights obtained after injection of extracted plasma 
containing equal concentrations of both compounds. The absolute recovery of 
Cimetidine and ranitidine is 90% and independent of the concentration with a 
coefficient of variation (C.V.) equal or less than 2.3% (Table 1) 
Efficiency of the deproteinization procedure 
To investigate the efficiency of protein precipitation by 5% (w/v) metaphosphoric 
acid, 0.3 ml aliquots of a series of ten spiked plasma samples were deproteinized. 
After centrifugation the volume of the supernatant was measured. The volume was 
found to be 2.43 ml (C.V. = 0.8%, n=10), which is 90% of the initial volume (0.5 
ml plasma + 2 ml 5% metaphosphoric acid + 100 ul standard solution + 100 ul 
internal standard solution). From these results it was concluded that Cimetidine and 
ranitidine existed completely free in the deproteinized sample, 90% in the superna­
tant and 10% in the pellet. 
Sensitivity, precision and applicability 
The limit of detection (two times baseline noise) of the method described was 5 
ng/ml. Table 2 shows the precision and accuracy of Cimetidine measurement in 
plasma. The intra-assay C.V. varied between 4.0 and 0.7% over a Cimetidine 
concentration range of 0.063 - 2.500 pg/ml. At the limit of quantitation (five times 
limit of detection) the C.V. was 14.1%. 
Various drugs that are often concurrently administered with Cimetidine were 
examined for possible interference with the assay. Plasma samples from patients 
who were treated with therapeutic doses of acetylsalicylic acid, amiloride, atenolol, 
azapropazone, diclofenac, furosemide, hydrochlorothiazide, indomethacin, naproxen, 
omeprazole, oxazepam, paracetamol, phenylbutazone, pinracam, prednisone, 
salazopyrine, and salicylic acid were examined. None of the drugs showed interfer-
Table 1. Recovery of Cimetidine and ranitidine from plasma' 
Compound 
Cimetidine 
Ranitidine 
Concentration 
(ц$/т1) 
0.25 
2.50 
0.50 
2.50 
Recovery 
(%) 
90 
90 
89 
91 
C.V. 
(%) 
2.3 
2.3 
2.2 
1.2 
'For all concentrations, η = 6: C.V. = coefficient of variation. 
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Table 2. Precision and accuracy of Cimetidine analysis in spiked plasma samples' 
Spiked 
concentration 
(Mg/ml) 
0.025 
0.063 
0.125 
0.188 
0.250 
0.625 
1.250 
1.875 
2.500 
Observed 
concentration 
(Hg/ml) 
0.025 
0.064 
0.128 
0.194 
0.245 
0.638 
1.298 
1.839 
2.503 
C.V. 
(%) 
14.1 
4.0 
3.9 
2.7 
2.3 
2.6 
0.7 
1.1 
0.7 
Accuracy 
(%) 
100.0 
98.4 
97.7 
96.9 
102.0 
98.0 
96.3 
102.0 
99.9 
'For all concentrations, л = 5; C.V. = coefficient of variation. 
ing peaks at the retention times for Cimetidine and ranitidine. The H2-antagonists 
nizatidine and metiamide do not interfere, whereas the retention time of famotidine 
coincides with that of Cimetidine. 
Conclusion 
The Cimetidine method described here for plasma or serum is a significant im­
provement over previously published methods in terms of sensitivity, recovery, 
stability and cleanliness of the final sample. It should prove to be valuable for 
clinical monitoring of plasma or serum levels and detailed pharmacokinetic studies. 
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Samenvatting en conclusies 
Een Nederlandse samenvatting van dit proefschrift voor niet-medici 
Spondylitis ankylopoëtica 
Spondylitis ankylopoëtica (SA), ook wel de ziekte van Bechterew genoemd, is een 
chronisch reumatische ziekte. 'Spondylitis' betekent een ontsteking van de 
gewrichtjes van de wervelkolom, en 'ankylopoëtica' dat deze ontsteking kan leiden 
tot verstijving van deze gewrichtjes. Het sacro-iliacale gewricht, tussen darmbeen 
en heiligbeen in het bekken, ondergaat een soortgelijke ontsteking en verstijving. 
De oorzaak van SA is niet bekend. Wel is het duidelijk dat er een erfelijke aanleg 
tot het krijgen van de ziekte aanwezig is in de vorm van een bepaalde 'bloed-
groep', het HLA-B27. Doorgaans manifesteert SA zich tussen het 18e en 35e 
levensjaar. De ziekte komt bij mannen drie keer zoveel voor als bij vrouwen. 
De belangrijkste symptomen van SA zijn pijn en stijfheid. De pijn zit voorna-
melijk in de (onder)rug, is vroeg in de ochtend op z'n hevigst, en gaat gepaard 
met stijfheid. Doorgaans verdwijnt deze pijnlijke stijfheid na beweging. Ook kan er 
pijn en stijfheid van de borstkas optreden, evenals ontstekingen van de overgangen 
van bot naar pees - enthesis genoemd - en van gewrichten van de ledematen. Al 
deze verschijnselen bij elkaar kunnen een verminderd functioneren veroorzaken. 
Ook buiten het bewegingsapparaat kan SA zich manifesteren, enkele voorbeelden 
hiervan zijn een regenboogvliesontsteking en aften in de mond en op de geslachts-
organen. Bovendien komen chronische ontstekingsziekten van de darm (ziekte van 
Crohn, colitis ulcerosa) en psoriasis vaker voor. 
Op de röntgenfoto is blijvende, irreversibele gewrichtsschade zichtbaar, zoals: 
a) totale verbening van het sacro-iliacale gewricht; b) verkalking van de randen 
van de tussenwervelschijven, waardoor de wervels als het ware aan elkaar vast-
groeien; c) kalkafzetting en een aanvreten van het bot (zgn. erosies) op de plaats 
van de entheses; en d) erosies en ernstige beschadiging van gewrichten van de 
ledematea 
Geneesmiddelen, gebruikt bij de behandeling van SA, zijn de zogeheten niet-
steroïde anti-inflammatoire geneesmiddelen (NS AID's), ook wel eerste lijns anti-
reumatica genoemd. NSATD's hebben een pijnstillend en ontstekingsremmend 
effect. Helaas veroorzaken ze frequent bijwerkingen van het maag-darm kanaal, 
variërend van misselijkheid tot zelfs een maagbloeding. Tweede lijns anti-reumati-
ca worden al geruime tijd gebruikt bij andere reumatische aandoeningen, en het 
lijkt dat ze dan het beloop van de ziekte in gunstige zin beïnvloeden. Ze werken 
alleen ontstekingsremmend en daardoor hebben ze ook hun weerslag op de pijn en 
stijfheid. Hun werking treedt doorgaans pas na enkele maanden gebruik op, en 
daarom worden ze in combinatie met NS AID's voorgeschreven. Tot voor een 
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aantal jaren geleden was het vrij ongebruikelijk om voor een zo 'onschuldige' 
aandoening als SA tweede lijns anti-reumatica voor te schrijven. Er is echter een 
groeiende interesse voor deze geneesmiddelen in de behandeling van SA. 
Naast medicamenteuze behandeling speelt oefentherapie en fysiotherapie een 
belangrijke rol. Immers, om verstijving in voorovergebogen houding te voorkomen, 
is een goede houding en goed gebruik van de rug noodzakelijk. Ademhalingsoefe-
ningen kunnen nuttig zijn als de patiënt pijn aan de borstkas heeft, die bij elke 
ademteug gevoeld wordt. Uiteindelijk kan de aandoening, ondanks behandeling 
met medicamenten, leiden tot bewegingsbeperkingen en een verminderd functione-
ren. Maatschappelijke begeleiding en ergotherapie kunnen dan nodig wordea 
Dit proefschrift 
In dit proefschrift is aandacht besteed aan zowel de eerste als de tweede lijns anti-
reumatica bij de behandeling van SA. Tevens is onderzoek verricht naar de wijze 
van meten van ziekte-acüviteit, blijvende schade, en functionaliteit (wat kunnen 
patiënten nog aan lichamelijke activiteiten, doorgaans een optelsom van ziekte-
activiteit en restschade ten gevolge van ontsteking). De verschillende studies met 
hun conclusies zullen hieronder worden samengevat. 
ß-cyclodextrine-piroxicam (Brexine) versus naproxen in SA 
Twee NSAID's die veel gebruikt worden zijn piroxicam en naproxen. Door Piroxi-
cam te verbinden met de suiker, ß-cyclodextrine, wordt piroxicam sneller opgeno-
men in de bloedbaan, waardoor er mogelijk minder maag-darm bijwerkingen 
zouden kunnen optreden. Bij 59 SA-paüënten zijn de effectiviteit (werkzaamheid) 
en toxiciteit (mate van bijwerkingen en nadelige effecten) van ß-cyclodextrine-
piroxicam vergeleken met die van naproxen in een 48 weken durende studie 
(hoofdstuk 2). Patiënten werden in totaal 12 keer gezien op de polikliniek. Om in 
aanmerking te komen voor deelname aan dit onderzoek moesten patiënten een 
duidelijk actieve ziekte hebben. Dit werd bekeken door de patiënten voor de start 
van het onderzoek te laten stoppen met het door hun gebruikte NSAID, en dan de 
ernst van hun klachten te beoordelen. Om tot een zo eerlijk mogelijke beoordeling 
van deze twee geneesmiddelen te komen, is het onderzoek dubbel-blind uitgevoerd. 
Dit betekent dat zowel de patiënt als de behandelend arts, c.q. de onderzoeker, niet 
wisten met welk van de twee geneesmiddelen de patiënt behandeld werd. Beide 
NSAID's lieten een significante verbetering zien na de start van de behandeling. 
Er was geen verschil in effectiviteit en toxiciteit tussen de twee NSAID's. 
Maag-darm bijwerkingen van NSAID's 
Hoofdstuk 3 beschrijft hoe in bovenstaand NSAID-onderzoek de maag-darm toxi-
citeit nader werd onderzocht. Naast het aantal maag-/darmklachten, is de mate van 
bloedverlies in het maag-/darmkanaal gemeten. De hoeveelheid bloedverlies in het 
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maag-Maimkanaal geeft aan in hoeverre bet slijmvlies van het maag-/darmkanaal 
geïrriteerd is, d.w.z. hoe meer bloedverlies des te meer irritatie. Het bloedverlies 
werd in ontlasting gemeten, die verzameld was gedurende een periode van 48 uur, 
bij de start van het NSAID (week 0) en na 4, 24 en 48 weken behandeling. Er 
waren geen verschillen tussen de beide NSAID's in het aantal en de ernst van 
optredende maag-/darmbijwerkingen, en in de mate van bloedverlies. Het bloed-
verlies bij SA-paüënten was aanmerkelijk hoger (gemiddeld 1600 ml op jaarbasis) 
dan bij gezonde vrijwilligers die NSAID's gebruiken (gemiddeld 400 ml per jaar). 
Dit verschil zou kunnen berusten op de veelvuldig bij SA voorkomende chronische 
ontstekingsziekten van de darm, die ook gepaard kunnen gaan met bloedverlies. 
Opmerkelijk was dat er een toename van bloedverlies van week 0 naar week 4 te 
zien was, en een daling van week 4 naar week 24 en 48. Dit wijst op een mogelijk 
aanpassingsmechanisme van het maagslijmvlies bij chronisch NSAID-gebruik. 
Pseudoporfyrie ten gevolge van naproxen 
In het NSAID-onderzoek ontwikkelden twee patiënten een niet vaak voorkomende 
huidbijwerking van naproxen - pseudoporfyrie. Pseudoporfyrie is een huidaandoe-
ning die blaren geeft bij aan zonlicht blootgestelde huid, waarbij met name bet 
gelaat, de hand- en voetrug aangedaan zijn. De blaren genezen met littekenvorming 
en aldaar verminderde pigmentarie. Na het stoppen van naproxen verdwijnt de 
aandoening. In hoofdstuk 4 wordt alle beschikbare literatuur over pseudoporfyrie 
ten gevolge van naproxen kort samengevat, en wordt de ziektegeschiedenis van 
drie patiënten beschreven. 
Farmacokinetische interactie tussen ß-cyclodextrine-piroxicam en 
twee H2-receptor antagonisten 
NSAID's kunnen maagzweren veroorzaken, die dan met een ander geneesmiddel, 
een Hj-receptor antagonist, behandeld worden. H2-receptor antagonisten remmen de 
maagzuurproduktie. Omdat reumapatiënten niet langdurig zonder NSAID's kunnen, 
worden de twee geneesmiddelen vaak samen voorgeschreven. Dit kan leiden tot 
interactie. Hoofdstuk 5 beschrijft een onderzoek bij gezonde vrijwilligers naar de 
interactie van ß-cyclodextrine-piroxicam met twee frequent voorgeschreven Hj-
receptor antagonisten, Cimetidine (Tagamet) en ranitidine (Zantac). De farmacoki-
netiek - opname, verdeling, omzetting door de lever en uitscheiding door de nier -
van piroxicam werd niet gewijzigd door de H2-receptor antagonisten. Dit betekent 
dat er geen interactie bestaat tussen ß-cyclodextrine-piroxicam en Cimetidine en 
ranitidine. In de appendix wordt een nieuwe methode beschreven om de concen-
tratie van Cimetidine in bloed en urine te bepalen. 
Tweede lijns behandeling 
Een literatuuronderzoek naar de tweede lijns behandeling van spondylarthropathie-
en, de groep ziekten waartoe SA behoort, is beschreven in hoofdstuk 6. Tot de 
tweede lijns behandeling worden gerekend: hydroxy-chloroquine, goud, d-penicil-
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lamine, sulfasalazine, methotrexaat, cyclofosfamide, 6-mercaptopurine, azathiopri-
ne, Ciclosporine, levamisol, alsmede radiotherapie en hoimoontoediening in de 
vorm van prednison of corticotrofine. Alleen naar sulfasalazine (salazopyrine) 
waren voldoende onderzoeken gedaan om een conclusie te kunnen trekken omtrent 
de werkzaamheid bij spondylarthropathieën. Methotrexaat en azathioprine leken 
veelbelovend in diverse rapportages. Radiotherapie liet een snel effect zien, maar 
bleek op de lange termijn een verhoogd risico op kanker, waaronder met name 
bot- en bloedkanker, te geven. 
Methotrexaat bij de behandeling van ernstige SA 
Na dit literatuuronderzoek is besloten om methotrexaat (MTX) te bestuderen in 
een kleine groep van patiënten met ernstige SA, die niet genoeg baat hadden bij 
behandeling met NSAID's en salazopyrine. Patiënten werden in een open onder-
zoek gedurende 24 weken behandeld met één toediening MTX per week, terwijl de 
dosis van het NSAID constant werd gehouden. Twee patiënten vielen uit, en in 
week 24 bleek er een verbetering te zien te zijn bij het merendeel van de paü-
entea Patiënten mochten zelf beslissen aan de hand van het door hun ervaren 
effect of ze wilden doorgaan met de behandeling met MTX. Vier patiënten 
besloten door te gaan met MTX, bij drie van hen kon de dosis van het NSAID 
worden verminderd en een patiënt kon volledig stoppen met het NSAID. De 
overige vijf patiënten besloten te stoppen met MTX. Bij drie van deze vijf 
verergerde de ziekte daarna zodanig dat ze opnieuw startten met MTX. Bijwer-
kingen waren alle mild en voorbijgaand. 
Functionaliteit bij SA 
Hoofdstuk 7 beschrijft de ontwikkeling en evaluatie van een Nederlandse Functi-
onele Index om de functionaliteit bij SA-patiënten te meten. Voor dit doel werd 
een bestaande Franse vragenlijst vertaald. Omdat deze Franse vragenlijst niet alle 
aspecten van functionaliteit leek te bevatten, zijn er vragen toegevoegd met 
betrekking tot statische activiteiten, zoals 30 minuten zitten of staan, alsmede 
vragen rondom een typisch Nederlandse activiteit: fietsen. De Nederlandse vragen-
lijst bevat in totaal 34 vragen over onder meer het zichzelf aankleden, wassen, 
voorover bukken, iets optillen of oprapen, een bepaalde tijd staan of zitten 
enzovoort. Om te onderzoeken of deze Nederlandse Functionele Index reprodu-
ceerbaar was, daadwerkelijk mat wat patiënten konden en gevoelig genoeg was 
voor veranderingen, werden verschillende groepen patiënten onderzocht. Conclude-
rend bleek deze Nederlandse Functionele Index een betrouwbaar, reproduceerbaar 
en gevoelig instrument te zijn om functionaliteit te meten bij SA-patiënten. 
Ziekte-activiteit bij SA 
Zoals voorafgaand beschreven, zijn pijn en stijfheid de belangrijkste symptomen 
bij SA. Het is algemeen bekend dat deze twee symptomen moeilijk objectiveerbaar 
zijn. Dit blijkt ook uit het grote aantal beschikbare metingen. Zo zijn er talloze 
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manieren ontwikkeld om de beweeglijkheid van de wervelkolom te bepalen. In het 
bloed kan de bezdnking (een maat voor ontsteking) verhoogd zijn, evenals de 
concentratie van bepaalde eiwitten zoals het CRP en het IgA, maar dat is niet zo 
bij elke SA-patiënt. 
Een probleem bij al deze variabelen is dat het onduidelijk is in hoeverre ze nu 
daadwerkelijk ziekte-activiteit meten, dan wel restschade. Bijvoorbeeld bij pijn is 
de beweeglijkheid van de wervelkolom afgenomen, maar dat is ook het geval als 
de wervelkolom is verstijfd zonder dat dit pijnlijk is. In hoofdstuk 8 is beschreven 
hoe uit 27 veelgebruikte variabelen een selectie gemaakt kon worden van een 
kleine groep variabelen die met name ziekte-activiteit meten. De waarnemingen bij 
de patiënten uit de NSAID- en de MTX-studie, zijn onderverdeeld in twee 
groepen, namelijk die met hoge en die met lage ziekte-activiteit. Vervolgens is er 
met diverse statistische methodes bekeken hoe deze twee groepen zich van elkaar 
onderscheidden. Het bleek dat er een groepje variabelen geselecteerd kon worden, 
dat het beste het verschil weergaf tussen hoge en lage ziekte-activiteit Uiteindelijk 
kon er met een bepaalde statistische analyse een formule gemaakt worden voor een 
ziekte-activiteitsscore bij SA (AS-DAS). Met behulp van deze formule kan de 
ziekte-activiteit als een getal worden weergegeven, waarbij een hoog getal 
overeenkomt met een hoge ziekte-activiteit, en andersom. De formule maakt 
gebruik van vijf variabelen: a) de Nederlandse Functionele Index; b) een enthesis 
index (een maat voor pijn aan bot-peesaanhechtingen); c) het CRP (een maat voor 
ontsteking); d) rugpijn overdag (gemeten op een schaal van 0 tot 10 cm); en e) de 
'wortel-gewrichts' index (een maat voor pijn van heupen en schouders). De AS-
DAS is een eerste aanzet om met minder variabelen ziekte-activiteit bij SA te 
meten, echter de AS-DAS zal in de toekomst geëvalueerd moeten worden net zoals 
met de Nederlandse Functionele Index is gebeurd. 
Röntgenscore bij SA 
Op de röntgenfoto is de blijvende schade ten gevolge van de ontsteking bij SA 
zichtbaar, dit wordt röntgenschade genoemd. Het uiteindelijk gewenste resultaat 
van een behandeling zou in het ideale geval een uitblijven van schade moeten zijn. 
Om röntgenschade en -progressie van de ziekte nauwkeurig vast te stellen is een 
meetmethode nodig. Daarom wordt in hoofdstuk 9 de ontwikkeling en evaluatie 
van een röntgenscore methode voor SA beschreven, bestaande uit een score van de 
nek- en lendewervelkolom, de entheses van het bekken en de heupgewrichten. In 
het NSATD-onderzoek (hoofdstuk 2) zijn hiervoor röntgenfoto's gemaakt bij de 
start van het onderzoek (week 0) en in week 48. Er wordt verondersteld dat met 
NSAID's voornamelijk een symptomatische behandeling wordt gegeven, zonder 
dat er iets verandert aan het beloop van de ziekte. Zodoende mag aangenomen 
worden dat er progressie van de ziekte is ondanks behandeling met NSAID's. Een 
statistisch significante toename in röntgenscore van week 0 naar week 48 kon 
worden vastgesteld. Hieruit blijkt dat deze röntgenscore-methode gevoelig genoeg 
is om veranderingen te meten. Er werd geen verschil gezien in de mate van 
röntgenprogressie tussen de beide bestudeerde NSAID's, ß-cyclodextrine-piroxicam 
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en naproxen, tussen mannen en vrouwen, en tussen degenen die wel en die niet 
goed reageerden op de behandeling met NS AID's. 
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vele gezellige momenten. 
Dr. P. (Piet) van Riel en Dr. M. (Marcel) Franssen leverden het oorspronkelijke 
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weg. 
Alle collegae en medewerkers van de afdelingen reumatologie van het AZN en de 
SMK wil ik bedanken voor de prettige sfeer, Marlou Prevoo, Anke van Gestel en 
mijn keldergenoot Jan Stolk vooral bedankt voor het meedenken en jullie begrip bij 
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STELLINGEN 
Behorende bij het proefschrift 
Clinical and methodological studies in ankylosing spondylitis 
I 
De toename van bloedverlies in de tractus digestivus bij patiënten met spondylitis 
ankylopoëtica - die nog wordt vergroot door het gebruik van eerste-lijns antireumatica 
(NS AID's) - is een van de argumenten om op salazopyrine over te schakelen. 
dit proefschrift; J. Hayllar, Arthritis Rheum. 1994;8:1146-50 
Π 
Men dient zich af te vragen of het feit dat pseudoporfyrie ten gevolge van naproxen 
zelden wordt gezien het gevolg is van daadwerkelijk zeldzaam voorkomen of van 
onderdiagnostisering. 
eigen waarneming, dit proefschrift 
Ш 
Het is frappant dat, hoewel de effectiviteit van tweede-lijnsgeneesmiddelen bij 
invaliderende auto-immuunziekten sinds 1960 in dubbelblinde klinische studies is 
bestudeerd, deze benadering pas 20 jaar later bij spondylitis ankylopoëtica aan de orde 
kwam. 
eigen waarneming, dit proefschrift 
TV 
Op basis van het aantal gemaakte cervicale-wervelkolomfoto's zou men verwachten 
dat de prevalentie van nekklachten bij patiënten met spondylitis ankylopoëtica laag is; 
het tegendeel is het geval. 
eigen waarneming 
V 
Bij patiënten met een continu hoge ziekte-activiteit gedurende een lange periode, kan 
verbetering na interventie in een open studie niet alleen verklaard worden door 
'regression to the mean'. 
VI 
Door het overigens terecht grote belang dat aan statistische significantie wordt gehecht, 
dreigt de klinische relevantie als punt van beschouwing vaak uit het oog verloren te 
worden. 
eigen waarneming 
VII 
Omdat een praktizerend medicus altijd leidinggevende taken heeft, reeds te beginnen 
in de patiëntenzorg, zou een managementcursus een verplicht onderdeel moeten zijn 
van de opleiding. 
Ш 
Werktijden naar de letter van de dienaangaande Algemene Maatregel van Bestuur 
kunnen mede verwezenlijkt worden door niet iedereen de bevoegdheid te geven op elk 
moment het sein van de arts-assistent te bellen. 
EX 
Zolang vrouwen uit eigen beweging kiezen voor part-time werken omwille van 
kinderen worden mannen zelden gedwongen die keuze te maken. 
X 
De belangstelling voor stellingen is omgekeerd evenredig met de tijd die het kost om 
ze te maken. 
Nijmegen, 12 december 1994 
Marjonne Creemers 
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